<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<?xml-stylesheet type="text/xsl" href="annotation.xsl"?>
<?oxygen NVDLSchema="annotation.nvdl"?>
<fulltext-document system="ops.epo.org" fulltext-format="text-only" xmlns="http://www.epo.org/fulltext"><bibliographic-data><publication-reference data-format="docdb"><document-id><country>WO</country><doc-number>2007104062</doc-number><kind>A2</kind></document-id></publication-reference></bibliographic-data><description lang="EN"><p>DESCRIPTION</p><p>COMPOSITIONS AND METHODS RELATED TO PROFILING A PLURALITY OF CELL LINES BASED ON PEPTIDE BINDING</p><p>[0001] The United States Government owns rights in present invention pursuant to grant number DAMD 17-03 -1-0638 from the Department of Defense, and grant CA103056 from the National Institutes of Health.</p><p>[0002] This application claims the benfit of <bibl type="patent" xmlns="http://www.tei-c.org/ns/1.0">U.S. Provisional Patent Application No. 60/780,893</bibl>, filed on March 9, 2006. 1. TECHNICAL FIELD</p><p>[0003] The present invention is directed generally to method and compositions related to molecular biology, virology, and oncology. In certain aspects it is directed to compositions comprising and methods of profiling and/or classifying a plurality of cells or cell lines based on peptide binding characteristics.</p><p>BRIEF SUMMARY OF THE INVENTION</p><p>[0004] An embodiment of the invention includes methods of profiling cell lines and/or identifying peptide sequences or structures that bind a target population or family of cells. The methods include providing a plurality of cell lines; contacting each cell line with a library of phage displaying random heterologous peptides on their surface; obtaining phage that bind each of the cell lines; identifying peptides that bind each cell line; and classifying each cell line based on the identified peptides. The method can further comprise classifying each identified peptide based on the cell lines that bind each identified peptide. In one aspect, the cell lines include cancer cell lines. Cancer cell lines may include, but are not limited to kidney, breast, colon, lung, prostate, brain, liver, pancreatic, uterine, neuronal, skin, head and neck, leukemic, lymphocytic, or ovarian cancer cell lines. In another aspect, the panel is cancer cell lines. In a particular aspect, the panel is a NCI 60 panel of cancer cell lines. The methods further include identifying a peptide that binds to a majority of the cancer cell lines or cancer cells of common origin. Furthermore, methods can also include analyzing the identified peptides to identify similarities with known receptor ligands.</p><p>[0005] In certain aspects, classifying the cell line is performed by clustering analysis. Clustering analysis can be used to construct a clustered image map (CIM). In a particular aspect, classifying the identified peptide is performed by clustering analysis. Clustering analysis can be used to construct a clustered image map. In another aspect, the methods may also include identifying receptors for at least one of the identified peptides comprising the steps of providing an identified peptide; labeling the identified peptide; contacting an appropriate cell line with the labeled peptide; isolating a receptor - peptide complex; and identifying the receptor bound to the labeled peptide.</p><p>[0006] In another embodiment, a group of peptides comprising five or more peptides can be classified or identified as selectively bind to a sub-population of cell lines, wherein the peptides include, but are not limited to those listed in Table 3 and described herein. In certain aspects, a sub sequence of the peptide may be identified as conferring to the peptide a certain binding characteristic.</p><p>[0007] In still further embodiments, methods of the invention can be used to classify a cell or cell line. Methods of classifying a cell line include, but are not limited to steps comprising: contacting a cell with a group of selected peptides or polypeptides that differentially bind cells of a known origin; detecting the peptides that bind the cell line; and assessing the classification of the cell line based on the peptide(s) that bind the cell line. Thus, in certain aspects, classifying a cell may comprise determining whether as cell expresses a certain receptor polypeptide, is susceptible to a particular therapy or determining the tissue of origin for the cell. In certain aspects of the invention, a group of selected peptide for use according to the invention are further defined as cyclic or partially peptides, such as peptides comprising a disulfide bond. In certain cases, a group of selected peptides or polypeptides may comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more distinct peptides or polypeptides.</p><p>[0008] Thus, in a further specific embodiment there is provided a method for classifying a cell comprising obtaining or having a sample comprising a cell; contacting the cell with a group of peptides or polypeptides that differentially bind cells of a known origin or type; detecting the peptides that bind to the cell and classifying the cell based on the peptide binding. As described supra, in certain aspects, a group of selected peptides or polypeptides comprise amino acid sequences selected from those provided in Table 3. Thus, in certain cases a group of selected peptides or polypeptides comprise 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more members that comprising an amino acid sequence according to Table 3. The skilled artisan will recognize that selected peptide or polypeptides of the invention may in some aspects be labeled for example with an enzyme, a fluorophor or a radio isotope.</p><p>[0009] In some aspects, a selected peptide or polypeptide may be a cyclic or partially polypeptide such as a peptide or polypeptide comprising a disulfide bond. In some preffered aspects, the cyclic region of a peptide or polypeptide comprises 5, 6, 7, 8, 9, 10 or more amino acids. For example, in certain aspects, a selected peptide or polypeptide comprises an amino acid sequence provided in Table 3 wherein the given amino acid sequence is comprised in the cyclic region of the polypeptide. Thus, it is contemplated that a selected peptide or polypeptide may comprise an amino acid sequence of Table 3 wherein the sequence is flanked by cysteine residues such that the cysteine residues may be linked by a disulfide bond.</p><p>[0010] In some aspects of the invention a method for classifying a cell according to the invention may comprise comparing the binding profile of a group of selected peptides or polypeptides to a cell to a similar binding profile from a cell with a known classification. Such a comparison may be performed directly or may performed by consulting a chart or database of binding profiles. For example, a chart or database of binding profiles may comprise binding profiles from cells of 5, 10, 15, 20, 25 or more different classifications. In certain aspects, a chart or database of binding profiles may comprise clustering analysis of the binding of selected peptides or polypeptide to cells of different classification. Thus, in some cases a chart or database of binding profiles may comprise a clustered image map (CIM). Thus, classifying a cell may be performed by for example clustering analysis.</p><p>[0011] In still further aspects of the invention there is provided a method for treating a subject comprising obtaining or having a sample from the subject comprising a cell; classifying the cell (e.g., by the methods described supra); and treating the subject with a therapeutic based upon the classification of the cell. For example, in some cases a subject may be defined as a cancer patient. In this case a cancer cell from the subject may be classified. Classification of the cell may for example comprising determining the tissue of origin, receptor status or susceptibility of the cell to particular anticancer therapy. Thus, based upon the classification of the cell the subject may be treated with an appropriate anticancer therapy. For example, methods of the invention may be used to classify a cell as susceptible or resistant to radiation therapy, immunotherapy, surgical therapy or chemotherapy. Furthermore, methods of the invention may be used to classify the cell as susceptible or resistant to a particular chemotherapeutic agent or class of chemotherapeutic agents. Thus, methods of the invention may involve classifying a cancer cell from a subject as susceptible or resistant to an anticancer therapy and treating the subject with one or more anticancer therapies that the cell is susceptible to. [0012] In certain aspects the invention concerns obtaining or having a sample such as a cell. It is contemplated that in cases where a sample is from a subject the sample may be directly obtained or may be obtained by a third party and subsequently subjected to methods described herein. Furthermore, in certain aspects it is contemplated that methods of the invention may be defined as a method for aiding in the therapy of a subject comprising classify a cell from the subject (e.g., as having certain protein receptor expression or being from a tissue of a particular origin) and providing the classification information to a third party such as a medical professional to aid in the therapy of the subject.</p><p>[0013] In yet another embodiment of the invention includes a method of classifying a peptide(s). Methods of peptide classification include, but are not limited to steps comprising: contacting a plurality of cell lines with a library of peptides that differentially bind the cells; detecting the peptides that bind the cell line; and classifying the peptides based on the cells that bind the peptide.</p><p>[0014] In certain aspects an EphA5 receptor can be targeted by using a composition comprising a peptide sequence of CSGIGSGGC (SEQ ID NO:2) or CRFESSGGC (SEQ ID NO:3). The skilled artisan will further recognize that in certain aspects a peptide targeting sequence of the invention is cyclic. Thus, there is provided EphA5 receptor targeting composition comprising a cyclic polypeptide wherein the cyclic polypeptide comprises the amino acid sequence SGIGSGG (SEQ ID NO:4) or RFESSGG (SEQ ID NO:5). As exemplified herein in certain aspects an cyclic EphA5 targeting composition may comprise a peptide sequence according to SEQ ID NO:4 or SEQ ID NO:5 flanked by cysteine residues thereby forming a cyclic targeting agent via disulfide bonds between the cysteine residues. As used herein the termed flanked means that the indicated amino acid sequence are between two cysteine residues however it is contemplated that in some cases additional amino acids may also be comprised between the two cysteine residues.</p><p>[0015] A composition of the invention can be coupled (either non-covalently or covalently, or indirectly via an intermediate such as a liposome or directly) to a therapeutic or imaging agent. The therapeutic can include, but is not limited to a small molecule, a drug, or a therapeutic peptide. For example, in certain aspects, a therapeutic composition of the invention comprises a polypeptide. In these aspects the therapeutic Eph5A receptor targeting composition may comprise a fusion protein. Thus, in some very specific cases the therapeutic polypeptide may be a toxin or other cytotoxic molecule capable of inducing cell death in Eph5A receptor expressing cells. Imaging agents for use in the invention include but are not limited to MRI contrast agents, radio isotopes, fluorophors and mass tags (e.g., for detection via mass spectrometry).</p><p>[0016] In certain aspects there is provided an EphA5 receptor agonist comprising the amino acid sequence SGIGSGG (SEQ ID NO:4) or RFESSGG (SEQ ID NO:5). As described above in some cases the EphA5 receptor agonist is a cyclic peptide or polypeptide wherein the cyclic region comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5. Thus, in some case the agonist is a cyclic peptide or polypeptide comprising a disulfide bond such as a peptide or polypeptide wherein the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5 are flanked by cysteine residues (e.g., as in SEQ ID NO:2 or SEQ ID NO:3).</p><p>[0017] Thus, in still further aspects of the invention there is provided a method for treating an Eph5A receptor positive cell comprising administering to the cell an EphA5 receptor targeting therapeutic as described supra. Thus, in some aspects a method of the invention may be further defined as a methods for treating a subject comprising an EphA5 receptor positive cell by administering an effective amount of an EphA5 receptor targeting therapeutic. For example, in certain cases a subject may be a cancer patient comprising an EphA5 receptor positive positive cancer such as a lung cancer or neuronal cancer. In still further aspects there is provided a method for treating a subject with a an EphA5 receptor positive cancer by administering an EphA5 receptor targeting therapeutic wherein the therapeutic comprising a cytotoxic agent or an anticancer agent.</p><p>[0018] The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."</p><p>[0019] The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or."</p><p>[0020] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS</p><p>[0021] For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawing, in which:</p><p>[0022] FIG. 1: Selectivity of broad-specificity tripeptides for clusters of NCI-60 cell lines. Two-dimensional hierarchical clustering was applied to the frequencies of 38 tripeptides (rows) encountered in CX7C peptides selected on NCI-60 cell lines (columns). Tripeptides selected on all but one cell line of common origin were clustered based on their correlations with cell lines; cell lines were clustered based on their correlations with the tripeptides. Tripeptide frequencies were mean subtracted and average linkage clustered with correlation metric. Amino acid color code: red, hydrophobic; green, neutral and polar; purple, basic. The color in each CIM segment ranges from blue (negative correlation) to red (positive correlation), as indicated by the scale bar. Cell lines are color-coded based on previously defined histologic tumor origin (Monks et al, 1991, Weinstein et al., 1997. Bars underneath dendrogram, clusters of cells of similar tumor tissue origin (one exception allowed). Boxed, cluster of lung cancer-derived cell lines and associated/dissociated tripeptides.</p><p>[0023] FIGs. 2A-B: Identification of peptides mimicking EGFR ligands. FIG. 2A, EGFR-binding peptide sequences isolated from the SKOV-3 selected phage pool were matched in each orientation to protein sequences of biological human EGFR ligands (leader peptide sequence underlined). Matches displayed are peptides with three or more amino acids being identical (red) and one or more being from the same class (green) as the correspondingly positioned protein amino acids. Tripeptides listed in Table 1 (yellow). FIG. 2B, isolation of peptides targeting EGFR. Binding of SKO V3 -selected phage pool to immobilized EGFR compared with BSA in rounds 1 and 2 of biopanning of SKO V3 -selected phage pool on immobilized human EGFR.</p><p>[0024] FIGs. 3A-3B: Phage selection on immobilized EphA5 receptor. FIG. 3A, Ephrin-mimic phage displaying the enriched motif GGS were selected on EphA5-coated microtiter wells. Phage showing specific binding to EphA5 was analyzed for its distinctive binding to EphA5 compared to EphA4 receptor (FIG. 3B). BSA and fd-tet insertless phage were used as negative controls.</p><p>[0025] FIG. 4: EphA5 receptor expression in the NCI-60. From microarray analysis reported at dtp.nci.nih.gov/mtweb/servlet/moltidsearch?moltid=MT894. [0026] FIG. 5: EphA5 and EphA4 receptor expression by the lung cancer cell lines Hop92 and H460. The OVCAR3 cell line was used as negative control. 1OX magnification.</p><p>[0027] FIG. 6: Specific binding of the CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)- phage to lung cancer cells Ho[rho]92 and H460 but not to the ovarian cancer cell line OVCAR-3. Insertless phage (fd-tet) was used as negative control.</p><p>[0028] FIGs. 7A-B: A. Clustered image map relating all isolated NCI-60-binding tripeptides to NCI-60 cell lines. FIG. 7A, Two-dimensional hierarchical clustering was applied to the frequencies of 3,280 unique tripeptides (rows) found in cell-binding CX7C peptides selected on the NCI-60 cells (columns). Tripeptides were clustered based on their correlations with cell lines; cell lines were clustered based on their correlations with tripeptides. Tripeptide frequencies were mean-subtracted and average-linkage clustered with correlation metric (the data were transformed to the mean of 0; variance of 1). The color in each CIM segment ranges from blue (high negative correlation) to red (high positive correlation), as indicated by the scale bar. Cell lines are color-coded based on previously defined histological tumor origin. FIG. 7B, A control two-dimensional hierarchical cluste[pi]ng applied under the Poisson assumption to 3,280 randomly simulated tripeptide frequencies (rows) showed no obvious pattern, thus indicating that clusters in A were not generated at random.</p><p>[0029] FIG. 8: Targeted peptides mediate ligand-receptor cell internalization. CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage were permeabilized into A549 cells. No internalization was observed when cells were incubated with insertless phage</p><p>[0030] FIG. 9A-B: Biological effects of the peptides CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3 on lung cancer cells. Promotion of cell survivial and proliferative response of starved lung cancer cells to the ephrin mimic peptides, control peptide and complete culture medium (A549 (FIG. 9A), H460 cells (FIG. 9B)). Concentrations of peptide were optimized. Values in the Y-axis correspond to the number of viable cells under each experimental condition evaluated after a 72h incubation period. Data bars represent the mean and corresponding standard error of the mean.</p><p>DETAILED DESCRIPTION OF THE INVENTION</p><p>[0031] A collection of 60 cell lines derived from human tumors (NCI-60) has been widely explored as a tool for anticancer drug discovery. In one aspect of the invention, the cell surface of the NCI-60 was profiled by high-throughput screening of a phage-displayed random peptide library and classified the cell lines according to the binding selectivity of 26,031 recovered tripeptide motifs. By analyzing selected cell-homing peptide motifs and their NCI-60 recognition patterns, the inventors established that some of these motifs (a) are similar to domains of human proteins known as ligands for tumor cell receptors and (b) segregate among the NCI-60 in a pattern correlating with expression profiles of the corresponding receptors. The inventors biochemically validated some of the motifs as mimic peptides of native ligands for the epidermal growth factor receptor. The results indicate that ligand-directed profiling of tumor cell lines can select functional peptides from combinatorial libraries based on the expression of tumor cell surface molecules, which in turn could be exploited as "draggable" receptors in specific types of cancer (Kolonin et al, 2006).</p><p>[0032] The National Cancer Institute panel of human cancer cell lines from different histologic origins and grades (NCI-60) has been extensively used to screen compounds for anticancer activity (Monks et al, 1991; Weinstein et al, 1997). The NCI-60 includes carcinomas of several origins (kidney, breast, colon, lung, prostate, and ovarian), tumors of the central nervous system, malignant melanomas, leukemias, and lymphomas. Gene expression determined by high-throughput microarrays has been used to survey the variation in abundance of thousands of distinct transcripts in the NCI-60; such data provided functional insights about the corresponding gene products in tumor cell transformation (Weinstein et al, 1997; Scherf et al, 2000; Nishizuka et al, 2003). This information-intensive genomic approach has yielded candidate diagnostic tumor markers to be validated at the protein level in prospective studies (Nishizuka et al, 2003). Moreover, systematic proteomic studies based on two-dimensional PAGE (Myers et al, 1997) and protein microarrays (Nishizuka et al, 2003) have also been implemented. Finally, in parallel with the NCI-60 transcriptome and proteome initiatives, pharmacologic sensitivity of the cells to &gt;10&lt;5&gt; different chemical compounds has been registered (Monks et al, 1991; Weinstein et al, 1997). Indeed, for some genes, correlation of expression data to drag sensitivity profiles has uncovered the mechanistic basis for the drag activity (Scherf et al, 2000; Zaharevitz et al, 2002; Blower et al, 2002; Rabow et al, 2002; Wallqvist et al, 2002; Szakacs et al, 2004). Thus, conventional genomic and proteomic approaches have identified several potential tumor markers and drug targets. However, despite such advances, correlation between drug activity and gene expression profiles has not as yet been established for most of the compounds tested (Wallqvist et al, 2002; Brown, 1997; Walloyist et al, 2003). This suggests the likely existence of unknown factors and the need to develop alternative methodology to discover "draggable" molecular targets.</p><p>[0033] Over the past few years, it has been proposed that (a) characterization of molecular diversity at the tumor cell surface level (represented primarily by membrane- associated proteins that are often modified by lipids and carbohydrates) is required for the development of ligand-directed anticancer therapies, and that (Zaharevitz et al, 2002) peptides binding to surface receptors preferentially expressed on tumor cells may be used to ligand-direct therapeutics to sites of disease with potential for increased therapeutic windows (Arap et al, 1998; Kolonin et al, 2001). It has become increasingly clear that selective cell surface features can be mapped by screening libraries of peptides (Kolonin et al, 2001; Pasqualini and Ruoslahti, 1996; Giordano et al, 2001; Arap et al, 2002). In fact, combinatorial peptide libraries displayed from pill protein of an M 13 -derived phage have now been successfully screened on intact cells and in vivo (Arap et al, 1998; Kolonin et al, 2001; Pasqualini and Ruoslahti, 1996). Peptide ligands selected from unbiased screens without any predetermined notions about the nature of the cellular receptor repertoire have been used for the subsequent identification of the corresponding target cell surface receptors (Giordano et al, 2001; Arap et al, 2002; Pasqualini et al, 2000; Kolonin et al, 2002; Kolonin et al, 2004; Pasqualini et al, 2001). In addition, novel techniques, such as the biopanning and rapid analysis of selective interactive ligands (BRASIL), have enabled high- throughput phage library screening on cells (Giordano et al, 2001). Here, the BRASIL method is used to systematically screen combinatorial libraries on tumor cells of the NCI-60 panel. Results of this feasibility study suggest that tumor cells can be grouped by profiles of their peptide ligands directed to differentially expressed cell surface receptors. The data support the notion that many tumor cell surface-exposed receptors are expressed irrespective of tumor origin, thus suggesting they could be developed as broad tumor targets. Integration of ligand-directed surface profiling with other approaches related to the NCI-60 may uncover functional ligand-receptor pairs for the targeted drag delivery. I. CELL TARGETING MOLECULES</p><p>[0034] Modified cell targeting molecules of the present invention may be produced by chemical synthetic methods, by chemical linkage between the two moieties or in some cases by fusion of a second polypeptide coding sequence to the targeting moiety. It is contemplated that modified cell targeting molecules of the invention may be used as therapeutics and/or as imaging agents to target specific classes of cells. [0035] As mentioned above, in certain aspects of the invention, a modified cell targeting moiety may comprise a second polypeptide wherein the two polypeptides together comprise a fusion protein. For example, in certain aspects the second polypeptide may be a therapeutic or cytotoxic (e.g., a toxin) polypeptide as exemplified below. A fusion of two polypeptide coding sequences can be achieved by methods well known in the art of molecular biology. It is preferred that a fusion polynucleotide contain only the AUG translation initiation codon at the 5 ' end of the first coding sequence without the initiation codon of the second coding sequence to avoid the production of two separate encoded products. In addition, a leader sequence may be placed at the 5 ' end of the polynucleotide in order to target the expressed product to a specific site or compartment within a host cell to facilitate secretion or subsequent purification after gene expression. The two coding sequences can be fused directly without any linker or by using a flexible polylinker.</p><p>A. Cell Targeting Moieties</p><p>[0036] Cell targeting moities as provided here may, in some aspects, comprise peptides or polypeptides that exhibit binding to a specific class of cells. For example, in some cases the cell targeting moiety is selected from one of the polypeptide sequences provided in Table 3. The skilled artisan will understand that such sequences may comprise additional amino acids or other covalent modifications. For instance, in preferred embodiments a polypeptide sequence from Table 3 is provided a cyclic polypeptide. Thus, in some specific examples, an amino acid sequence from Table 3 is flanked by cysteine residues that may form a disulfide bond thereby providing a cyclic polypeptide. Thus, in some aspects the invention provides compositions and methods for targeting any of the classes of cells that bind to the peptides and polypeptides provided herein (e.g., as indicated in Table 3) such as leukemia cells, lung cancer cells, colon cancer cells, CNS cancer cells, melanoma cells, ovarian cancer cells, prostate cancer cells, renal cancer cells or breast cancer cells.</p><p>B. Therapeutic Moieties</p><p>[0037] As mentioned above in certain aspects, a therapeutic moiety may be a toxin such as radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, cytotoxins (cytotoxic agents), or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, Pseudomonas exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha- emitters such as, for example, Bi, or other radioisotopes such as, for example, &lt;103&gt;Pd, &lt;133&gt;Xe, &lt;131&gt;I, &lt;68&gt;Ge, &lt;57&gt;Co, &lt;65&gt;Zn, &lt;85&gt;Sr, &lt;32&gt;P, &lt;35&gt;S, &lt;90&gt;Y, &lt;153&gt;Sm, &lt;153&gt;Gd, &lt;169&gt;Yb, &lt;51&gt;Cr, &lt;54&gt;Mn, &lt;75&gt;Se, &lt;113&gt;Sn, &lt;90&gt;Yttrium, &lt;117&gt; Tin, &lt;186&gt;Rhenium, &lt;166&gt;Holmium, and &lt;188&gt;Rhenium; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin. Furthermore, a therapeutic moiety may be a pro-apoptotic protein such as a BCL2 family member, a caspase or a granzyme. IL CANCER THERAPIES</p><p>[0038] A variety of conventional cancer therapies are currently used in the treatment of cancer. Thus, in some aspects of the invention there are provided methods for classifying cancer cells such as cells that are sensitive or resistant to an anticancer therapy. Some examples of conventional cancer therapies discussed below. It is contemplated that methods according to the invention may be used to identify cells that are sensitive or resistant to any particular cancer treatment. Furthermore, some aspects of the invention concern compositions and methods for cell targeted anticancer therapy. Thus, it is contemplated that any anticancer method known to those in the art (as exemplified below) may be used in combination or conjunction with compositions and methods provided herein.</p><p>A. Chemotherapy</p><p>[0039] Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments. Combination chemotherapies include, for example, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.</p><p>B. Radiotherapy</p><p>[0040] Other factors that cause DNA damage and have been used extensively include what are commonly known as [gamma]-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such asmicrowaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.</p><p>[0041] The terms "contacted" and "exposed," when applied to a cell, are used herein to describe the process by which a therapeutic construct and a chemotherapeutic or radiotherapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing. C. Immunotherapy</p><p>[0042] Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.</p><p>[0043] Immunotherapy, thus, could be used as part of a combined therapy, in conjunction with gene therapy. The general approach for combined therapy is discussed below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and pi 55. III. EXAMPLES</p><p>Example 1 Combinatorial library screening on cells</p><p>[0044] All the NCI-60 cell lines (1), except MDA-N (unavailable), were grown in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and 5 mmol/L L-glutamine. A phage display random peptide library based on the vector fUSE5 displaying the insert CX7C (SEQ ID NO:1) was screened by using BRASIL as described (Giordano et al, 2001). Exponentially growing cells were harvested with 0.5 mmol/L EDTA, 0.4 g/L KCl, 8 g/L NaCl, and 1 g/L dextrose, washed once with phosphate buffer saline (PBS), and resuspended in RPMI containing 1% bovine serum albumin (BSA) and 1 mmol/L HEPES. Cells (~ 10&lt;6&gt;) were incubated for 2 hours on ice with 10&lt;9&gt; transduction units (T.U.) of CX7C phage in 200- [mu]L suspension, transferred to the top of a nonmiscible organic lower phase (dibutyl phtalate/cyclohexane, 9:1), and centrifuged at 10,000 x g for 10 minutes. The phage-bound cell pellet was incubated with 200 [mu]L of K91 bacterial culture, and the bound phages were amplified and used in the following round. To prevent preferential isolation of peptides containing the RGD motif, which is selected on tissue-cultured cells due to expression of cell adhesion molecules binding to vitronectin, library screening was done in the presence of 1 mg/mL of the synthetic peptide RGD-4C (AnaSpec, San Diego, CA) in each round. After three rounds of selection, phage peptide-encoding inserts were sequenced as described (Pasqualini and Ruoslahti, 1996; Arap et al, 2002; Pasqualini et al, 2001).</p><p>Example 2 Hierarchical cluster analysis of peptide motif/cell line association</p><p>[0045] The inventors created an interactive sequence management database of all peptide sequences isolated in the screen. Calculation of tripeptide motif frequencies in CX7C peptides (in both directions) was done by using a character pattern recognition program based on SAS (version 8.1.2, SAS Institute, Cary, NC) and Perl (version 5.6.1) as described (Arap et al, 2002). To identify the most closely related tripeptides and cell lines, clustered image maps (CIM) were generated by using online software CIMminer available at discover.nci.nih.gov/tools.jsp. Data were centered (mean subtracted and divided by SD) on both cell lines and tripeptide motifs; correlation coefficient metric with average linkage algorithm was used as distance measurement. The tripeptide motif frequencies across the NCI-60 cell lines formed a two-dimensional data matrix that was used to correlate motif enrichment with groups of cell lines. To evaluate whether CIMMiner algorithm is appropriate for clustering analysis of peptide frequency data, a simulation test was devised assuming that the frequencies of tripeptide motifs in a given data set follow an independent Poisson distribution. The inventors simulated a random 3,280 x 59 data matrix of the dimension identical to that of tripeptide motif frequency data matrix (corresponding to the set of 3,280 tripeptides and 59 cell lines). These simulated data were centered the same way as the experimental data by transforming to mean of 0, variance of 1. For CIM in FIG. 1, tripeptides selected on all but one cell line of common origin (Arap et al, 2002) were used. Specificity of five tripeptides selectively overrepresented or underrepresented in lung tumor cell binding peptides for the 11 boxed cell lines (against the other 48 cell lines) was evaluated by using the R Package, version 2.0.0 (www.r-project.org) by performing two-sample t test (one tailed), as well as using Wilcoxon rank sum test (one tailed) and Fisher exact test (one tailed) as described (Arap et al, 2002).</p><p>Example 3 Identification of candidate targeted receptors</p><p>[0046] To identify lead receptors targeted by tripeptide motifs, the Molecular Target Database (www.dtp.nci.nih.gov) was screened to identify proteins, expression levels of which in individual cell lines of the NCI-60 correlated with frequencies of individual tripeptides from FIG. 1 in the corresponding cell lines. The inventors used the COMPARE software (dtp.nci.nih.gov/docs/compare/compare.html) to calculate pairwise Pearson correlations between tripeptide frequencies in cell lines and the protein expression patterns in the database. Minimum Pearson correlation coefficient of 0.2 served as cutoff for the selection of lead receptors, as it provided a reasonable number of candidate molecular targets for which NCI-60 expression profiles and tripeptide frequency distribution profiles correlated. To initially restrict the candidate targets analyzed to broad-specificity receptors, only putative cell surface molecules (Table 1) were included, expression of which in the NCI-60 was found to correlate with the frequency profile of at least 25% of the tripeptides.</p><p>Example 4 Protein database screening for peptide motif similarity</p><p>[0047] To identify natural prototype ligands of candidate receptors that are mimicked by selected peptides, the inventors screened all 7-mer peptides selected in the screen by using online ClustalW software (www.ebi.ac.uk/clustalw/) to identify extended (four or longer amino acids) motifs shared between multiple peptides containing the broad-specificity tripeptides (FIG. 1). Nonredundant databases of human proteins were searched by the BLAST software (www.ncbi.nlm.nih.gov/BLAST/) for proteins containing the cell-targeting 4-mers under the condition that at least the tripeptide part of the motif is identical to the part of the BLAST match.</p><p>Example 5 Validation of epidermal growth factor receptor as one of the peptide targets</p><p>[0048] To isolate peptides binding to epidermal growth factor receptor (EGFR), phage clones selected on SKO V3 in rounds 2 and 3 of the screening were individually amplified and pooled, and 10&lt;9&gt; transduction units of the mixed phage were incubated overnight at 4[deg.]C with 10 [mu]g of purified human EGFR (Sigma, St. Louis, MO), or BSA control immobilized on plastic. Unbound phages were extensively washed off with PBS, and then the bound phages were recovered by infecting host K91 Escherichia coli directly on the plate, and tetracycline- resistant clones were selected, quantified, and sequenced. To identify EGFR ligand-matching motifs among phage-displayed SKOV3-binding peptides, custom-designed Perl 5.8.1- based software was used to run peptide sequences against biological EGFR ligand sequences. Each 7-mer peptide sequence was aligned in each orientation against the EGFR ligand sequences from the NH2 to COOH terminus in one-amino-acid shifts. The peptide/protein similarity scores for each residue were calculated based on a BLOSUM62 matrix modified to identify peptide matches of at least three amino acids in any position being identical and one being similar to the corresponding amino acid positions in the EGFR ligands (FIG. 2A).</p><p>Example 6 Isolation of peptides binding to surface of the NCI-60 cancer cells</p><p>[0049] As an initial attempt to profile cell surface of the tumor cell panel, a large (2 x 10&lt;8&gt; unique sequences) cyclic random peptide library was screened with the basic structure CX7C (C, cysteine; X any residue) on every cell line of the NCI-60. Phage selection was done in the excess of a competing Arg-Gly-Asp (RGD) synthetic integrin-binding peptide (Arap et al, 1009) to minimize the recovery of RGD-containing peptides. This strategy was designed to facilitate the recovery of ligands binding to nonintegrin families of cell surface receptors because RGD tends to become dominant in the screening due to the high levels of integrin expression in adherent cells (unpublished observation). Preferential cell binding of specific cell-targeting peptides results in enrichment, defined by the increased recovery frequency of these peptide motifs in each subsequent round of the screen (Kolonin et al, 2001; Pasqualini et al, 2001). Thus, the inventors set out to profile the expression of nonintegrin cell surface molecules among the cell lines of the NCI-60 according to the differential selection of motifs enriched in the screen.</p><p>Example 7 Hierarchical cluster analysis of peptides binding to the NCI-60 cells</p><p>[0050] To analyze the spectrum of the peptides resulting from the screening and compare those among different cell lines of the panel, a combinatorial statistical approach was adopted based on the premise that three residue motifs (tripeptides) provide a sufficient structure for protein-peptide interactions in the context of phage display (Arap et al, 2002). For each NCI-60 cell line, CX7C peptide-encoding DNA inserts from 96 phage clones recovered after three rounds of selection were sequenced. A computer-assisted survey of all tripeptides within the library-derived sequences selected on each cell line by analyzing a database of 26,031 tripeptides contained within the 5,270 CX7C-encoded 7-mer peptides isolated (an average of eighty-nine 7-mer peptide sequences analyzed per each NCI-60 cell line) was performed. Thus, each cell line was assigned a unique set of tripeptides that was identified during the selection for cell surface binders, and the frequencies of each motif among all peptides for a given cell line were calculated.</p><p>[0051] To classify cell lines according to their association with particular motifs, which might provide inference on the targeted surface molecules, a hierarchical clustering analysis of the 3,280 nonredundant tripeptides was done based on the frequency of association with the NCI-60 cell lines. For the construction of a CIM, the inventors adapted a hierarchical clustering algorithm and a pseudo-color visualization matrix initially designed to address differential gene expression among the cells of the panel (Scherf et al, 2000; Zaharevitz et al, 2002; Blower et al, 2002; Rabow et al, 2002). CIMMiner (Weinstein et al, 1997) was used for inference of the variation in peptide binding specificity across the cell lines by comparing relative frequencies of tripeptides found in 7-mer peptides binding to each cell. Clustering of peptide motifs with similar cell selectivity revealed that the peptide distribution of the combinatorial library within the NCI-60 set was nonrandom. Computer simulations of the permutated data set show that the observed pattern could not be generated by random chance, thus indicating that the discontinuous tripeptide frequency data is applicable for cluster analysis.</p><p>[0052] The selective spectra of peptide motifs interacting with the clustered cell lines suggest the existence of shared targeted surface receptor(s) expressed in these lines. In this study, the inventors chose to focus on putative peptide-targeted receptors with broad cell line specificity, which would be more informative for an initial peptide binding/receptor expression correlation analysis, the inventors therefore excluded from the data set motifs selected only on a single or few cell lines. Instead, the inventors focused on 38 tripeptides that showed a semiubiquitous distribution among the NCI-60 lines (FIG. 1). A CIM constructed according to the isolation frequency of these broader-specificity tripeptides from each cell line revealed several apparent clusters of cell lines that displayed distinct profiles of association with certain classes of peptide motifs. For example, the majority of lung cancer- derived cell lines segregated as a separate group, suggesting that some of the receptors targeted may be conserved among cell lines derived from a common origin (FIG. 1). Thus, although the analysis was severely restricted by limiting it to semiubiquitous tripeptides, clustering of some of them (predominantly with cell lines derived from the same tumor type) is consistent with their relative tissue specificity. To evaluate individual motifs for selectivity, a distinct cluster of five tripeptides associated with lung tumor-derived cell lines (FIG. 1 , boxed) were identified. The inventors compared tripeptide frequencies for the 11 cell lines within this cluster with their frequencies for the rest of NCI-60 lines by using statistical tests (Fisher exact, Wilcoxon rank-sum, and t test). Consistently, the GGS motif was isolated for the clustered lines significantly (P &lt; 0.05) more frequently than for the other NCI-60 cell lines.</p><p>[0053] Notably, the distribution of cell lines in the dendrogram (FIG. 1) was partially consistent with the reported association of cells derived from tumors with common tissue origin (Scherf et ah, 2000; Nishizuka et ah, 2003). This suggests that some of the receptors, such as the one presumably recognized by the lung tumor-specific tripeptide GGS (FIG. 1), may be up-regulated only in certain cancer origins. However, the tumor cell phylogeny was recapitulated only to an extent; the majority of the observed clusters contained cell lines derived from unrelated tumor types (FIG. 1). The limited grouping of lines derived from tumors of common origin is perhaps not surprising: the relationship between different cell lines in the study is based on peptide binding to putative cell surface molecules, many of which may be tumor induced rather than characteristic of the tissue of origin. If so, the analysis of broad-specificity motif distribution may be well suitable for identification of specific surface molecules that are generally up-regulated by tumors and thus may constitute broad drug targets against cancer. Example 8 Identification of candidate receptor targets for peptide motifs</p><p>[0054] The inventors proceeded to identify the targets for the 38 broad-specificity tripeptides, most of which presumably bind to receptors expressed by multiple NCI-60 cell lines. The NCI Molecular Targets Database that contains detailed information on the expression and activity of 1,218 human proteins measured by nonarray methods was used (Holbeck, 2004). By using the COMPARE algorithm (Zaharevitz et al, 2002), the inventors correlated the selectivity profiles of the 38 tripeptide motifs with the expression profiles of the characterized molecular targets. It was observed that several of the qualifying proteins, expression of which correlated with enrichment profiles of certain motifs, represented tyrosine kinase receptors, such as those for ligands belonging to families of EGFs, fibroblast growth factors (FGF), nerve growth factors (NGF), and ephrins (Table 1). When transferred to molecular target correlation data, the order of the 38-tripeptide motif set in the dendrogram (FIG. 1) revealed clusters of tripeptides for which cell line association profile correlated with expression profiles of EGF, FGF, NGF, or ephrin receptors (Table 1).</p><p>[0055] The peptide distribution-correlating tyrosine kinase receptors, belonging to EGFR, FGFR, NGFR, and ephrin receptor families (Table 1), are often up-regulated in many types of cancer (Vogelstein and Kinzler, 2004). To determine if the cell-binding peptides may target these tyrosine kinases, the inventors employed the notion that receptor-binding peptide motifs often mimic natural ligands for these receptors (Giordano et al., 2001; Arap et al., 2002; Kolonin et al., 2002). Thus, the selected motifs mimic ligands for the candidate tyrosine kinases were tested by determining whether tripeptides listed in Table 1 are embedded into longer peptides that may be responsible for cell surface binding. The inventors analyzed the CX7C (SEQ ID NO:1) phage inserts containing the 38 tripeptides by using the ClustalW software and compiled extended motifs containing the tripeptides shared among multiple peptides selected during the screen (data not shown). To identify candidate prototype human ligands, epitopes of which could be mimicked, each of the ClustalW- extended motifs were screened against the nonredundant database of human proteins by using the BLAST software (National Center for Biotechnology Information). As a result of this analysis, the inventors found the motifs containing 34 of 38 tripeptides (89%) to be identical or very similar to segments of proven or putative ligands for the tyrosine kinase receptors listed (Table 1). Example 9 Validation of EGFR as a targeted receptor</p><p>[0056] To show that the approach taken can lead to actual targetable tumor cell surface proteins, the inventors chose to test if the EGFR is bound by any of the tripeptide motifs distributed in the panel in a profile correlating with EGFR expression. Consistently, 24 of 38 tripeptides surveyed displayed NCI-60 cell line association pattern consistent with that of EGFR expression (Table 1). Of these tripeptides, 22 were isolated in the screens on ovarian cancer cell lines SKO V3 and OVCAR4 (data not shown). Because EGFR is well known to be associated with ovarian cancer (Vogelstein and Kinzler, 2004), the inventors deemed these cell lines to be likely expressers of targetable EGFR, which would account for the selection of EGFR ligand-mimicking motifs. To validate EGFR binding by the selected motifs, the SKOV3-binding phage sublibrary (pooled clones recovered in rounds 2 and 3) were screened against immobilized human EGFR. After two rounds of selection, phage displaying the EGFR-binding peptides were analyzed: the majority were comprised by different 7-mer peptides (FIG. 2K) that contained 17 of 22 SKO V3 -selected tripeptide motifs distributed in the panel in a profile correlating with EGFR expression (Table 1). Phage displaying these peptides had specific affinity to EGFR, as determined by subjecting the same sublibrary to immobilized BSA control binding (FIG. 2B). Remarkably, computer-assisted analysis of sequences (FIG. 2A) revealed that 12 of the 7-mer EGFR-binding peptides contained amino acid motifs similar to those present in some of the biological EGFR ligands (Vogelstein and Kinzler, 2004). These peptides, containing eight of the candidate tripeptides (RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS), were found highly similar to fragments of EGF, amphiregulin, heparin-binding EGF-like growth factor, and epiregulin (FIG. 2A). Similarity search using the same algorithm on the same twelve 7-mers did not reveal any matches to two other EGFR ligands, transforming growth factor-[alpha] and [beta]-cellulin, or randomly chosen control ligands of tyrosine kinase receptors from the three other candidate families listed in Table 1 : ephrin A, NGF-[beta], and FGF6 (data not shown). Taken together, these data suggest that at least some of the peptides selected on the NCI-60 cells target EGFR, whereas others may bind to different tyrosine kinases, possibly including those from TRK, ephrin, or FGF receptor families.</p><p>[0057] Expression profiles of the candidate receptor targets for peptides identified in the screen illustrate the concept that in cancer, at least some tumor-associated cell surface molecules seem up-regulated regardless of cancer tissue origin. As such, this is the case for the EGFR and other tyrosine kinases possibly targeted by peptide ligands selected on the NCI-60 cell panel. This may also be the case for many other receptors with a role in tumorigenesis, expression profiles of which may not correlate with the overall proteomic profile of the original tumor tissue. In fact, these observations may account for the relatively limited success in correlating drug toxicity profiles with the genomic and/or proteomic profiles of the NCI-60 panel (Walloyist et al, 2003). On the other hand, some of the receptors, such as EphA5 presumably targeted by GGS tripeptide and its derivatives predominantly selective for lung tumor-derived cell lines (FIG. 1), seem to be at least partially specific for the progenitor cancer type.</p><p>[0058] The candidate ligand-receptor leads identified in this study can be characterized further for the development of targeted agents selective for tumors. Moreover, the peptides identified by the approach described here may map receptor interaction domains of biological (native) ligands. Similarity of peptides to the corresponding receptor-binding ligands has already been used for validation of the IL-I l Ra receptor as a target of an interleukin-11 mimic peptide homing to blood vessels in the prostate (Arap et al, 2002; Zurita et al, 2004). The inventors and others have modeled the usage of peptides homing to receptors expressed by tumors (Pasqualini et al, 2000) or non-malignant tissues (Kolonin et al, 2002; Kolonin et al, 2004) for directing the delivery of cytotoxics, proapoptotic peptides, metalloprotease inhibitors, cytokines, fluorophores, and genes (Arap et al, 1998; Kolonin et al, 2001). Thus, the approach provides a straightforward way to identify drug-accessible tumor cell surface receptors and to discover peptide ligands that can serve as mimetic prototype drugs. Unlike genomic or proteomic-based approaches that rely on differential expression levels of transcripts or protein products, this discovery platform directly addresses functional protein- protein interactions at the level of physical binding. In contrast to protein array systems, it is possible to select binding peptides even if the ligand-receptor interaction is mediated by conformational (rather than linear) epitopes. Ligand-directed screening of combinatorial libraries on tumor cell surfaces can lead to improved selection of functionally relevant peptides that can be developed for targeting "draggable" molecular targets. Screen a combi[pi]ato[pi]al phage-displayed library for peptides that bind to cells of each line of the NCI-60 panel (using BRASIL approach)</p><p>&lt;EMI ID=23.1&gt;</p><p>Create database of sequences coding for candidate biological ligands of the receptor that could be mimicked by peptides based on information published for identified candidate receptor targets</p><p>V</p><p>SJ</p><p>Create database of sequences coding for candidate biological ligands of the receptor that could be mimicked by peptides based on information published for identified candidate receptor targets</p><p>JJ</p><p>Identify the peptide-mimicked biological ligands to be validated by subjecting the extended motifs to similarity search (BLAST software) within the database of sequences coding for ligand candidates</p><p>&lt;EMI ID=23.2&gt;</p><p>Chart 1. Platform strategy for systematic identification hgand/receptor pairs operating on cancer cell surface using ligand- mimicking peptides isolated from combinatorial phage display libraries Table 1. Candidate ligand-receptor interactions mimicked*</p><p>RLS ErbB2, ErbB4 FGF2,4 EGF-TM7</p><p>RGV</p><p>RGS ErbB4 FGF2 EphA2,A3,A4,A8,B EGF-TM7, FGF- 12b, FGF-5,</p><p>1 NGF-beta</p><p>RAV ErbB2 MEGF7, NGF-beta. NTF 6 alpha</p><p>RAS TRKA FGF-20, NRG-3</p><p>GAG EGFR FGF 1,2, MEGF4. FGF6, NGF-beta</p><p>AVS EGFR, ErbB2, FGFl TRKB,C EphA2,A3,A4,A7,B TRKl</p><p>ErbB4 1,B2,B3,B5</p><p>LLS Amphlregulin</p><p>LLR TRKA EphA4</p><p>LRV EGFR, ErbB2, FGF3 TRKA1B, EphA2,A3,A7 FGF-12b, Eph-B3</p><p>ErbB4 C</p><p>LRS ErbB3 MEGF4, MEGF5, MEGFS, NRG-</p><p>3, NGF-beta</p><p>RVS EGFR, Erb B2, FGFl, 2 TRKB EphA7 MEGFlO, amphiregulin</p><p>ErbB4</p><p>RSS FGF3 TRKA EphAS EGF-TM7, FGF-S, NRG-3</p><p>AGS EGFR TRKA MEGF6, brain NGF</p><p>AGR MEGF2, MEGF4, FGF6, NTF-5,</p><p>NTF-6</p><p>AGL EGFR, ErbB2, FGF 1,3 EphAS,A6,A8 MEGF 12</p><p>ErbB3</p><p>AGG EphA5 HB-EGF, Ephr-B3</p><p>GVR EGFR, ErbB2, FGFl, 2 TRKB EphA7 MEGF4, MEGF6 MEGF8, FGF-5,</p><p>ErbB4 bFGF, brain NGF</p><p>GVL FGF 1,2 EphA2,A3,A5,A6,B NGF2, Ephrin-B3,</p><p>3</p><p>GAV MEGFS, MEGF6, NGF-beta</p><p>GLV ErbB4 FGF4 EphA5 ESF-TM7, betaceilulin, NTF 3,</p><p>Eph-B3,</p><p>GLR ErbB4 MEGF5, EGFL5, FGF-12b, FGF-</p><p>16, NRG-3</p><p>LVS FGF 1,4 EphA5,A6 EGFL5. FGF23, GDNF, Eph-B3</p><p>ARG ErbB2 FGF2,4 TRKA EphAI FGF-12b, FGF23, NGF-beta.</p><p>GDNF. NTF 6</p><p>ASL FGF 1,2 TRKC EGF-TM7, FGFRl</p><p>AAV TRKB EphA2,A3,A4,A7,B -</p><p>3,B5</p><p>AAS FGF 1,2 TRKC -</p><p>GGS EphA5 Eph-B3, Eph A4</p><p>GGR EGFR.ErbB2 FGF2 EGF-TM7, HB-EGF, FGF23,</p><p>Ephrin-B3</p><p>GLG ErbB2, ErbB3 FGF2,3, EphAI, A6 heparin binding growth factor 8</p><p>4 GGL ErbB2 HB-EGF, MEGF5, EGFL5, NRG-3</p><p>GSS EGFR, ErbB2 FGF3 TRKA,C EphA5 MEGFS</p><p>GSG EGFR EphA5</p><p>GSV EGFR, ErbB2, FGF4 TRKB EphA7,B2 MEGF5, NRG-3, Ephrin-B3</p><p>ErbB4</p><p>GRV EGFR MEGFS, EGF-TM7, FGF23, NTF5</p><p>GRL EGFR.EAB2 EphAS,Bl ,B2,B4 betacellulin, EGFL5, NGF2, NTF5,</p><p>EphB3, EphA4</p><p>GPS EGFR, ErbB2, FGF3 TRKB EpnA2,A3,A4,A7,B MEGFS, EGFL5, EGF-like EMR3,</p><p>ERB4 2,B5 SPGF GVS EGFR FGF4 TRKA MEGF-I , MEGF5, NRG-3, NTF-6,</p><p>NTF-5</p><p>[0059] * NOTE: Candidate peptide motif receptors are the human cell surface proteins (identified by COMPARE) expressed in profiles correlating with the selectivity of the corresponding tripeptides. Candidate peptide-mimicked receptor ligands are human proteins (identified by automated BLAST) that contained the corresponding tripeptides. Tripeptides in the column are ordered as in FIG. 1. Receptors of the same family and their corresponding candidate biological ligands identified based on tripeptide similarity are coded by the same color [EGFR, blue; FGFR, green; TRK receptor (NGFR), purple; ephrin receptor, red]. Tripeptides that both have a selectivity correlating with EGFR family receptor expression and are found within EGFR ligands (boldface). Tripeptides that were confirmed to reside within EGFR-binding SKOV3- sleeted peptides (FIG. 2; blue).</p><p>Example 10 Molecular Fingerprinting of Cancer Cell Lines</p><p>[0060] Proteomics can be defined as the systematic analysis of the proteins in biological samples that aims to document the overall distribution of proteins in tumor cells or tumor- associated cells, identify and characterize individual proteins of interest and to elucidate their relationships and functional roles. Ultimately, high-throughput profiling of protein expression will lead to the "proteome", a protein-based fingerprint, for each tissue in humans and other species. As technologies related to proteomics advance, new approaches for systematic molecular analysis of cancer at the protein level are surfacing. However, methods for systematic protein expression profiling may also easily overlook potential targets for intervention. These methods often do not take anatomical context into account. Therefore, for the generation of molecular map of accessible receptors that can be used for targeting therapeutics, information derived from conventional protein profiling approaches should be enhanced by integration with data from functional screenings ex vivo and in vivo. Studies by the inventors and others have advanced the concept of cancer proteomics: the molecular phenotyping of tumor cells and cells forming blood vessels at the protein-protein interaction level. Exploiting the molecular diversity of cell surface receptors expressed in cancer will eventually result in a ligand-receptor functional map for targeted delivery.</p><p>A major goal in drug development has long been to generate targeted therapies. This approach would improve drug therapeutic indexes by limiting the systemic exposure of other tissues to untoward or toxic effects. Thus, the promise for the identification of selectively expressed tumor- associated receptors and the ligands that home to these receptors is translation of this knowledge into the development of targeted therapeutics. Generally, coupling of homing peptides yields targeted compounds that are more effective and less toxic than the parental compound. So far, peptides selected by homing to tumor vasculature have been used as carriers to guide the delivery of cytotoxic drugs, pro-apoptotic peptides, metalloprotease inhibitors, cytokines, fluorofores, and genes in transgenic and xenograft mouse models of human disease.</p><p>[0061] Recognition of molecular diversity in human cancer is essential for the development of targeted therapies. The methods developed have two main applications. First, they may identify ligands targeting human cancer. Second, the determination of molecular profiles of biomarkers in specific types of tumors may enable identification of differentially expressed cancer markers. Thus, the approach may lead to construction of a molecular profile of human tumors. Early identification of targets, optimized regimens tailored to molecular profile of individual cancer patients, combined with the identification of new vascular addresses may result in revisiting or salvaging of drug candidates that are ineffective or too toxic. Ultimately, it may be possible to guide imaging or therapeutic compounds to tumor targets in cancer patients.</p><p>[0062] By fingerprinting lung cancer cells the inventors have confirmed the expression of a previously characterized molecular target, EGFR, in multiple cancer origins, which demonstrates the power of the approach. Recently, the inventors used this approach to identify a new cancer origin-selective molecular target, Ephrin A5 receptor, which the inventors have preliminary validated in the context of human lung cancer cell lines and tissues.</p><p>Example 11</p><p>Motifs targeting NCI-60 cells in correlation with EGFR expression pattern are found within peptides similar to domains of biological EGFR ligands and bind to EGFR</p><p>[0063] To show that the approach taken can lead to actual targetable tumor cell surface proteins, the inventors chose to test if the EGF receptor (EGFR) is bound by any of the tripeptide motifs distributed in the panel in a profile correlating with EGFR expression. Consistently, 24 out of 38 tripeptides surveyed displayed NCI-60 cell line association pattern consistent with that of EGFR expression (Kolonin et ah, 2001). Of these, tripeptides, 22 were isolated in the screens on ovarian cancer cell lines SKO V3 and OVCAR4 (data not shown). Since EGFR is well known to be associated with ovarian cancer (Vogelstein, 2004; Maihle and Lafky, 2002), the inventors deemed these cell lines to be likely expressers of targetable EGFR, which would account for the selection of EGFR ligand-mimicking motifs. To validate EGFR binding by the selected motifs, the SKOV3-binding phage sub-library (pooled clones recovered in rounds 2 and 3) were screened against immobilized human EGFR. After 2 rounds of selection, phage displaying the EGFR-binding peptides were analyzed: the majority were comprised by different seven-mer peptides (FIG. 3A) that contained 17 out of 22 SKO V3 -selected tripeptide motifs distributed in the panel in a profile correlating with EGFR expression.</p><p>[0064] Phage displaying these peptides had specific affinity to EGFR, as determined by subjecting the same sub-library to immobilized bovine serum albumin (BSA) control binding (FIG. 2B). Remarkably, computer-assisted analysis of sequences (FIG. 2A) revealed that 12 of the seven-mer EGFR-binding peptides contained amino acid motifs similar to those present in some of the biological EGFR ligands. These peptides, containing eight of the candidate tripeptides (RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS) were found highly similar to fragments of EGF, Amphiregulin, heparin-binding EGF-like growth factor, and Epiregulin (FIG. 2A). Similarity search using the same algorithm on the same 12 seven-mers did not reveal any matches to two other EGFR ligands, TGF-[alpha] and betacellulin, or randomly chosen control ligands of tyrosine kinase receptors from the three other candidate families listed in Table 2 (Kolonin et al. 2001): Ephrin A, NGF-[beta], and FGF6. Taken together, these data suggest that at least some of the peptides selected on the NCI-60 cells target EGFR, while others may bind to different tyrosine kinases, possibly including those from TRK, Ephrin, or FGF receptor families.</p><p>[0065] A phage-displayed combinatorial library was systematically screened for peptides capable of targeting the cell lines in the NCI-60 panel. By statistical analysis of peptide motif sequences, each NCI-60 cell line was assigned a unique set of peptide motifs that were isolated during the selection for cell surface binders. It was shown that tumor cells can be grouped by profiles of their phage display-derived peptide ligands directed to differentially expressed cell surface receptors.</p><p>[0066] An approach for peptide-targeted receptor identification was designed. Profiles of peptide motif preference for specific lines of the NCI-60 were correlated with expression profiles of known breast cancer-related targets. Some of the peptide motifs were found within proteins known to bind the receptors that had NCI-60 expression profiles matching cell line recognition profiles of the peptides, and that are implicated in cancer.</p><p>[0067] Candidate targeted cell surface molecules were identified, which included a number of tyrosine kinase receptors. As a proof of principle, EGFR, a receptor known to be upregulated in various cancers, was validated as a target of tripeptides RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS, which were The results desc[pi]bed uncover a previously overlooked phenomenon. The data support the notion that many tumor cell surface-exposed receptors are expressed irrespective of tumor origin, thus suggesting they could be explored as broad tumor targets.</p><p>Example 12 Ephrin A5 receptor as a lung cancer cell surface marker</p><p>[0068] The peptide distribution-correlating tyrosine kinase receptors, belonging to EGFR, FGFR, NGFR and Ephrin receptor families are often up-regulated in many types of cancer. On the other hand, some of the receptors, such as EphA5 presumably targeted by GGS tripeptide and its derivatives predominantly selective for lung tumor-derived cell lines appear to be at least partially specific for the progenitor cancer type. Since this approach clearly allowed identification of cell surface receptors ubiquitously upregulated in various cancers, the inventors took a step further to attempt identification of cancer type-specific receptors. Having chosen lung cancer for the initial procedure establishment, the inventors identified a distinct cluster of five tripeptides associated with lung tumor-derived cell lines. The inventors compared tripeptide frequencies for the 11 cell lines within this cluster with their frequencies for the rest of NCI-60 lines by using statistical tests (Fisher exact, Wilcoxon rank-sum, and t-test). Consistently, the inventors observed that motif GGS was isolated for the clustered lines significantly (P&lt;0.05) more frequently than for the other NCI-60 cell lines (Table 2).</p><p>Table 2 Association of specific tripeptides with lung cancer-derived cell lines:</p><p>&lt;EMI ID=28.1&gt;</p><p>[0069] To determine statistical significance of association or dissociation between exemplary tripeptides and cell lines, normalized frequencies of five tripeptides predominantly associated (GGS, GGR, GLG, and GGL) or dissociated (GSS) with the cluster containing the majority of lung tumor-derived cell lines (FIG. 1, boxed) were compared for cell lines inside the cluster and outside the cluster. Selective association of tripeptide GGS with the clustered cell lines was found significant according to t-test, Fisher exact test and Wilcoxon rank-sum test (all tests one-tailed).</p><p>[0070] Based on the automated BLAST analysis (Table 2) the inventors identified proteins of the ephrin family candidate prototypes of the GGS-containing peptides: ephrins -B3 and A4 contain the GGS, consistent with a functional mimickry. Ephrins (A and B) and their receptors (EphA and EphB) represent a large class of cell-cell communication molecules with well-defined developmental functions. Their role in healthy adult tissues and in human disease is still largely unknown, although diverse roles in carcinogenesis have been postulated and a number of Eph receptors have been found overexpressed by various cancers (Hafner et ah, 2004). Based on the COMPARE analysis of GGS distribution within NCI-60 (Kolonin et al, 2001, Table 2), the receptor expressed in the corresponding pattern is EphA5. The EphA5 expression (FIG. 4 has been explored using cDNA microarray analysis and is reported at the DTP server (dtp.nci.nih.gov/mtweb/servlet/moltidsearch?moltid=MT894), however, no studies of EphA5 function in cancer have been published. Intriguingly EphA5 is not expressed in normal lung and normally is only thought to have brain-specific functions.</p><p>Example 13 Validation of ephrin-mimic peptides in lung cancer</p><p>[0071] To validate phage containing the motif GGS as a ligand of Eph receptors, the inventors tested phage binding to the EphA5 immobilized receptor. The inventors started testing eight peptides (CAGLSGGTC, CSGIGSGGC, CSSGGVLGC, CSWGSGGSC, CTLVLGGSC, CRFESSGGC, CHVSGGSGC, CTGGSLGAC) containing the enriched motif GGS, all of them displayed by phage clones obtained from the screening on different cell lines known to express the E[rho]hA5 receptor (FIG. 3A). From this first round of selection, 5 clones (CAGLSGGTC, CSGIGSGGC, CSSGGVLGC, CRFESSGGC and CSWGSGGSC) showed good binding to the receptor relative to the control (BSA) and were further analyzed by their ability to specifically bind to EphA5 but not to the control EphA4 receptor (FIG. 3B). Phage displaying the peptide sequences CSGIGSGGC and CRFESSGGC showed binding specificity and were chosen for characterization.</p><p>The inventors investigated the binding of the selected phage to the lung cancer cells Hop92 and H460. These cells are known to express EphA5 receptor on its surface, as confirmed by immunofluorescence analysis (FIG. 5). The ovarian cancer cell line OVCAR-3, negative for EphA5 expression, was used as control. [0072] Next, the inventors used the BRASIL method (biopanning and rapid analysis of selective interactive ligands) to analyze binding of selected phage to lung cancer cells. The inventors observed specific binding of phage displaying the sequences CSGIGSGGC and CRFESSGGC to Hop92 and H460, confirming the data obtained from the screening on the immobilized EphA5 receptor (FIG. 6).</p><p>[0073] Finally, by using banked sections or patient tissues from the MD Anderson Cancer Center, the inventors showed that EphA5 protein is overexpressed by human lung adenocarcinoma epithelium.</p><p>[0074] Immunohistochemistry (polyclonal anti-prohibitin antibody) on formalin-fixed paraffin sections of human non-small cell lung cancer (NSLC) or normal prostate with EphA5 or EphA4-specif[iota]c antibodies. Immunostaining demonstrates selective EphA5 upregulation of EphA5 protein expression in NSLC lung adenocarcinoma epithelium, but not stroma, as compared with the control prostate tissue.</p><p>Taken together, these data suggest that the two selected phage displaying the motif GGS are ligands of EphA5 receptor. Upregulation of EphA5 in gliomas has been reported, without any functional connections, and, up to date, there has been no reports of investigation of this tyrosine kinase receptor in lung cancer. Therefore, EphA5 protein overexpression in lung cancer cells (FIG. 4) in light of candidate ephrin mimics (GGS peptides) targeting these cells provides an original evidence for EphA5 being a lung cancer marker and has potential functional implications.</p><p>[0075] It is contemplated by the inventors that the cancer-associated motifs identified here can be used for the development of approaches for targeted imaging or therapy of breast tumors in patients. Their receptors, including EGFR, EphA5, and other cell surface molecules, can be further explored for their oncogenic properties and the potential to serve as universal or origin/grade-selective targets of cancer.</p><p>Example 14 Cell internalization of ephrin-mimic peptides</p><p>[0076] The ability of ephrin-mimic peptides to mediate cell internaization was assessed. The A549 cell line was used as a representative human lung cancer-derived cells expressing the EphA5 receptor on the cell surface. Each phage clone or control insertless phage was incubated with cells for 4h at 37 &lt;0&gt;C. Both CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3) - phage were internalized into A549 cells while only background fluorescence was obtained when nontargeted control phage was used (see FIG. 8). Example 15 Activation of cells by ephrin-mimic peptide</p><p>[0077] Activation of the EphA5 receptor by the peptides CSGIGSGGC (SEQ ID NO: 2) and CRFESSGGC (SEQ ID NO:3) lead to proliferation and/or survival of lung cancer cells. In the absence of sera, this peptides increased lung cancer cells proliferation by 4-fold (FIG. 9A-B). This effect was confirmed in two different human cell lines, which express the EphA5 receptor. </p><p>Table 3. Peptides andMotifs Associated with CCRF-CEM Leukemia</p><p>NCI-60 cell lines. (SEQ ID NO:) GLG CCRF-CEM Leukemia</p><p>GGL EVGGGLT (38) CCRF-CEM Leukemia</p><p>Motif Peptide Cell Line FDARGGL (39) CCRF-CEM Leukemia</p><p>RLS LRLSSIP (6) CCRF-CEM Leukemia GSS CCRF-CEM Leukemia</p><p>RGV ARGVLLM (7) CCRF-CEM Leukemia GSG CCRF-CEM Leukemia</p><p>RGS RGSHLVP (8) CCRF-CEM Leukemia GSV CCRF-CEM Leukemia</p><p>DVETRGS GRV TGRVVRR (40) CCRF-CEM Leukemia</p><p>(9) CCRF-CEM Leukemia</p><p>RAV SRAVIDM (10) CCRF-CEM Leukemia GRL CCRF-CEM Leukemia</p><p>RAS CCRF-CEM Leukemia GPS MGMSGPS (41) CCRF-CEM Leukemia</p><p>GAG CCRF-CEM Leukemia GVS CCRF-CEM Leukemia</p><p>AVS CCRF-CEM Leukemia</p><p>LLS GLLSLXL (H) CCRF-CEM Leukemia RLS HL-60 -Leukemia</p><p>TSLLSFR (12) CCRF-CEM Leukemia RGV AVRGVAR (42) HL-60 -Leukemia</p><p>LLR CCRF-CEM Leukemia DRGVPGL (43) HL-60 -Leukemia</p><p>LRV CCRF-CEM Leukemia RGS LSFSRGS (44) HL-60 -Leukemia</p><p>LRS CCRF-CEM Leukemia RGSVRVL (45) HL-60 -Leukemia</p><p>RVS RRVSLVA (13) CCRF-CEM Leukemia PVRGSVD (46) HL-60 -Leukemia</p><p>SRFRVSI (14) CCRF-CEM Leukemia QVMMRGS (47) HL-60 -Leukemia</p><p>RSS CCRF-CEM Leukemia NGRGSGW (48) HL-60 -Leukemia</p><p>AGS AGSLSVF (15) CCRF-CEM Leukemia RAV RAVGRVA (49) HL-60 -Leukemia</p><p>AGR AGRICEG (16) CCRF-CEM Leukemia RAS RASCALT (50) HL-60 -Leukemia</p><p>QVAGRER (17) CCRF-CEM Leukemia GAG ADIGAGG (51) HL-60 -Leukemia</p><p>VEYAAGR (18) CCRF-CEM Leukemia FMGAGFA (52) HL-60 -Leukemia</p><p>AGL YNRSAGL (19) CCRF-CEM Leukemia AVS AGVFAVS (53) HL-60 -Leukemia</p><p>AGG AVLVAGG (20) CCRF-CEM Leukemia LLS HL-60 -Leukemia</p><p>LAGGVPG (21) CCRF-CEM Leukemia LLR VMLLRPE (54) HL-60 -Leukemia</p><p>GVR DWWAGVR (22) CCRF-CEM Leukemia LLRGLEL (55) HL-60 -Leukemia</p><p>EPDGVRS (23) CCRF-CEM Leukemia LPLLRGI (56) HL-60 -Leukemia</p><p>EQLSGVR (24) CCRF-CEM Leukemia LRV DPRGLRV (57) HL-60 -Leukemia</p><p>GVL GVLARVT (25) CCRF-CEM Leukemia LRS HL-60 -Leukemia</p><p>ARGVLLM (26) CCRF-CEM Leukemia RVS LVRVSGR (58) HL-60 -Leukemia</p><p>GAV GGAVLVA (27) CCRF-CEM Leukemia SGSRVSL (59) HL-60 -Leukemia</p><p>RERGAVQ (28) CCRF-CEM Leukemia RSS HL-60 -Leukemia</p><p>GLV RALGLVS (29) CCRF-CEM Leukemia AGS AGSIALR (60) HL-60 -Leukemia</p><p>GLR SLGLRNQ (30) CCRF-CEM Leukemia AGR MLASAGR (61) HL-60 -Leukemia</p><p>LVS RALGLVS (31) CCRF-CEM Leukemia AGL HL-60 -Leukemia</p><p>GAYRLVS (32) CCRF-CEM Leukemia AGG ADIGAGG (62) HL-60 -Leukemia</p><p>ARG FDARGGL (33) CCRF-CEM Leukemia FAGGSTD (63) HL-60 -Leukemia</p><p>MFARGWE (34) CCRF-CEM Leukemia GVR HL-60 -Leukemia</p><p>ARGVLLM (35) CCRF-CEM Leukemia GVL HL-60 -Leukemia</p><p>ASL CCRF-CEM Leukemia GAV TGFGAVG (64) HL-60 -Leukemia</p><p>AAV CCRF-CEM Leukemia HL-60 -Leukemia</p><p>AAS CCRF-CEM Leukemia GLV HL-60 -Leukemia</p><p>GGS GGGSDGV (36) CCRF-CEM Leukemia GLR FGLRNSR (65) HL-60 -Leukemia</p><p>GGR LGGRADF (37) CCRF-CEM Leukemia DPRGLRV (66) HL-60 -Leukemia</p><p>LVS LVSSGSK (67) HL-60 -Leukemia LVSSSEP (68) HL-60 -Leukemia AGL K-562 -Leukemia</p><p>ARG HL-60 -Leukemia AGG K-562 -Leukemia</p><p>ASL HL-60 -Leukemia GVR K-562 -Leukemia</p><p>AAV AAVWAAD (69) HL-60 -Leukemia GVL GVLHSIA (100) K-562 -Leukemia</p><p>AAS HL-60 -Leukemia GAV RQTTGAV (101) K-562 -Leukemia</p><p>GGS FAGGSTD (70) HL-60 -Leukemia GLV CQGLVLQ (102) K-562 -Leukemia</p><p>GGR HL-60 -Leukemia GLR PPPWGLR (103) K-562 -Leukemia</p><p>GLG HL-60 -Leukemia LVS K-562 -Leukemia</p><p>GGL TFGKGGL (71) HL-60 -Leukemia ARG SNARGPR (104) K-562 -Leukemia</p><p>GSS KSGSSVL (72) HL-60 -Leukemia ASL LLSASLV (105) K-562 -Leukemia</p><p>HL-60 -Leukemia AAV AAVFVRS (106) K-562 -Leukemia</p><p>GSG WGSGRGN (73) HL-60 -Leukemia AAS K-562 -Leukemia</p><p>GSV RGSVRVL (74) HL-60 -Leukemia GGS FFGGSRA (107) K-562 -Leukemia</p><p>PVRGSVD (75) HL-60 -Leukemia GGSQCDT (108) K-562 -Leukemia</p><p>TEGSVTV (76) HL-60 -Leukemia VWGVGGS (109) K-562 -Leukemia</p><p>GRV RAVGRVA (77) HL-60 -Leukemia GGR FAWGGRG (110) K-562 -Leukemia</p><p>DVSGRVP (78) HL-60 -Leukemia GLG GLGIMGP (111) K-562 -Leukemia</p><p>LGQCGRV (79) HL-60 -Leukemia GGL K-562 -Leukemia</p><p>GRL GRLRLTD (80) HL-60 -Leukemia GSS SSGSSNG (112) K-562 -Leukemia</p><p>LELGRLL (81) HL-60 -Leukemia GSG K-562 -Leukemia</p><p>IGRLLPL (82) HL-60 -Leukemia GSV WTKRGSV (113) K-562 -Leukemia</p><p>SDENGRL (83) HL-60 -Leukemia GRV K-562 -Leukemia</p><p>GPS HL-60 -Leukemia GRL K-562 -Leukemia</p><p>GVS HL-60 -Leukemia GPS K-562 -Leukemia</p><p>GVS GVSTGFT (114) K-562 -Leukemia</p><p>RLS K-562 -Leukemia</p><p>RGV ELHPRGV (84) K-562 -Leukemia RLS Molt-4 -Leukemia</p><p>FDRGVEA (85) K-562 -Leukemia RGV CHARGVT (115) Molt-4 -Leukemia</p><p>RGS EAVSRGS (86) K-562 -Leukemia RGS WGRGSVA (116) Molt-4 -Leukemia</p><p>WTKRGSV (87) K-562 -Leukemia RAV Molt-4 -Leukemia</p><p>RAV K-562 -Leukemia RAS Molt-4 -Leukemia</p><p>RAS ERASQTA (88) K-562 -Leukemia GAG LRSGAGS (117) Molt-4 -Leukemia</p><p>GAG K-562 -Leukemia AVS RAAVSAI (118) Molt-4 -Leukemia</p><p>AVS EAVSRGS (89) K-562 -Leukemia AVSGRGW (119) Molt-4 -Leukemia</p><p>LLS AATLLSF (90) K-562 -Leukemia LLS LLSFLGR (120) Molt-4 -Leukemia</p><p>LLSASLV (91) K-562 -Leukemia LLR Molt-4 -Leukemia</p><p>RRHGLLS (92) K-562 -Leukemia LRV Molt-4 -Leukemia</p><p>LLR RYSTLLR (93) K-562 -Leukemia LRS GFYWLRS (121) Molt-4 -Leukemia</p><p>LRV FTLRVDK (94) K-562 -Leukemia RVS RGARVSA (122) Molt-4 -Leukemia</p><p>LRS K-562 -Leukemia RSS GGRSSHP (123) Molt-4 -Leukemia</p><p>RVS SHRVSDS (95) K-562 -Leukemia RSSIAPS (124) Molt-4 -Leukemia</p><p>K-562 -Leukemia AGS LAGSGSH (125) Molt-4 -Leukemia</p><p>RSS NRSSAKF (96) K-562 -Leukemia LRSGAGS (126) Molt-4 -Leukemia</p><p>LRRSSFS (97) K-562 -Leukemia AGR ASVRAGR (127) Molt-4 -Leukemia</p><p>AGS AIRAGSD (98) K-562 -Leukemia AGL Molt-4 -Leukemia</p><p>VLFSAGS (99) K-562 -Leukemia AGG Molt-4 -Leukemia</p><p>AGR K-562 -Leukemia GVR IGVRGFF (128) Molt-4 -Leukemia GVL ANGVLEL (129) Molt-4 -Leukemia LRV RPMI-8226-Leukemia</p><p>Molt-4 -Leukemia LRS LLLRSGG (164) RPMI-8226-Leukemia</p><p>GAV WFGAVGL (130) Molt-4 -Leukemia GRYSLRS (165) RPMI-8226-Leukemia</p><p>GLV GLVRGTA (131) Molt-4 -Leukemia LRSGRGS (166) RPMI-8226-Leukemia</p><p>GLVRGTA Molt-4 -Leukemia LRYDLRS (167) RPMI-8226-Leukemia</p><p>EGLVSVV (132) Molt-4 -Leukemia LRYNLRS (168) RPMI-8226-Leukemia</p><p>GLR DLGLRPV (133) Molt-4 -Leukemia LLRSAAP (169) RPMI-8226-Leukemia</p><p>LVS ALVSRRG (134) Molt-4 -Leukemia SKYRLRS (170) RPMI-8226-Leukemia</p><p>EVLVSGD (135) Molt-4 -Leukemia RVS VHRVSGG (171) RPMI-8226-Leukemia</p><p>EGLVSVV (136) Molt-4 -Leukemia RSS RPMI-8226-Leukemia</p><p>ARG CHARGVT (137) Molt-4 -Leukemia AGS GAGSISD (172) RPMI-8226-Leukemia</p><p>ASL Molt-4 -Leukemia AGR FAGRVPS (173) RPMI-8226-Leukemia</p><p>AAV RAAVSAI (138) Molt-4 -Leukemia AGL AGLSGSQ (174) RPMI-8226-Leukemia</p><p>AAS Molt-4 -Leukemia TDLAGLH (175) RPMI-8226-Leukemia</p><p>GGS HRGGSQS (139) Molt-4 -Leukemia AGG LAAGGEL (176) RPMI-8226-Leukemia</p><p>GGR GGRSSHP (140) Molt-4 -Leukemia GAGGMAR (177) RPMI-8226-Leukemia</p><p>SQSGGRH (141) Molt-4 -Leukemia RAAGGSR (178) RPMI-8226-Leukemia</p><p>GLG ARAIGLG (142) Molt-4 -Leukemia GVR LYGVRYG (179) RPMI-8226-Leukemia</p><p>GGL STEGGGL (143) Molt-4 -Leukemia PRYGVRA (180) RPMI-8226-Leukemia</p><p>GSS Molt-4 -Leukemia GVL RPMI-8226-Leukemia</p><p>GSG LAGSGSH (144) Molt-4 -Leukemia GAV GAVDGSR (181) RPMI-8226-Leukemia</p><p>GSV DGSVLVE (145) Molt-4 -Leukemia GLV ADFFGLV (182) RPMI-8226-Leukemia</p><p>WGRGSVA (146) Molt-4 -Leukemia GLR KYYGLRR (183) RPMI-8226-Leukemia</p><p>GRV ATGRVLG (147) Molt-4 -Leukemia SRYGLRR (184) RPMI-8226-Leukemia</p><p>ATGRVLG (148) Molt-4 -Leukemia LVS RPMI-8226-Leukemia</p><p>FFGRVGI (149) Molt-4 -Leukemia ARG RPMI-8226-Leukemia</p><p>RIGRVWA (150) Molt-4 -Leukemia ASL RPMI-8226-Leukemia</p><p>GRL RGRLEVP (151) Molt-4 -Leukemia AAV RPMI-8226-Leukemia</p><p>GPS Molt-4 -Leukemia AAS PAASRLL (185) RPMI-8226-Leukemia</p><p>GVS Molt-4 -Leukemia RLRAASY (186) RPMI-8226-Leukemia</p><p>RPMI-8226-Leukemia</p><p>RLS RRLSYRD (152) RPMI-8226-Leukemia GGS GGSRLLL (187) RPMI-8226-Leukemia</p><p>SRLSYRG (153) RPMI-8226-Leukemia RAAGGSR (188) RPMI-8226-Leukemia</p><p>RGV FSSKRGV (154) RPMI-8226-Leukemia GGSVRHV (189) RPMI-8226-Leukemia</p><p>RGS RGSAQNF (155) RPMI-8226-Leukemia GGR GGRSWVN (190) RPMI-8226-Leukemia</p><p>LRSGRGS (156) RPMI-8226-Leukemia GLG GLGNRPT (191) RPMI-8226-Leukemia</p><p>LRSGRGS RPMI-8226-Leukemia HGLGSGT (192) RPMI-8226-Leukemia</p><p>LRSGRGS RPMI-8226-Leukemia GGL RPMI-8226-Leukemia</p><p>YRGSSGK (157) RPMI-8226-Leukemia GSS GSSLHLL (193) RPMI-8226-Leukemia</p><p>RAV RPMI-8226-Leukemia YRGSSGK (194) RPMI-8226-Leukemia</p><p>RAS FWISRAS (158) RPMI-8226-Leukemia GSG EGSGVDC (195) RPMI-8226-Leukemia</p><p>GAG GAGSISD (159) RPMI-8226-Leukemia HGLGSGT (196) RPMI-8226-Leukemia</p><p>RAMGGAG (160) RPMI-8226-Leukemia GSV SGSVNRG (197) RPMI-8226-Leukemia</p><p>AVS RPMI-8226-Leukemia GGSVRHV (198) RPMI-8226-Leukemia</p><p>LLS LLSTSIR (161) RPMI-8226-Leukemia GRV FAGRVPS (199) RPMI-8226-Leukemia</p><p>LLR LLLRSGG (162) RPMI-8226-Leukemia GRL AMRPGRL (200) RPMI-8226-Leukemia</p><p>LLRSAAP (163) RPMI-8226-Leukemia GRLYYYR (201) RPMI-8226-Leukemia GPS PAFGPSR (202) RPMI-8226-Leukemia ERARGYP (240) SR Leukemia</p><p>GVS HSGVSHG (203) RPMI-8226-Leukemia GSARGML (241) SR Leukemia</p><p>ASL ASLRYYV (242) SR Leukemia</p><p>RLS VYYRLSA (204) SR Leukemia NAASLPS (243) SR Leukemia</p><p>RGV SR Leukemia WLDASLM (244) SR Leukemia</p><p>RGS GRGSFES (205) SR Leukemia AAV SR Leukemia</p><p>RRGSSRN (206) SR Leukemia AAS NAASLPS (245) SR Leukemia</p><p>RAV HSRAVAP (207) SR Leukemia GGS FHVAGGS (246) SR Leukemia</p><p>RAS RASFRAG(208) SR Leukemia GEHLGGS (247) SR Leukemia</p><p>LMGRASG (209) SR Leukemia GGR SR Leukemia</p><p>WRASAFT (210) SR Leukemia GLG SR Leukemia</p><p>GAG GAGRTVM (211) SR Leukemia GGL SGGLHEG (248) SR Leukemia</p><p>AVS PLAVSMV (212) SR Leukemia</p><p>LLS SR Leukemia</p><p>LLR FLLRSSF(213) SR Leukemia RLS SRLSYRS (249) A549-Lung</p><p>WRLLRRQ (214) SR Leukemia RGV GGLRGVR (250) A549-Lung</p><p>LRV SR Leukemia VAWRGVS (251) A549-Lung</p><p>LRS FLLRSSF(215) SR Leukemia SVEGRGV (252) A549-Lung</p><p>LRSRLGF(216) SR Leukemia RGS FWRGSVP (253) A549-Lung</p><p>RVS GRRVSLV (217) SR Leukemia RAV A549-Lung</p><p>RSS FLLRSSF(218) SR Leukemia RAS EFTRRAS (254) A549-Lung</p><p>NRSSGRR(219) SR Leukemia WGWRASS (255) A549-Lung</p><p>VLGMRSS (220) SR Leukemia GAG A549-Lung</p><p>THRNRSS (221) SR Leukemia AVS A549-Lung</p><p>AGS LAGSTRR (222) SR Leukemia LLS A549-Lung</p><p>AGR AGRTGVG (223) SR Leukemia LLR A549-Lung</p><p>EFAVAGR (224) SR Leukemia LRV A549-Lung</p><p>GAGRTVM (225) SR Leukemia LRS RFYHLRS (256) A549-Lung</p><p>REEFAGR (226) SR Leukemia SRYSLRS (257) A549-Lung</p><p>AGL SR Leukemia RVS A549-Lung</p><p>AGG AGGPTKY (227) SR Leukemia RSS RRSSKQA(258) A549-Lung</p><p>FHVAGGS (228) SR Leukemia DWGRSSF(259) A549-Lung</p><p>WSAGGPH (229) SR Leukemia RFTRSSG(260) A549-Lung</p><p>GVR SR Leukemia VFQRSSG(261) A549-Lung</p><p>GVL SR Leukemia AGS AGSQSWE (262) A549-Lung</p><p>GAV RGAVAFE (230) SR Leukemia AGR A549-Lung</p><p>SGGAVHF (231) SR Leukemia AGL A549-Lung</p><p>GAVRARL (232) SR Leukemia AGG EHPAGGM (263) A549-Lung</p><p>GLV GLVRGFP (233) SR Leukemia GVR GVRTAGP (264) A549-Lung</p><p>GAHGLVR (234) SR Leukemia GGLRGVR (265) A549-Lung</p><p>SSRMGLV (235) SR Leukemia LYGGVRY (266) A549-Lung</p><p>YVGLVVS (236) SR Leukemia GVL PVGGVLL (267) A549-Lung</p><p>GLR GLRKAGF (237) SR Leukemia GAV GAVVKPI (268) A549-Lung</p><p>AVDGLRL (238) SR Leukemia SVGAVGG (269) A549-Lung</p><p>FGLRSRL (239) SR Leukemia GLV GLVSVEA (270) A549-Lung</p><p>LVS SR Leukemia GLR GGLRGVR (271) A549-Lung</p><p>ARG SR Leukemia LVS DIALVSP(272) A549-Lung GLVSVEA (273) A549-Lung AGL AGLSGGT (308) EKVX-Lung</p><p>ARG A549-Lung AGG AGGGPPA (309) EKVX-Lung</p><p>ASL A549-Lung AGGGPPA (310) EKVX-Lung</p><p>AAV A549-Lung FFPAGGP (311) EKVX-Lung</p><p>AAS ARNAASP (274) A549-Lung PRAGGRW (312) EKVX-Lung</p><p>GGS AEGGSGH (275) A549-Lung GVR DVPGVRF (313) EKVX-Lung</p><p>GGSFSGL (276) A549-Lung GVL FGVLFRS (314) EKVX-Lung</p><p>GGR VTGGRVD (277) A549-Lung SRYGVLV (315) EKVX-Lung</p><p>GLG A549-Lung GAV EKVX-Lung</p><p>GGL GGLRGVR (278) A549-Lung GLV LRGGLVS (316) EKVX-Lung</p><p>A549-Lung GLR KSGLRPA (317) EKVX-Lung</p><p>GSS GSSWVVD (279) A549-Lung LVS ALVSFSV (318) EKVX-Lung</p><p>GSSRTFR(280) A549-Lung LRGGLVS (319) EKVX-Lung</p><p>GSSRQFV(281) A549-Lung ARG HKLARGR (320) EKVX-Lung</p><p>WVGSSKF (282) A549-Lung ASL ASLPPRA(321) EKVX-Lung</p><p>GSG AEGGSGH (283) A549-Lung AAV EKVX-Lung</p><p>EVIGSGI (284) A549-Lung AAS EKVX-Lung</p><p>GSV FWRGSVP (285) A549-Lung GGS TGGSLGA (322) EKVX-Lung</p><p>VGSVSVN (286) A549-Lung GGGSWLI (323) EKVX-Lung</p><p>GRV VTGGRVD (287) A549-Lung GGR DGGRRSS (324) EKVX-Lung</p><p>GRVTVAV (288) A549-Lung SVLGGRL (325) EKVX-Lung</p><p>GRL RVGRLGG (289) A549-Lung PRAGGRW (326) EKVX-Lung</p><p>GPS NYMGPSA (290) A549-Lung GLG YWFIGLG (327) EKVX-Lung</p><p>GWHGPSH (291) A549-Lung GGL GGLSVDL (328) EKVX-Lung</p><p>GVS GGVSPVD (292) A549-Lung LRGGLVS (329) EKVX-Lung</p><p>GVSKVRA (293) A549-Lung GSS SGVGSSL (330) EKVX-Lung</p><p>GGVAGVS (294) A549-Lung GSG GSGILDL (331) EKVX-Lung</p><p>VAWRGVS (295) A549-Lung GSV SLGSVGS (332) EKVX-Lung</p><p>GRV EKVX-Lung</p><p>RLS VIGSRLS (296) EKVX-Lung GRL VGRGRLH (333) EKVX-Lung</p><p>RGV HLRGRGV (297) EKVX-Lung SVLGGRL (334) EKVX-Lung</p><p>RGS EVRSRGS (298) EKVX-Lung MSAFGRL (335) EKVX-Lung</p><p>RGSRLPA (299) EKVX-Lung GPS EKVX-Lung</p><p>RAV DVRAVSS (300) EKVX-Lung GVS SGVSGLS (336) EKVX-Lung</p><p>RAS EKVX-Lung</p><p>GAG EKVX-Lung RLS Hop-62-Lung</p><p>AVS DVRAVSS (301) EKVX-Lung RGV GDSRRGV (337) Hop-62-Lung</p><p>LLS EKVX-Lung GKALRGV (338) Hop-62-Lung</p><p>LLR EKVX-Lung RGS PKAGRGS (339) Hop-62-Lung</p><p>LRV EKVX-Lung RAV FDRAVAN (340) Hop-62-Lung</p><p>LRS APLRSGR (302) EKVX-Lung LLRRAVF (341) Hop-62-Lung</p><p>SLRSGIV(303) EKVX-Lung RAS FRASSEV(342) Hop-62-Lung</p><p>RVS EKVX-Lung PDRASDG(343) Hop-62-Lung</p><p>RSS DGGRRSS (304) EKVX-Lung FRASLQY (344) Hop-62-Lung</p><p>AGS QAGSFLR (305) EKVX-Lung GAG Hop-62-Lung</p><p>DAGSDRR (306) EKVX-Lung AVS Hop-62-Lung</p><p>AGR AGRRFGG (307) EKVX-Lung LLS Hop-62-Lung LLR HVGLLRA (345) Hop-62-Lung GRV VRAAGRV (385) Hop-62-Lung</p><p>QVLLRSF (346) Hop-62-Lung GRL HNGRLEV (386) Hop-62-Lung</p><p>LLRRAVF (347) Hop-62-Lung VGRLAKG (387) Hop-62-Lung</p><p>LRV FLRVGEL (348) Hop-62-Lung GPS VMGGPSL (388) Hop-62-Lung</p><p>LRS QVLLRSF (349) Hop-62-Lung GVS GLGVSGV (389) Hop-62-Lung</p><p>RVS RRVSCDL (350) Hop-62-Lung SGVSVEG (390) Hop-62-Lung</p><p>RSS RSSGLGF(351) Hop-62-Lung</p><p>SSGPRSS (352) Hop-62-Lung RLS GESGRLS (391) Hop-92-Lung</p><p>YSQRSSL (353) Hop-62-Lung RGV GSGRGVA (392) Hop-92-Lung</p><p>Hop-62-Lung RGVVSAK (393) Hop-92-Lung</p><p>AGS Hop-62-Lung RGVVSGV (394) Hop-92-Lung</p><p>AGR DAGRTID (354) Hop-62-Lung RGS AVGRGSG (395) Hop-92-Lung</p><p>AAGREFR (355) Hop-62-Lung SLRGSEG (396) Hop-92-Lung</p><p>PKAGRGS (356) Hop-62-Lung PATRGSV (397) Hop-92-Lung</p><p>VRAAGRV (357) Hop-62-Lung RAV SLTRAVR (398) Hop-92-Lung</p><p>Hop-62-Lung VARAVPC (399) Hop-92-Lung</p><p>AGL Hop-62-Lung RAS EGARASD (400) Hop-92-Lung</p><p>AGG HGYRAGG (358) Hop-62-Lung GAG Hop-92-Lung</p><p>WGATAGG (359) Hop-62-Lung AVS MGSAVSL (401) Hop-92-Lung</p><p>YYAGGLK (360) Hop-62-Lung LLS Hop-92-Lung</p><p>GVR LEGVRLF (361) Hop-62-Lung LLR GGALLRG (402) Hop-92-Lung</p><p>GVRPFPR (362) Hop-62-Lung LRV Hop-92-Lung</p><p>GVL GTFGVLG (363) Hop-62-Lung LRS Hop-92-Lung</p><p>VWAGVLL (364) Hop-62-Lung RVS PNRRVSA (403) Hop-92-Lung</p><p>GAV GAVLFRV (365) Hop-62-Lung QDRVSRS (404) Hop-92-Lung</p><p>GLV GLVGFTG (366) Hop-62-Lung RSS SERSSLG(405) Hop-92-Lung</p><p>GLVSAFY (367) Hop-62-Lung LVRSSGL (406) Hop-92-Lung</p><p>GLR ARAMGLR (368) Hop-62-Lung AGS Hop-92-Lung</p><p>LVS GLVSAFY (369) Hop-62-Lung AGR Hop-92-Lung</p><p>SWRPLVS (370) Hop-62-Lung AGL INWAGLS (407) Hop-92-Lung</p><p>ARG Hop-62-Lung WAGLSPS (408) Hop-92-Lung</p><p>ASL FRASLQY (371) Hop-62-Lung AGG GRLLAGG (409) Hop-92-Lung</p><p>AAV HSESAAV (372) Hop-62-Lung GVR Hop-92-Lung</p><p>LFAVAAV (373) Hop-62-Lung GVL Hop-92-Lung</p><p>AAS VAASESH (374) Hop-62-Lung GAV Hop-92-Lung</p><p>GGS Hop-62-Lung GLV SYGLVLP (410) Hop-92-Lung</p><p>GGR HPSMGGR (375) Hop-62-Lung SGGLVLT (411) Hop-92-Lung</p><p>GLG GLGVSGV (376) Hop-62-Lung HAAHGLV (412) Hop-92-Lung</p><p>KRESGLG (377) Hop-62-Lung GLR GLRTRQV (413) Hop-92-Lung</p><p>RSSGLGF(378) Hop-62-Lung LVS LVSGYNG (414) Hop-92-Lung</p><p>VGLGHWP (379) Hop-62-Lung ARG AGIARGG (415) Hop-92-Lung</p><p>GGL YYAGGLK (380) Hop-62-Lung ASL Hop-92-Lung</p><p>GSS NYGSSFH(381) Hop-62-Lung AAV Hop-92-Lung</p><p>FGLGSSR(382) Hop-62-Lung AAS Hop-92-Lung</p><p>SSRPGSS (383) Hop-62-Lung GGS HVSGGSG (416) Hop-92-Lung</p><p>GSG Hop-62-Lung GGSSEFR(417) Hop-92-Lung</p><p>GSV VGSVGLG (384) Hop-62-Lung GGSGIGS(418) Hop-92-Lung SWGSGGS (419) Hop-92-Lung GLV H226 -Lung</p><p>TLVLGGS (420) Hop-92-Lung GLR RGLRSVN (451) H226 -Lung</p><p>GGR AVRGGRP (421) Hop-92-Lung LVS H226 -Lung</p><p>GGRAIGA (422) Hop-92-Lung ARG VARGQMQ (452) H226 -Lung</p><p>GLG Hop-92-Lung ASL H226 -Lung</p><p>GGL SGGLVLT (423) Hop-92-Lung AAV H226 -Lung</p><p>GSS RTGSSDL(424) Hop-92-Lung AAS H226 -Lung</p><p>LGSSRVL (425) Hop-92-Lung GGS GGSRNRW(453) H226 -Lung</p><p>GGSSEFR(426) Hop-92-Lung GGR GGGRSGV (454) H226 -Lung</p><p>GSG AVGRGSG (427) Hop-92-Lung GLG GLGGWVA (455) H226 -Lung</p><p>HVSGGSG (428) Hop-92-Lung GGL AVWGGLG (456) H226 -Lung</p><p>SGIGSGG(429) Hop-92-Lung GGLSECV (457) H226 -Lung</p><p>SWGSGGS (430) Hop-92-Lung GSS H226 -Lung</p><p>WVGSGSP (431) Hop-92-Lung GSG H226 -Lung</p><p>GSV GSGGSVH (432) Hop-92-Lung GSV AKLGSVY (458) H226 -Lung</p><p>GNYGSVL (433) Hop-92-Lung GRV QGRVNVK (459) H226 -Lung</p><p>VGSVVGR (434) Hop-92-Lung GRL GRLWGFW (460) H226 -Lung</p><p>PATRGSV (435) Hop-92-Lung GPS H226 -Lung</p><p>GRV PRGGRVA (436) Hop-92-Lung GVS RGVSLKG (461) H226 -Lung</p><p>GRVHLMP (437) Hop-92-Lung GSLGVSL (462) H226 -Lung</p><p>GRL GESGRLS (438) Hop-92-Lung</p><p>GRLLAGG (439) Hop-92-Lung RLS LLRLSLA (463) H23-Lung</p><p>GRLWWHT (440) Hop-92-Lung RGV H23-Lung</p><p>GRLWSRV (441) Hop-92-Lung RGS RRGSGGL (464) H23-Lung</p><p>GPS AGPSAWL (442) Hop-92-Lung VRGSVRA (465) H23-Lung</p><p>GVS SGVSRGQ (443) Hop-92-Lung RAV H23-Lung</p><p>RAS H23-Lung</p><p>RLS H226 -Lung GAG H23-Lung</p><p>RGV RGVSLKG (444) H226 -Lung AVS H23-Lung</p><p>RGS H226 -Lung LLS H23-Lung</p><p>RAV QMQGRAV (445) H226 -Lung LLR LLRLSLA (466) H23-Lung</p><p>RAS H226 -Lung LRV PLRVDNL (467) H23-Lung</p><p>GAG H226 -Lung LRVGIGY (468) H23-Lung</p><p>AVS H226 -Lung QGYALRV (469) H23-Lung</p><p>LLS H226 -Lung LRS PLRSFDS (470) H23-Lung</p><p>LLR H226 -Lung RVS ARVSGRV (471) H23-Lung</p><p>LRV H226 -Lung RSS PFPARSS (472) H23-Lung</p><p>LRS RGLRSVN (446) H226 -Lung AGS AGSPLAK(473) H23-Lung</p><p>RVS H226 -Lung FVDIAGS (474) H23-Lung</p><p>RSS RSSLGLP(447) H226 -Lung AGR SYFRAGR (475) H23-Lung</p><p>AGS LEAGSQL (448) H226 -Lung AGL AGLGHEG (476) H23-Lung</p><p>AGR H226 -Lung AGG AGGSLGS (477) H23-Lung</p><p>AGL H226 -Lung GVR YGIGVRL (478) H23-Lung</p><p>AGG AGGQSER (449) H226 -Lung GVL RANGVLV (479) H23-Lung</p><p>GVR H226 -Lung GAV H23-Lung</p><p>GVL GGVLYLE (450) H226 -Lung GLV H23-Lung</p><p>GAV H226 -Lung GLR H23-Lung LVS H23-Lung GLR LGLRAFV (514) H322-Lung</p><p>ARG H23-Lung LVS TELVSWS (515) H322-Lung</p><p>ASL LASLGVG (480) H23-Lung ARG CGARGAA (516) H322-Lung</p><p>AAV RAAVGAR (481) H23-Lung ASL H322-Lung</p><p>AAS H23-Lung AAV H322-Lung</p><p>GGS GCDGGSA (482) H23-Lung AAS H322-Lung</p><p>GGSGELG (483) H23-Lung GGS GGSRAAE (517) H322-Lung</p><p>LGGSGRR (484) H23-Lung VNLGGSW (518) H322-Lung</p><p>AGGSLGS (485) H23-Lung GGR LIGPGGR(519) H322-Lung</p><p>GGR IGGREIT(486) H23-Lung GLG H322-Lung</p><p>GLG GEHGLGA (487) H23-Lung GGL LGGLSPH (520) H322-Lung</p><p>GGL RRGSGGL (488) H23-Lung WSGGLNV (521) H322-Lung</p><p>GSS RSGSSVY (489) H23-Lung GSS TAGSSRL (522) H322-Lung</p><p>GSG GLEGSGG (490) H23-Lung SDVSGSS (523) H322-Lung</p><p>LGGSGRR (491) H23-Lung WGSSTVR (524) H322-Lung</p><p>GSV TTGSVIV(492) H23-Lung GSG H322-Lung</p><p>VRGSVRA (493) H23-Lung GSV NLADGSV (525) H322-Lung</p><p>GRV HGRVHRL (494) H23-Lung SSGSVDS (526) H322-Lung</p><p>ARVSGRV (495) H23-Lung GRV GRVPGFE (527) H322-Lung</p><p>GRL H23-Lung GRVVGEA (528) H322-Lung</p><p>GPS H23-Lung GRL H322-Lung</p><p>GVS SGHGVSA (496) H23-Lung GPS SRFGPSV(529) H322-Lung</p><p>GVS ARVGVSP (530) H322-Lung</p><p>RLS AVWRLSH (497) H322-Lung</p><p>RGV RGVFYGK (498) H322-Lung RLS H460-Lung</p><p>RGVGWAK (499) H322-Lung RGV PGKRGVQ (531) H460-Lung</p><p>RGS SRGSTAG (500) H322-Lung RGVASRS (532) H460-Lung</p><p>RAV H322-Lung RGS ERGSPSR(533) H460-Lung</p><p>RAS H322-Lung RAV LIRAVSA(534) H460-Lung</p><p>GAG SEDEGAG (501) H322-Lung RAVEMGT (535) H460-Lung</p><p>STSLGAG (502) H322-Lung RAS H460-Lung</p><p>AVS H322-Lung GAG WGAGFWM (536) H460-Lung</p><p>LLS H322-Lung AVS LIRAVSA (537) H460-Lung</p><p>LLR DLLRYLA (503) H322-Lung LLS H460-Lung</p><p>LRV LRVRYAV (504) H322-Lung LLR H460-Lung</p><p>LRS LRSSGAT (505) H322-Lung LRV H460-Lung</p><p>LSMLRSA (506) H322-Lung LRS DRYMLRS (538) H460-Lung</p><p>RVS REAERVS (507) H322-Lung RVS H460-Lung</p><p>RSS LRSSGAT (508) H322-Lung RSS PRSSYNE (539) H460-Lung</p><p>AGS TAGSSRL (509) H322-Lung PRSSLVV (540) H460-Lung</p><p>AGR AAGRAGC (510) H322-Lung AGS H460-Lung</p><p>AGL GAGLSTS (511) H322-Lung AGR H460-Lung</p><p>AGG H322-Lung AGL RRFWAGL (541) H460-Lung</p><p>GVR PSVGVRA (512) H322-Lung AGG PVHSAGG (542) H460-Lung</p><p>GVL H322-Lung GVR H460-Lung</p><p>GAV VGAVYFL (513) H322-Lung GVL FGGSGVL (543) H460-Lung</p><p>GLV H322-Lung SSGGVLG (544) H460-Lung GAV H460-Lung AGG H522-Lung</p><p>GLV GLVGGSS (545) H460-Lung GVR H522-Lung</p><p>LSSGLVS (546) H460-Lung GVL H522-Lung</p><p>GLR H460-Lung GAV H522-Lung</p><p>LVS LSSGLVS (547) H460-Lung GLV H522-Lung</p><p>WFSWLVS (548) H460-Lung GLR RHFGLRE (566) H522-Lung</p><p>ARG H460-Lung RREGLRS (567) H522-Lung</p><p>ASL GASLTGD (549) H460-Lung H522-Lung</p><p>WSSTASL(550) H460-Lung LVS H522-Lung</p><p>AAV H460-Lung ARG H522-Lung</p><p>AAS H460-Lung ASL GQGAASL (568) H522-Lung</p><p>GGS FGGSGVL (551) H460-Lung AAV H522-Lung</p><p>GLVGGSS (552) H460-Lung AAS GQGAASL (569) H522-Lung</p><p>GGR H460-Lung H522-Lung</p><p>GLG H460-Lung GGS H522-Lung</p><p>GGL GGLSPHR(553) H460-Lung GGR H522-Lung</p><p>GSS GLVGGSS (554) H460-Lung GLG H522-Lung</p><p>SVLGSSL(555) H460-Lung GGL H522-Lung</p><p>GSG FGGSGVL (556) H460-Lung GSS H522-Lung</p><p>GSV H460-Lung GSG H522-Lung</p><p>GRV DVRGRVW (557) H460-Lung GSV YGSVALR (570) H522-Lung</p><p>AEPRGRV (558) H460-Lung H522-Lung</p><p>GRL H460-Lung GRV H522-Lung</p><p>GPS SIGPSTN(559) H460-Lung GRL H522-Lung</p><p>GVS GVSIRQL (560) H460-Lung GPS H522-Lung</p><p>GVS H522-Lung</p><p>RLS H522-Lung</p><p>RGV H522-Lung RLS COLO-205-Colon</p><p>RGS H522-Lung RGV ARRGVLG (571) COLO-205-Colon</p><p>RAV H522-Lung LRIARGV (572) COLO-205-Colon</p><p>RAS H522-Lung RGS YRGSMVG (573) COLO-205-Colon</p><p>GAG H522-Lung GLRGSVW (574) COLO-205-Colon</p><p>AVS AVSKRLP (561) H522-Lung RAV GPFRAVP (575) COLO-205-Colon</p><p>RLAVSGY (562) H522-Lung RAS COLO-205-Colon</p><p>H522-Lung GAG COLO-205-Colon</p><p>LLS H522-Lung AVS COLO-205-Colon</p><p>LLR H522-Lung LLS COLO-205-Colon</p><p>LRV H522-Lung LLR COLO-205-Colon</p><p>LRS RREGLRS (563) H522-Lung LRV COLO-205-Colon</p><p>SRYWLRS (564) H522-Lung LRS AHYTLRS (576) COLO-205-Colon</p><p>H522-Lung SELRSIR(577) COLO-205-Colon</p><p>RVS H522-Lung SVYALRS (578) COLO-205-Colon</p><p>RSS H522-Lung RVS COLO-205-Colon</p><p>AGS H522-Lung RSS COLO-205-Colon</p><p>AGR AVYRAGR (565) H522-Lung AGS COLO-205-Colon</p><p>H522-Lung AGR COLO-205-Colon</p><p>AGL H522-Lung AGL COLO-205-Colon AGG COLO-205-Colon AGR HCC-2998-Colon</p><p>GVR COLO-205-Colon AGL HCC-2998-Colon</p><p>GVL ARRGVLG (579) COLO-205-Colon AGG AAGGLLV (605) HCC-2998-Colon</p><p>GAV PGAVLTV (580) COLO-205-Colon GVR HCC-2998-Colon</p><p>GLV GLVGRRA (581) COLO-205-Colon GVL HCC-2998-Colon</p><p>GLVRCVL (582) COLO-205-Colon GAV HCC-2998-Colon</p><p>YDGLVSG (583) COLO-205-Colon GLV HCC-2998-Colon</p><p>GLVTAPL (584) COLO-205-Colon GLR HCC-2998-Colon</p><p>RGLVRVV (585) COLO-205-Colon LVS HCC-2998-Colon</p><p>GLR GLRGSVW (586) COLO-205-Colon ARG HCC-2998-Colon</p><p>NSFGLRY (587) COLO-205-Colon ASL LRASLLW (606) HCC-2998-Colon</p><p>LVS YDGLVSG (588) COLO-205-Colon AAV HCC-2998-Colon</p><p>ARG AARGLEA (589) COLO-205-Colon AAS HCC-2998-Colon</p><p>DNDGARG (590) COLO-205-Colon GGS HCC-2998-Colon</p><p>LRIARGV (591) COLO-205-Colon GGR HCC-2998-Colon</p><p>ASL COLO-205-Colon GLG LWGLGWL (607) HCC-2998-Colon</p><p>AAV MSNLAAV (592) COLO-205-Colon RRSGLGD (608) HCC-2998-Colon</p><p>AAS COLO-205-Colon WWGLGWL (609) HCC-2998-Colon</p><p>GGS COLO-205-Colon GGL AAGGLLV (610) HCC-2998-Colon</p><p>GGR COLO-205-Colon GSS HCC-2998-Colon</p><p>GLG COLO-205-Colon GSG HCC-2998-Colon</p><p>GGL COLO-205-Colon GSV HCC-2998-Colon</p><p>GSS YSGSSDF(593) COLO-205-Colon GRV HCC-2998-Colon</p><p>GSG COLO-205-Colon GRL HCC-2998-Colon</p><p>GSV GSVLGDY (594) COLO-205-Colon GPS HCC-2998-Colon</p><p>GLRGSVW (595) COLO-205-Colon GVS HCC-2998-Colon</p><p>GRV DLDGRVV (596) COLO-205-Colon</p><p>GRL WVSGRLG (597) COLO-205-Colon RLS HCT-116 Colon</p><p>GPS GPSSMTF(598) COLO-205-Colon RGV GLRGVVK (611) HCT-116 Colon</p><p>GVS DGVSSDY (599) COLO-205-Colon RGS AVEGRGS (612) HCT-116 Colon</p><p>FTSGVSW (600) COLO-205-Colon NAVRGSA (613) HCT-116 Colon</p><p>RAV HCT-116 Colon</p><p>RLS HCC-2998-Colon RAS HCT-116 Colon</p><p>RGV HCC-2998-Colon GAG HCT-116 Colon</p><p>RGS HCC-2998-Colon AVS HCT-116 Colon</p><p>RAV HCC-2998-Colon LLS HCT-116 Colon</p><p>RAS VLTRAST (601) HCC-2998-Colon LLR LLRSSLG (614) HCT-116 Colon</p><p>LRASLLW (602) HCC-2998-Colon MYLRLLR (615) HCT-116 Colon</p><p>GAG HCC-2998-Colon LRV HCT-116 Colon</p><p>AVS HCC-2998-Colon LRS LLRSSLG(616) HCT-116 Colon</p><p>LLS WLLSARL (603) HCC-2998-Colon DEGLRSR (617) HCT-116 Colon</p><p>LLR LLRPGTV (604) HCC-2998-Colon RVS YWQHRVS (618) HCT-116 Colon</p><p>LRV HCC-2998-Colon RSS ARSSHRA(619) HCT-116 Colon</p><p>LRS HCC-2998-Colon LLRSSLG(620) HCT-116 Colon</p><p>RVS HCC-2998-Colon AGS HCT-116 Colon</p><p>RSS HCC-2998-Colon AGR AGRSCNL (621) HCT-116 Colon</p><p>AGS HCC-2998-Colon AGRPRAT (622) HCT-116 Colon AGL HCT-116 Colon WRVRSSG (655) HCT-15 Colon</p><p>AGG HCT-116 Colon AGS HCT-15 Colon</p><p>GVR GGVRIAA (623) HCT-116 Colon AGR AAGRIRP (656) HCT-15 Colon</p><p>GVRYLRT (624) HCT-116 Colon RAAGRVG (657) HCT-15 Colon</p><p>GVL HCT-116 Colon AGL AGLQHAV (658) HCT-15 Colon</p><p>GAV HCT-116 Colon AGG AGGWWVG (659) HCT-15 Colon</p><p>GLV PLAVGLV (625) HCT-116 Colon GVR GVRGAAR (660) HCT-15 Colon</p><p>GLR GLRGVVK (626) HCT-116 Colon GVL GVLPVVT (661) HCT-15 Colon</p><p>DEGLRSR (627) HCT-116 Colon GVLPVVT HCT-15 Colon</p><p>LVS QLVSGSL (628) HCT-116 Colon GAV HCT-15 Colon</p><p>ARG HCT-116 Colon GLV GLVSSLP (662) HCT-15 Colon</p><p>ASL GWSASLG (629) HCT-116 Colon SRHGLVR (663) HCT-15 Colon</p><p>AAV IAAVWRS (630) HCT-116 Colon SDRGLVV (664) HCT-15 Colon</p><p>AAS HCT-116 Colon SDRGLVV (665) HCT-15 Colon</p><p>GGS GGSSLDA (631) HCT-116 Colon GLR HCT-15 Colon</p><p>LGGSRDL (632) HCT-116 Colon LVS GLVSSLP(666) HCT-15 Colon</p><p>GGR LIGGRNA (633) HCT-116 Colon LVSVWSR (667) HCT-15 Colon</p><p>GLG HCT-116 Colon ARG GSWARGY (668) HCT-15 Colon</p><p>GGL LDRSGGL (634) HCT-116 Colon ASL GFASLLR (669) HCT-15 Colon</p><p>GSS GGSSLDA (635) HCT-116 Colon AAV HAAVMSL (670) HCT-15 Colon</p><p>GSSYSGP(636) HCT-116 Colon AAS HCT-15 Colon</p><p>GSG TVGSGCL (637) HCT-116 Colon GGS HCT-15 Colon</p><p>GSV LSGSVLQ (638) HCT-116 Colon GGR DGGRRTD (671) HCT-15 Colon</p><p>GRV ASGRVAN (639) HCT-116 Colon GRPLGGR (672) HCT-15 Colon</p><p>GRL KVVGRLG (640) HCT-116 Colon GRVTGGR (673) HCT-15 Colon</p><p>GRLVWGL (641) HCT-116 Colon GLG HCT-15 Colon</p><p>NEFLGRL (642) HCT-116 Colon GGL RGGLPRG (674) HCT-15 Colon</p><p>GPS LCDAGPS (643) HCT-116 Colon YGQYGGL (675) HCT-15 Colon</p><p>GVS FRAGVSH (644) HCT-116 Colon GSS GSSRPSI (676) HCT-15 Colon</p><p>PGSSFVG (677) HCT-15 Colon</p><p>RLS AGDSRLS (645) HCT-15 Colon GSSRVRW (678) HCT-15 Colon</p><p>RGV HCT-15 Colon GSG HCT-15 Colon</p><p>RGS HCT-15 Colon GSV HCT-15 Colon</p><p>RAV DWRRRAV (646) HCT-15 Colon GRV RAAGRVG (679) HCT-15 Colon</p><p>RAS WTERASA (647) HCT-15 Colon GRVTGGR (680) HCT-15 Colon</p><p>GAG HCT-15 Colon YVRIGRV (681) HCT-15 Colon</p><p>AVS HCT-15 Colon GRL MITRGRL (682) HCT-15 Colon</p><p>LLS RLLSAFG (648) HCT-15 Colon GPS HCT-15 Colon</p><p>LLR GFASLLR (649) HCT-15 Colon GVS SVVGVST (683) HCT-15 Colon</p><p>LRV GALRVPW (650) HCT-15 Colon WSGVSRL (684) HCT-15 Colon</p><p>GALRVPW HCT-15 Colon</p><p>GALRVPW HCT-15 Colon RLS RRLSYFH (685) HT-29 Colon</p><p>LRS SLRSDGA (651) HCT-15 Colon PRLSWVL (686) HT-29 Colon</p><p>DTLRSQW (652) HCT-15 Colon RLSALTD (687) HT-29 Colon</p><p>LRSVGSW (653) HCT-15 Colon RGV GRGVGTD (688) HT-29 Colon</p><p>RVS HCT-15 Colon LKVRGVL (689) HT-29 Colon</p><p>RSS ISPRSSG(654) HCT-15 Colon SSTRGVY (690) HT-29 Colon QVRRGVV (691) HT-29 Colon LVS LAGLVSG (736) HT-29 Colon</p><p>GRGVTIW (692) HT-29 Colon LGLVSTT (737) HT-29 Colon</p><p>RGS RGSVASA (693) HT-29 Colon RQLVSPA(738) HT-29 Colon</p><p>HFIRGSV (694) HT-29 Colon ARG LRARGGH (739) HT-29 Colon</p><p>RGSWAGV (695) HT-29 Colon ASL ELWASLG (740) HT-29 Colon</p><p>VRGSRWR (696) HT-29 Colon DTLASLR (741) HT-29 Colon</p><p>RAV LERAVRT (697) HT-29 Colon VVASLPH (742) HT-29 Colon</p><p>RAS GYSRASD (698) HT-29 Colon AAV HT-29 Colon</p><p>SRASGHG (699) HT-29 Colon AAS VLRAASR (743) HT-29 Colon</p><p>GHYRASV (700) HT-29 Colon AASGSYY (744) HT-29 Colon</p><p>DWVCRAS (701) HT-29 Colon GGS GGSALFG (745) HT-29 Colon</p><p>GAG GAGRGTP (702) HT-29 Colon GRGGSGY (746) HT-29 Colon</p><p>LSLAGAG (703) HT-29 Colon GGR YGSGGRG (747) HT-29 Colon</p><p>AVS ASAVSGR (704) HT-29 Colon GTLGGRV (748) HT-29 Colon</p><p>FSGDAVS (705) HT-29 Colon AGGRWNL (749) HT-29 Colon</p><p>LLS LKLLSVP (706) HT-29 Colon HGGRARL (750) HT-29 Colon</p><p>LLR HT-29 Colon RGGRSPS (751) HT-29 Colon</p><p>LRV GTLRVGS (707) HT-29 Colon RKPGGGR (752) HT-29 Colon</p><p>LRS EHYRLRS (708) HT-29 Colon EGGRTHW (753) HT-29 Colon</p><p>LRSWLLF (709) HT-29 Colon GLG GEVGLGV (754) HT-29 Colon</p><p>RRPGLRS (710) HT-29 Colon GLGAVGW (755) HT-29 Colon</p><p>SKYNLRS (711) HT-29 Colon GGL PGGLVPG (756) HT-29 Colon</p><p>WQVALRS (712) HT-29 Colon VRGGLTG (757) HT-29 Colon</p><p>LRSDPRS (713) HT-29 Colon RQKCGGL (758) HT-29 Colon</p><p>VPLRSSA(714) HT-29 Colon RYGVGGL (759) HT-29 Colon</p><p>RVS HT-29 Colon GSS EMGSSRG (760) HT-29 Colon</p><p>RSS GRSSGME (715) HT-29 Colon GSG AGSGFPF(761) HT-29 Colon</p><p>VPLRSSA (716) HT-29 Colon GRGGSGY (762) HT-29 Colon</p><p>AGS AGSGFPF(717) HT-29 Colon GSV GSVSAGA (763) HT-29 Colon</p><p>AGR GAGRGTP (718) HT-29 Colon RGSVASA (764) HT-29 Colon</p><p>AGRIASK (719) HT-29 Colon DLGSVQH (765) HT-29 Colon</p><p>AGL WGVAGLG (720) HT-29 Colon HFIRGSV(766) HT-29 Colon</p><p>LAGLVSG (721) HT-29 Colon GSVLGAL (767) HT-29 Colon</p><p>AGG DAGGMDL (722) HT-29 Colon GRV GTLGGRV (768) HT-29 Colon</p><p>AGGRWNL (723) HT-29 Colon LGRVHVW (769) HT-29 Colon</p><p>GVR GCGGVRD (724) HT-29 Colon LVGRVKL (770) HT-29 Colon</p><p>SGVRLTG (725) HT-29 Colon RWRSGRV (771) HT-29 Colon</p><p>GVL LKVRGVL (726) HT-29 Colon GRL RNPGRLA (772) HT-29 Colon</p><p>GAV GLGAVGW (727) HT-29 Colon PRGRLFD (773) HT-29 Colon</p><p>PGAVPGA (728) HT-29 Colon GRLAVVA (774) HT-29 Colon</p><p>RIGAVWY (729) HT-29 Colon LAQGRLA (775) HT-29 Colon</p><p>GLV FSGLVVA (730) HT-29 Colon GGMNGRL (776) HT-29 Colon</p><p>PGGLVPG (731) HT-29 Colon GPS RSTLGPS (777) HT-29 Colon</p><p>LAGLVSG (732) HT-29 Colon GVS GVSALSL (778) HT-29 Colon</p><p>LGLVSTT (733) HT-29 Colon</p><p>GLR GLRLGVT (734) HT-29 Colon RLS SRLSYYA (779) KM-12C Colon</p><p>RRPGLRS (735) HT-29 Colon SRLSYYA KM-12C Colon RGV ARGVSAP (780) KM-12C Colon GSV RVGSVQW (802) KM-12C Colon</p><p>GRGVLAF (781) KM-12C Colon EGTSGSV(803) KM-12C Colon</p><p>RGS MRGSGRN (782) KM-12C Colon GRV GRVPTVV (804) KM-12C Colon</p><p>RAV RDGRAVR (783) KM-12C Colon KM-12C Colon</p><p>GRAVWMV (784) KM-12C Colon GRL ADGRLRY (805) KM-12C Colon</p><p>RAS KM-12C Colon GPS KM-12C Colon</p><p>GAG KM-12C Colon GVS ARGVSAP (806) KM-12C Colon</p><p>AVS KM-12C Colon</p><p>LLS KM-12C Colon RLS SW620-Colon</p><p>LLR KM-12C Colon RGV RGVKLGD (807) SW620-Colon</p><p>LRV LRVPGGP (785) KM-12C Colon RGS LRGSYVL (808) SW620-Colon</p><p>LRS AYYSLRS (786) KM-12C Colon RRGSLMF (809) SW620-Colon</p><p>AYYSLRS KM-12C Colon RGSVGPS (810) SW620-Colon</p><p>VLRSALQ (787) KM-12C Colon RAV SW620-Colon</p><p>VYYALRS (788) KM-12C Colon RAS SRASDVT (811) SW620-Colon</p><p>VYYALRS KM-12C Colon GAG SW620-Colon</p><p>VYYALRS KM-12C Colon AVS SW620-Colon</p><p>VYYALRS KM-12C Colon LLS AAKTLLS (812) SW620-Colon</p><p>VYYALRS KM-12C Colon LLR SW620-Colon</p><p>VYYALRS KM-12C Colon LRV SW620-Colon</p><p>VYYALRS KM-12C Colon LRS RSYPLRS (813) SW620-Colon</p><p>RVS RYRVSVY (789) KM-12C Colon RVS YLGRRVS (814) SW620-Colon</p><p>RSS KM-12C Colon RSS RSSPVWT (815) SW620-Colon</p><p>AGS KM-12C Colon AGS DLRRAGS (816) SW620-Colon</p><p>AGR KM-12C Colon AGR SW620-Colon</p><p>AGL KM-12C Colon AGL GVAGLRW (817) SW620-Colon</p><p>AGG AGGIWIR(790) KM-12C Colon AGG RIDAGGG(818) SW620-Colon</p><p>GVR WQVSGVR (791) KM-12C Colon GVAGGAT (819) SW620-Colon</p><p>GVL GRGVLAF (792) KM-12C Colon GVR SW620-Colon</p><p>GAV KM-12C Colon GVL SW620-Colon</p><p>GLV KM-12C Colon GAV TAGGAVG (820) SW620-Colon</p><p>GLR KM-12C Colon WRLGAVG (821) SW620-Colon</p><p>LVS HAELVSL (793) KM-12C Colon GLV SGLVAMV (822) SW620-Colon</p><p>ARG ARGVSAP (794) KM-12C Colon GLR VGLRDWG (823) SW620-Colon</p><p>RVARGDR (795) KM-12C Colon GVAGLRW (824) SW620-Colon</p><p>VMWVARG (796) KM-12C Colon LVS SW620-Colon</p><p>ASL KM-12C Colon ARG ARGIVRV (825) SW620-Colon</p><p>AAV AAVTVVR (797) KM-12C Colon ASL ASLHHRR (826) SW620-Colon</p><p>AAS KM-12C Colon AAV SW620-Colon</p><p>GGS KM-12C Colon AAS GAAASGY (827) SW620-Colon</p><p>GGR KM-12C Colon GGS SW620-Colon</p><p>GLG KM-12C Colon GGR SW620-Colon</p><p>GGL TREGGLD (798) KM-12C Colon GLG LAIRGLG (828) SW620-Colon</p><p>LGGGGLL (799) KM-12C Colon GGL GGLSNVV (829) SW620-Colon</p><p>GSS KM-12C Colon PPGGLKW(830) SW620-Colon</p><p>GSG GSGHSFA(800) KM-12C Colon GSS SW620-Colon</p><p>MRGSGRN (801) KM-12C Colon GSG SW620-Colon GSV EGSVDAH (831) SW620-Colon GSS FGSSNRS (866) SF-268 CNS</p><p>RGSVGPS (832) SW620-Colon GSG SF-268 CNS</p><p>GRV SW620-Colon GSV GSVSDRF(867) SF-268 CNS</p><p>GRL LVYSGRL (833) SW620-Colon GRV SF-268 CNS</p><p>VEEGRLR (834) SW620-Colon GRL AGGRLGL (868) SF-268 CNS</p><p>GPS RGSVGPS (835) SW620-Colon GPS WFKGPSV (869) SF-268 CNS</p><p>GVS SPGVSGR(836) SW620-Colon GVS SF-268 CNS</p><p>RGV RVGRGVL (837) SF-268 CNS RLS SF-295 CNS</p><p>RGS SF-268 CNS RGV LSERRGV (870) SF-295 CNS</p><p>RAV WIWRAVS (838) SF-268 CNS ARGVAEY (871) SF-295 CNS</p><p>RAS SF-268 CNS SF-295 CNS</p><p>GAG VTDGAGQ (839) SF-268 CNS RGS FDRGSLT (872) SF-295 CNS</p><p>AVS LGTAVSS (840) SF-268 CNS SF-295 CNS</p><p>WIWRAVS (841) SF-268 CNS RAV SF-295 CNS</p><p>DTPSAVS (842) SF-268 CNS RAS GRLRASL (873) SF-295 CNS</p><p>LLS GLLSAGI (843) SF-268 CNS SF-295 CNS</p><p>LLR YLLRALG (844) SF-268 CNS GAG RDGRGAG (874) SF-295 CNS</p><p>LRV SF-268 CNS SF-295 CNS</p><p>LRS LRSGSLG (845) SF-268 CNS AVS GAVSVLA (875) SF-295 CNS</p><p>PLRSVWS (846) SF-268 CNS TRGDAVS (876) SF-295 CNS</p><p>RVS SF-268 CNS SF-295 CNS</p><p>RSS ARSSIVR(847) SF-268 CNS LLS LLSPRGT (877) SF-295 CNS</p><p>AGS SF-268 CNS SF-295 CNS</p><p>AGR SF-268 CNS LLR LLRSHGV (878) SF-295 CNS</p><p>AGL SF-268 CNS SF-295 CNS</p><p>AGG AGGRLGL (848) SF-268 CNS LRV PLRVLKR (879) SF-295 CNS</p><p>AGGWRGR (849) SF-268 CNS GRLRLRV (880) SF-295 CNS</p><p>GVR LVGRGVR (850) SF-268 CNS SF-295 CNS</p><p>GVL DVVGVLK (851) SF-268 CNS LRS LLRSHGV (881) SF-295 CNS</p><p>RVGRGVL (852) SF-268 CNS VLRSGEL (882) SF-295 CNS</p><p>GAV GAVTGYP (853) SF-268 CNS VLRSIPS (883) SF-295 CNS</p><p>GLV WGLVRHA (854) SF-268 CNS VLRSIPS SF-295 CNS</p><p>GLR LGLRGGA (855) SF-268 CNS SF-295 CNS</p><p>LVS SF-268 CNS RVS GSMHRVS (884) SF-295 CNS</p><p>ARG SF-268 CNS YSIMRVS (885) SF-295 CNS</p><p>ASL IGASLLG (856) SF-268 CNS SF-295 CNS</p><p>AAV AAVETGV (857) SF-268 CNS RSS SF-295 CNS</p><p>AAS SF-268 CNS AGS RAGSRVQ (886) SF-295 CNS</p><p>GGS GLGGGGS (858) SF-268 CNS SF-295 CNS</p><p>GGR EVLWGGR (859) SF-268 CNS AGR RRDAGRM (887) SF-295 CNS</p><p>AGGRLGL (860) SF-268 CNS GAGRGDR (888) SF-295 CNS</p><p>GGRSKKV (861) SF-268 CNS SF-295 CNS</p><p>GLG GLGGGGS (862) SF-268 CNS AGL RWAGLVA (889) SF-295 CNS</p><p>GGL SGGGGLG (863) SF-268 CNS SF-295 CNS</p><p>GAYGGLL (864) SF-268 CNS AGG QTLSAGG (890) SF-295 CNS</p><p>GGLSRSN (865) SF-268 CNS LAGGWGS (891) SF-295 CNS SF-295 CNS RGV SNB-19 CNS</p><p>GVR RHGVRSK (892) SF-295 CNS RGS ARGSLRV (914) SNB-19 CNS</p><p>SF-295 CNS FSPRGSV(915) SNB-19 CNS</p><p>GVL SF-295 CNS RAV GGRLRAV (916) SNB-19 CNS</p><p>GAV GAVSVLA (893) SF-295 CNS RAS SNB-19 CNS</p><p>SF-295 CNS GAG SNB-19 CNS</p><p>GLV RWAGLVA (894) SF-295 CNS AVS VLSAVSS (917) SNB-19 CNS</p><p>SF-295 CNS LLS SNB-19 CNS</p><p>GLR GRGLRTD (895) SF-295 CNS LLR SNB-19 CNS</p><p>TLGGLRT (896) SF-295 CNS LRV ARGSLRV (918) SNB-19 CNS</p><p>SF-295 CNS LRS LRSYAWS (919) SNB-19 CNS</p><p>LVS ALVSVAG (897) SF-295 CNS RVS KGRVSAG (920) SNB-19 CNS</p><p>SF-295 CNS RSS SNB-19 CNS</p><p>ARG ARGVAEY (898) SF-295 CNS AGS SNB-19 CNS</p><p>SF-295 CNS AGR SNB-19 CNS</p><p>ASL GGASLTQ (899) SF-295 CNS AGL AGLTIGI (921) SNB-19 CNS</p><p>GRLRASL (900) SF-295 CNS AGG AWRHAGG (922) SNB-19 CNS</p><p>SNHTASL (901) SF-295 CNS WARAGGF (923) SNB-19 CNS</p><p>SF-295 CNS GVR SNB-19 CNS</p><p>AAV YADGAAV (902) SF-295 CNS GVL MGVLTAE (924) SNB-19 CNS</p><p>SF-295 CNS FAGYGVL (925) SNB-19 CNS</p><p>AAS SF-295 CNS GAV RIFHGAV (926) SNB-19 CNS</p><p>GGS SF-295 CNS GLV EGLVVFE (927) SNB-19 CNS</p><p>GGR SF-295 CNS GLR REVPGLR (928) SNB-19 CNS</p><p>GLG LGGLGIH (903) SF-295 CNS LVS LVSVNGA (929) SNB-19 CNS</p><p>SF-295 CNS HSLVSQP(930) SNB-19 CNS</p><p>GGL GGFTGGL (904) SF-295 CNS ARG ARGSLRV (931) SNB-19 CNS</p><p>HIGLGGL (905) SF-295 CNS ASL SSVASLV (932) SNB-19 CNS</p><p>TRLGGLT (906) SF-295 CNS AAV AAVWQMK (933) SNB-19 CNS</p><p>SF-295 CNS QRAAVIV (934) SNB-19 CNS</p><p>GSS SF-295 CNS AAS SNB-19 CNS</p><p>GSG SF-295 CNS GGS PGGSDAA(935) SNB-19 CNS</p><p>GSV VMPGSVV (907) SF-295 CNS GGR GGRLRAV (936) SNB-19 CNS</p><p>SF-295 CNS GLG SNB-19 CNS</p><p>GRV SF-295 CNS GGL LPCGGLA (937) SNB-19 CNS</p><p>GRL GRLRASL (908) SF-295 CNS GSS GSSHDAL (938) SNB-19 CNS</p><p>GRLYLGI (909) SF-295 CNS TQYYGSS (939) SNB-19 CNS</p><p>GRLRLRV (910) SF-295 CNS GSG SNB-19 CNS</p><p>SF-295 CNS GSV FSPRGSV(940) SNB-19 CNS</p><p>SF-295 CNS GRV KGRVSAG (941) SNB-19 CNS</p><p>GPS SHCGPSN(911) SF-295 CNS QGRVNVK (942) SNB-19 CNS</p><p>SHCGPSN SF-295 CNS GRL GGRLRAV (943) SNB-19 CNS</p><p>SF-295 CNS YDGRLAR (944) SNB-19 CNS</p><p>GVS SF-295 CNS GPS SNB-19 CNS</p><p>GVS SNB-19 CNS</p><p>RLS VRLSGRA (912) SNB-19 CNS</p><p>RLSTFAG (913) SNB-19 CNS RLS SNB-75 CNS RGV PQGRGVK (945) SNB-75 CNS GVS SNB-75 CNS</p><p>RGS MVLRGSY (946) SNB-75 CNS</p><p>RAV GGWARAV (947) SNB-75 CNS RLS U251 CNS</p><p>VRAVCLM (948) SNB-75 CNS RGV U251 CNS</p><p>RAS TRASRRG (949) SNB-75 CNS RGS RGSRTGPC U251 CNS</p><p>GAG LGAGEGD (950) SNB-75 CNS RAV U251 CNS</p><p>AVS IGAVSGW (951) SNB-75 CNS RAS U251 CNS</p><p>LLS LLSRRVG (952) SNB-75 CNS GAG U251 CNS</p><p>LELLSVV (953) SNB-75 CNS AVS U251 CNS</p><p>RLLSEGY (954) SNB-75 CNS LLS U251 CNS</p><p>LLR QLPGLLR (955) SNB-75 CNS LLR U251 CNS</p><p>YGESLLR (956) SNB-75 CNS LRV U251 CNS</p><p>LRV LRVYGEG (957) SNB-75 CNS LRS U251 CNS</p><p>LRS SNB-75 CNS RVS U251 CNS</p><p>RVS YRVSSGS (958) SNB-75 CNS RSS U251 CNS</p><p>RSS RSSSSTR(959) SNB-75 CNS AGS U251 CNS</p><p>AGS WAGSNYS (960) SNB-75 CNS AGR U251 CNS</p><p>AGR CAGRARR (961) SNB-75 CNS AGL U251 CNS</p><p>AGL IAGLAVV (962) SNB-75 CNS AGG U251 CNS</p><p>DGEGAGL (963) SNB-75 CNS GVR U251 CNS</p><p>AGG ALAGGGL (964) SNB-75 CNS GVL U251 CNS</p><p>GVR GVRRSLL (965) SNB-75 CNS GAV U251 CNS</p><p>GVL ADWGVLE (966) SNB-75 CNS GLV U251 CNS</p><p>GAV IGAVSGW (967) SNB-75 CNS GLR U251 CNS</p><p>GLV ASGLVVT (968) SNB-75 CNS LVS U251 CNS</p><p>GLR IGLRGEN (969) SNB-75 CNS ARG U251 CNS</p><p>LVS SNB-75 CNS ASL U251 CNS</p><p>ARG RRARGAC (970) SNB-75 CNS AAV U251 CNS</p><p>ASL YAASLMG (971) SNB-75 CNS AAS U251 CNS</p><p>AAV LTAAVMV (972) SNB-75 CNS GGS U251 CNS</p><p>AAS YAASLMG (973) SNB-75 CNS GGR U251 CNS</p><p>GGS RARTGGS (974) SNB-75 CNS GLG U251 CNS</p><p>VSGDGGS (975) SNB-75 CNS GGL U251 CNS</p><p>GGR FGGRSLS (976) SNB-75 CNS GSS GSSACGA (989) U251 CNS</p><p>SLGGRTF (977) SNB-75 CNS GSG U251 CNS</p><p>GLG ARRGLGL (978) SNB-75 CNS GSV U251 CNS</p><p>GGL ALAGGGL (979) SNB-75 CNS GRV 0251 CNS</p><p>FRALGGL (980) SNB-75 CNS GRL U251 CNS</p><p>FTRGGLS (981) SNB-75 CNS GPS U251 CNS</p><p>GSS SGSSVRY (982) SNB-75 CNS GVS U251 CNS</p><p>GSG SNB-75 CNS</p><p>GSV WGSVAGI (983) SNB-75 CNS RLS VRLSGRA (990) SF-539 CNS</p><p>SGGDGSV (984) SNB-75 CNS RLSTFAG (991) SF-539 CNS</p><p>GRV SNB-75 CNS RGV SF-539 CNS</p><p>GRL NEGRLGI (985) SNB-75 CNS RGS ARGSLRV (992) SF-539 CNS</p><p>YSGRLVM (986) SNB-75 CNS FSPRGSV(993) SF-539 CNS</p><p>GPS DGPSGCS (987) SNB-75 CNS RAV GGRLRAV (994) SF-539 CNS RAS SF-539 CNS RAS LOX--IMVI Melanoma</p><p>GAG SF-539 CNS GAG IFGAGLR (1026) LOX--IMVI Melanoma</p><p>AVS VLSAVSS (995) SF-539 CNS AVS GWVAVSC (1027) LOX--IMVI Melanoma</p><p>LLS SF-539 CNS LLS LLSGVIL(1028) LOX--IMVI Melanoma</p><p>LLR SF-539 CNS GSTLLSR(1029) LOX--IMVI Melanoma</p><p>LRV ARGSLRV (996) SF-539 CNS LLR LOX--IMVI Melanoma</p><p>LRS LRSYAWS (997) SF-539 CNS LRV LOX--IMVI Melanoma</p><p>RVS KGRVSAG (998) SF-539 CNS LRS QWYSLRS (1030) LOX--IMVI Melanoma</p><p>RSS SF-539 CNS RVS TWIGRVS (1031) LOX--IMVI Melanoma</p><p>AGS SF-539 CNS RSS LOX--IMVI Melanoma</p><p>AGR SF-539 CNS AGS SVVLAGS (1032) LOX--IMVI Melanoma</p><p>AGL AGLTIGI (999) SF-539 CNS AGR LOX--IMVI Melanoma</p><p>AGG AWRHAGG(IOOO) SF-539 CNS AGL IFGAGLR (1033) LOX--IMVI Melanoma</p><p>WARAGGF(lOOl) SF-539 CNS AGG SAGGWCA (1034) LOX--IMVI Melanoma</p><p>GVR SF-539 CNS GVR RDGVRVG (1035) LOX--IMVI Melanoma</p><p>GVL MGVLTAE (1002) SF-539 CNS VSRIGVR (1036) LOX--IMVI Melanoma</p><p>FAGYGVL (1003) SF-539 CNS GVRSMPV (1037) LOX--IMVI Melanoma</p><p>GAV RIFHGAV (1004) SF-539 CNS GVL GGVLGSD (1038) LOX--IMVI Melanoma</p><p>GLV EGLVVFE (1005) SF-539 CNS WGVLQLE (1039) LOX--IMVI Melanoma</p><p>GLR REVPGLR (1006) SF-539 CNS GAV HGGPGAV (1040) LOX--IMVI Melanoma</p><p>LVS LVSVNGA (1007) SF-539 CNS GLV DSGLVGG (1041) LOX--IMVI Melanoma</p><p>HSLVSQP(1008) SF-539 CNS GLR IFGAGLR (1042) LOX--IMVI Melanoma</p><p>ARG ARGSLRV (1009) SF-539 CNS RMGFGLR (1043) LOX--IMVI Melanoma</p><p>ASL SSVASLV(IOIO) SF-539 CNS LVS LOX--IMVI Melanoma</p><p>AAV AAVWQMK (1011) SF-539 CNS ARG LOX--IMVI Melanoma</p><p>QRAAVIV (1012) SF-539 CNS ASL LOX--IMVI Melanoma</p><p>AAS SF-539 CNS AAV WLDAAVK (1044) LOX'-IMVI Melanoma</p><p>GGS SF-539 CNS AAS IAASYRG (1045) LOX--IMVI Melanoma</p><p>GGR GGRLRAV (1013) SF-539 CNS GGS ATIPGGS (1046) LOX--IMVI Melanoma</p><p>GLG SF-539 CNS DGGSLVV (1047) LOX'-IMVI Melanoma</p><p>GGL LPCGGLA(1014) SF-539 CNS FGGSGRG (1048) LOX'-IMVI Melanoma</p><p>GSS GSSHDAL(1015) SF-539 CNS GGR SPTGGRR (1049) LOX'-IMVI Melanoma</p><p>TQYYGSS (1016) SF-539 CNS TWSTGGR (1050) LOX'-IMVI Melanoma</p><p>GSG SF-539 CNS GLG LOX'-IMVI Melanoma</p><p>GSV FSPRGSV (1017) SF-539 CNS GGL SRSCGGL (1051) LOX'-IMVI Melanoma</p><p>GRV KGRVSAG (1018) SF-539 CNS GSS LOX'-IMVI Melanoma</p><p>QGRVNVK (1019) SF-539 CNS GSG CPGSGII (1052) LOX'-IMVI Melanoma</p><p>GRL GGRLRAV (1020) SF-539 CNS FGGSGRG (1053) LOX'-IMVI Melanoma</p><p>YDGRLAR (1021) SF-539 CNS GSV SGSVVQR (1054) LOX -IMVI Melanoma</p><p>GPS SF-539 CNS GRV TWIGRVS (1055) LOX -IMVI Melanoma</p><p>GVS SF-539 CNS GRL LOX'-IMVI Melanoma GPS GPSWATV (1056) LOX'-IMVI Melanoma</p><p>RLS SRLSYWQ(1022) LOX-IMVI Melanoma GVS LOX -IMVI Melanoma</p><p>RGV FVGSRGV (1023) LOX-IMVI Melanoma</p><p>SVDRGVI (1024) LOX-IMVI Melanoma RLS MALME-3M Melanoma</p><p>RGS GRGSGGF (1025) LOX-IMVI Melanoma RGV MALME-3M Melanoma</p><p>RAV LOX-IMVI Melanoma RGS ARRGSGL (1057; MALME-3M Melanoma RAV RAVGYNA (1058) MALME-3M Melanoma RAV M14 Melanoma</p><p>LRAVEFL (1059) MALME-3M Melanoma RAS RGGQRAS (1091) M14 Melanoma</p><p>RAS MALME-3M Melanoma GAG M14 Melanoma</p><p>GAG MALME-3M Melanoma AVS AVSGRSL (1092) M14 Melanoma</p><p>AVS MALME-3M Melanoma LLS GLLSSFS (1093) M14 Melanoma</p><p>LLS FEDLLSL(lO[beta]O) MALME-3M Melanoma LLR RMGLLRQ (1094) M14 Melanoma</p><p>RWLSLLS (1061) MALME-3M Melanoma LRV M14 Melanoma</p><p>LLR MALME-3M Melanoma LRS RLHYLRS (1095) M14 Melanoma</p><p>LRV HAPGLRV (1062) MALME-3M Melanoma GGYWLRS (1096) M14 Melanoma</p><p>LRS LRSSMML (1063) MALME-3M Melanoma RVS M14 Melanoma</p><p>RPKLRSV (1064) MALME-3M Melanoma RSS NRSSHCG(1097) M14 Melanoma</p><p>RVS SRVSFHE (1065) MALME-3M Melanoma QRSSDLT (1098) M14 Melanoma</p><p>RSS LRSSMML (1066) MALME-3M Melanoma AGS M14 Melanoma</p><p>SSGGRSS (1067) MALME-3M Melanoma AGR AAGRSRI (1099) M14 Melanoma</p><p>AGS MALME-3M Melanoma AGL M14 Melanoma</p><p>AGR VAGRVGI (1068) MALME-3M Melanoma AGG GRAGGNG (1100) M14 Melanoma</p><p>AGL AGLALTV (1069) MALME-3M Melanoma GVR ANASGVR (1101) M14 Melanoma</p><p>AGG MALME-3M Melanoma GVL WAHGVLS (1102) M14 Melanoma</p><p>GVR IGVRGAV (1070) MALME-3M Melanoma GAV M14 Melanoma</p><p>GVL LVRDGVL (1071) MALME-3M Melanoma GLV M14 Melanoma</p><p>GAV IGVRGAV (1072) MALME-3M Melanoma GLR SLYGLRW(1103) M14 Melanoma</p><p>GLV HGLVTHN(1073) MALME-3M Melanoma LVS Ml4 Melanoma</p><p>GLR HAPGLRV (1074) MALME-3M Melanoma ARG GNGGARG (1104) M14 Melanoma</p><p>LVS MALME-3M Melanoma LARGVPP (1105) M14 Melanoma</p><p>ARG VSSTARG(1075) MALME-3M Melanoma NWDARGR (1106) M14 Melanoma</p><p>ASL MALME-3M Melanoma ASL ASLPVLD (1107) M14 Melanoma</p><p>AAV RAAVIHT (1076) MALME-3M Melanoma PPGASLY (1108) M14 Melanoma</p><p>AAS AASTRSL (1077) MALME-3M Melanoma AAV AAVGGRV (1109) M14 Melanoma</p><p>GGS GWGGGSA (1078) MALME-3M Melanoma AAS AASSWAV (1110) M14 Melanoma</p><p>SSRGGSS (1079) MALME-3M Melanoma GGS AFKTGGS (1111) M14 Melanoma</p><p>GGR SSGGRSS (1080) MALME-3M Melanoma GGR FEGGRSG (1112) M14 Melanoma</p><p>GLG MALME-3M Melanoma RTWGGRM (1113) M14 Melanoma</p><p>GGL MALME-3M Melanoma SARQGGR (1114) M14 Melanoma</p><p>GSS SSRGGSS (1081) MALME-3M Melanoma AAVGGRV (1115) M14 Melanoma</p><p>GSG ARRGSGL (1082) MALME-3M Melanoma GLG M14 Melanoma</p><p>GSV MALME-3M Melanoma GGL M14 Melanoma</p><p>GRV VAGRVGI (1083) MALME-3M Melanoma GSS ARHGSSV(1116) M14 Melanoma</p><p>GRL EGRLMLA (1084) MALME-3M Melanoma SNFYGSS (1117) M14 Melanoma</p><p>GPS MALME-3M Melanoma GSG GSGQLIP(1118) Ml4 Melanoma</p><p>GVS MALME-3M Melanoma GSV LSRGSVA (1119) M14 Melanoma</p><p>GRV AEYGRVL (1120) M14 Melanoma</p><p>RLS RLSSAPS (1085) M14 Melanoma RGRVLLP (1121) M14 Melanoma</p><p>RRLSYHS (1086) M14 Melanoma AAVGGRV (1122) M14 Melanoma</p><p>FLHMRLS (1087) M14 Melanoma GRL RGRLALL (1123) M14 Melanoma</p><p>RGV LARGVPP (1088) M14 Melanoma SGPGRLP(1124) M14 Melanoma</p><p>RGS LSRGSVA(1089) M14 Melanoma TSGRLWV (1125) M14 Melanoma</p><p>VWLRGST (1090) M14 Melanoma GPS M14 Melanoma GVS MVYSGVS (1126) M14 Melanoma TCGGRSY (1168) SK-MEL-2 Melanoma</p><p>GLG GEALGLG (1169) SK-MEL-2 Melanoma</p><p>RLS WRLSREG (1127) SK-MEL-2 Melanoma PRGLGVG (1170) SK-MEL-2 Melanoma</p><p>LLRRLSW (1128) SK-MEL-2 Melanoma VGLGNSA (1171) SK-MEL-2 Melanoma</p><p>RGV AARGVMV (1129) SK-MEL-2 Melanoma GGL GGLVKRL (1172) SK-MEL-2 Melanoma</p><p>RGS ALARGSG (1130) SK-MEL-2 Melanoma GSS SK-MEL-2 Melanoma</p><p>NLRGSRS (1131) SK-MEL-2 Melanoma GSG GSGRALA (1173) SK-MEL-2 Melanoma</p><p>RAV RAVWRAS (1132) SK-MEL-2 Melanoma GSV SK-MEL-2 Melanoma</p><p>RAS RAVWRAS SK-MEL-2 Melanoma GRV SK-MEL-2 Melanoma</p><p>GAG GAGSFSS (1133) SK-MEL-2 Melanoma GRL SRSGRLN (1174) SK-MEL-2 Melanoma</p><p>AVS SK-MEL-2 Melanoma GPS SK-MEL-2 Melanoma</p><p>LLS LLSSRRC(1134) SK-MEL-2 Melanoma GVS SAGVSDS (1175) SK-MEL-2 Melanoma</p><p>LLSLDPG(1135) SK-MEL-2 Melanoma</p><p>SSLLSSL(1136) SK-MEL-2 Melanoma RLS PRLSDKS (1176) SK-MEL-28 Melanoma</p><p>LLR LLRPAHG (1137) SK-MEL-2 Melanoma RGV GRGDRGV (1177) SK-MEL-28 Melanoma</p><p>LLRRLSW (1138) SK-MEL-2 Melanoma RGVSGRL (1178) SK-MEL-28 Melanoma</p><p>LRV SK-MEL-2 Melanoma RGS INRGSRE (1179) SK-MEL-28 Melanoma</p><p>LRS CMLRSAT (1139) SK-MEL-2 Melanoma LRGSRQF (1180) SK-MEL-28 Melanoma</p><p>SKAVLRS (1140) SK-MEL-2 Melanoma LRGSVGR (1181) SK-MEL-28 Melanoma</p><p>RVS SRVSNPS (1141) SK-MEL-2 Melanoma RAV GLWYRAV (1182) SK-MEL-28 Melanoma</p><p>RSS CRRSSLL (1142) SK-MEL-2 Melanoma RVRAVLG (1183) SK-MEL-28 Melanoma</p><p>AGS GAGSFSS (1143) SK-MEL-2 Melanoma RAVLELW (1184) SK-MEL-28 Melanoma</p><p>AGR SAAGRTF (1144) SK-MEL-2 Melanoma RAS LVRASNG (1185) SK-MEL-28 Melanoma</p><p>PAGRMLS (1145) SK-MEL-2 Melanoma GAG SK-MEL-28 Melanoma</p><p>AGL IAMAGLR (1146) SK-MEL-2 Melanoma AVS SK-MEL-28 Melanoma</p><p>AGG AGGFRFI (1147) SK-MEL-2 Melanoma LLS SK-MEL-28 Melanoma</p><p>GVR SGVRPVI (1148) SK-MEL-2 Melanoma LLR ASGTLLR (1186) SK-MEL-28 Melanoma</p><p>GVL GVLSDRS (1149) SK-MEL-2 Melanoma LRV SK-MEL-28 Melanoma</p><p>GAV GAVTSAD (1150) SK-MEL-2 Melanoma LRS SK-MEL-28 Melanoma</p><p>GAVTSAD (1151) SK-MEL-2 Melanoma RVS GSGVRVS (1187) SK-MEL-28 Melanoma</p><p>GAVNTPA (1152) SK-MEL-2 Melanoma RSS VGSTRSS (1188) SK-MEL-28 Melanoma</p><p>GLV GGLVKRL (1153) SK-MEL-2 Melanoma AGS RAGSRYI (1189) SK-MEL-28 Melanoma</p><p>EVASGLV (1154) SK-MEL-2 Melanoma AGR SK-MEL-28 Melanoma</p><p>GLR IAMAGLR (1155) SK-MEL-2 Melanoma AGL SK-MEL-28 Melanoma</p><p>GTHSGLR(1156) SK-MEL-2 Melanoma AGG SK-MEL-28 Melanoma</p><p>LVS LVSTSNR(1157) SK-MEL-2 Melanoma GVR VGVRFSR (1190) SK-MEL-28 Melanoma</p><p>FSLVSFV (1158) SK-MEL-2 Melanoma GSGVRVS (1191) SK-MEL-28 Melanoma</p><p>ALVSSHV(1159) SK-MEL-2 Melanoma GVL IGVLASA (1192) SK-MEL-28 Melanoma</p><p>ARG AARGVMV (1160) SK-MEL-2 Melanoma GAV SK-MEL-28 Melanoma</p><p>ALARGSG (1161) SK-MEL-2 Melanoma GLV GLVARVR (1193) SK-MEL-28 Melanoma</p><p>ASL SK-MEL-2 Melanoma GLR SK-MEL-28 Melanoma</p><p>AAV LRYWAAV (1162) SK-MEL-2 Melanoma LVS SK-MEL-28 Melanoma</p><p>AAS FTRGAAS (1163) SK-MEL-2 Melanoma ARG SK-MEL-28 Melanoma</p><p>EWHAASG (1164) SK-MEL-2 Melanoma ASL SK-MEL-28 Melanoma</p><p>GGS FGGSMAP (1165) SK-MEL-2 Melanoma AAV SK-MEL-28 Melanoma</p><p>GGSLKWV (1166) SK-MEL-2 Melanoma AAS SK-MEL-28 Melanoma</p><p>GGR RGLQGGR (1167) SK-MEL-2 Melanoma GGS LLGIGGS (1194) SK-MEL-28 Melanoma QLGGSFR (1195) SK-MEL-28 Melanoma GGR SK-MEL-5 Melanoma</p><p>GGR LFRWGGR (1196) SK-MEL-28 Melanoma GLG SK-MEL-5 Melanoma</p><p>GLG SK-MEL-28 Melanoma GGL IYGGLVI (1225) SK-MEL-5 Melanoma</p><p>GGL RFSGGLQ (1197) SK-MEL-28 Melanoma LIGGLLS (1226) SK-MEL-5 Melanoma</p><p>GSS VGSSHGL (1198) SK-MEL-28 Melanoma GSS SK-MEL-5 Melanoma</p><p>GSG SVRVGSG (1199) SK-MEL-28 Melanoma GSG ACGSGLD (1227) SK-MEL-5 Melanoma</p><p>GSV GVNGSVS (1200) SK-MEL-28 Melanoma GSV AGSVDLV (1228) SK-MEL-5 Melanoma</p><p>LRGSVGR (1201) SK-MEL-28 Melanoma TLGSVRV (1229) SK-MEL-5 Melanoma</p><p>GRV HVKNGRV (1202) SK-MEL-28 Melanoma GRV HVRGRVA (1230) SK-MEL-5 Melanoma</p><p>GRL FQRSGRL (1203) SK-MEL-28 Melanoma IDLGRVN (1231) SK-MEL-5 Melanoma</p><p>HGRLAFG (1204) SK-MEL-28 Melanoma GRL GRLDAFG (1232) SK-MEL-5 Melanoma</p><p>RGVSGRL (1205) SK-MEL-28 Melanoma GPS WVGPSGG(1233) SK-MEL-5 Melanoma</p><p>GPS SK-MEL-28 Melanoma GVS SK-MEL-5 Melanoma</p><p>GVS RGVSGRL (1206) SK-MEL-28 Melanoma</p><p>RLS DLRLSFP (1234) UACC 257 Melanoma</p><p>RLS SK-MEL-5 Melanoma SARLSHV (1235) UACC 257 Melanoma</p><p>RGV FGIGRGV (1207) SK-MEL-5 Melanoma RGV VMDRGVA (1236) UACC 257 Melanoma</p><p>RGS SK-MEL-5 Melanoma RGS RGSLLWA (1237) UACC 257 Melanoma</p><p>RAV SK-MEL-5 Melanoma RGSPLTK(1238) UACC 257 Melanoma</p><p>RAS SK-MEL-5 Melanoma RAV UACC 257 Melanoma</p><p>GAG SK-MEL-5 Melanoma RAS RASIGIE(1239) UACC 257 Melanoma</p><p>AVS GVVQAVS (1208) SK-MEL-5 Melanoma VHSLRAS (1240) UACC 257 Melanoma</p><p>LSAVSVK (1209) SK-MEL-5 Melanoma GAG UACC 257 Melanoma</p><p>LLS LYLLSSA(1210) SK-MEL-5 Melanoma AVS UACC 257 Melanoma</p><p>LIGGLLS (1211) SK-MEL-5 Melanoma LLS AWLLSGR (1241) UACC 257 Melanoma</p><p>LLR LLRRGIG (1212) SK-MEL-5 Melanoma LLR UACC 257 Melanoma</p><p>LRV SK-MEL-5 Melanoma LRV UACC 257 Melanoma</p><p>LRS FLRSLSL (1213) SK-MEL-5 Melanoma LRS LWLRSRE (1242) UACC 257 Melanoma</p><p>RVS VRVSGLT (1214) SK-MEL-5 Melanoma RVS VTRIRVS (1243) UACC 257 Melanoma</p><p>RSS SK-MEL-5 Melanoma RSS NSQRSSV(1244) UACC 257 Melanoma</p><p>AGS AGSVDLV (1215) SK-MEL-5 Melanoma AGS AATRAGS (1245) UACC 257 Melanoma</p><p>AGR GFVAGRT (1216) SK-MEL-5 Melanoma AGR UACC 257 Melanoma</p><p>AGL SK-MEL-5 Melanoma AGL UACC 257 Melanoma</p><p>AGG SK-MEL-5 Melanoma AGG UACC 257 Melanoma</p><p>GVR SK-MEL-5 Melanoma GVR TDGVRAF (1246) UACC 257 Melanoma</p><p>GVL SK-MEL-5 Melanoma GVL FAASGVL (1247) UACC 257 Melanoma</p><p>GAV TRGAVFG (1217) SK-MEL-5 Melanoma GVLEGRR (1248) UACC 257 Melanoma</p><p>GLV IYGGLVI (1218) SK-MEL-5 Melanoma GAV EADPGAV (1249) UACC 257 Melanoma</p><p>GLR PTGEGLR (1219) SK-MEL-5 Melanoma DGAVILH (1250) UACC 257 Melanoma</p><p>LVS SK-MEL-5 Melanoma RDGAVNL (1251) UACC 257 Melanoma</p><p>ARG SK-MEL-5 Melanoma GLV UACC 257 Melanoma</p><p>ASL KVSVASL (1220) SK-MEL-5 Melanoma GLR GLRPHGA (1252) UACC 257 Melanoma</p><p>RYSMASL (1221) SK-MEL-5 Melanoma TSRGLRL (1253) UACC 257 Melanoma</p><p>AAV SK-MEL-5 Melanoma LVS RMLVSSF(1254) UACC 257 Melanoma</p><p>AAS ANAASSP (1222) SK-MEL-5 Melanoma ARG DVIARGW (1255) UACC 257 Melanoma</p><p>GGS PGGSRHA (1223) SK-MEL-5 Melanoma UACC 257 Melanoma</p><p>GGSPGVW (1224) SK-MEL-5 Melanoma ASL UACC 257 Melanoma AAV TLTAAVF (1256) UACC 257 Melanoma GTLGVLS (1291) UACC62 Melanoma</p><p>GWLNAAV (1257) UACC 257 Melanoma GVLLWRP (1292) UACC62 Melanoma</p><p>AAS FAASGVL (1258) UACC 257 Melanoma GAV UACC62 Melanoma</p><p>GGS GGSKGSA(1259) UACC 257 Melanoma GLV UACC62 Melanoma</p><p>AVALGGS (1260) UACC 257 Melanoma GLR GLREAHV (1293) UACC62 Melanoma</p><p>GGR HGGRYRH (1261) UACC 257 Melanoma LVS UACC62 Melanoma</p><p>SGVGGRY (1262) UACC 257 Melanoma ARG AARGELR (1294) UACC62 Melanoma</p><p>GLG UACC 257 Melanoma ASL AASLRGT (1295) UACC62 Melanoma</p><p>GGL SGGLAVA (1263) UACC 257 Melanoma AAV PVGAAVA (1296) UACC62 Melanoma</p><p>GSS UACC 257 Melanoma AAS AASLRGT (1297) UACC62 Melanoma</p><p>GSG UACC 257 Melanoma GGS UACC62 Melanoma</p><p>GSV UACC 257 Melanoma GGR UACC62 Melanoma</p><p>GRV UACC 257 Melanoma GLG UACC62 Melanoma</p><p>GRL GRLAKSI (1264) UACC 257 Melanoma GGL UACC62 Melanoma</p><p>GPS AGPSRGP (1265) UACC 257 Melanoma GSS UACC62 Melanoma</p><p>UACC 257 Melanoma GSG SNPGSGS (1298! UACC62 Melanoma</p><p>GVS UACC 257 Melanoma GSV UACC62 Melanoma GRV GRVRETP (1299) UACC62 Melanoma</p><p>RLS GLMRLSH (1266) UACC62 Melanoma UACC62 Melanoma</p><p>VRVGRLS (1267) UACC62 Melanoma GRL FGRLLSP (1300) UACC62 Melanoma</p><p>TGRLSAA (1268) UACC62 Melanoma VRVGRLS (1301) UACC62 Melanoma</p><p>RGV SLRGVRV (1269) UACC62 Melanoma TGRLSAA (1302) UACC62 Melanoma</p><p>DNCERGV (1270) UACC62 Melanoma VGRLQTT (1303) UACC62 Melanoma</p><p>TTQLRGV (1271) UACC62 Melanoma GPS DGPSCVI (1304) UACC62 Melanoma</p><p>RGS GVIGRGS (1272) UACC62 Melanoma UACC62 Melanoma</p><p>LAGMRGS (1273) UACC62 Melanoma GVS UACC62 Melanoma</p><p>RAV VRPRAVL (1274) UACC62 Melanoma</p><p>PPRAVTN (1275) UACC62 Melanoma RLS IGROVl Ovarian</p><p>RAS WRARASP (1276) UACC62 Melanoma RGV IGROVl Ovarian</p><p>GAG UACC62 Melanoma RGS IGROVl Ovarian</p><p>AVS UACC62 Melanoma RAV RFSSRAV (1305) IGROVl Ovarian</p><p>LLS FGRLLSP (1277) UACC62 Melanoma RAS HAGSRAS (1306) IGROVl Ovarian</p><p>LLR PSLLRGF (1278) UACC62 Melanoma GAG GAGLGVS (1307) IGROVl Ovarian</p><p>LRV RDLRVHL (1279) UACC62 Melanoma LLGAGTP (1308) IGROVl Ovarian</p><p>LRVSNPR (1280) UACC62 Melanoma AVS IGROVl Ovarian</p><p>LRVDQLY (1281) UACC62 Melanoma LLS LLSILKA(1309) IGROVl Ovarian</p><p>LRS HRLRSMS (1282) UACC62 Melanoma GLLSGGT (1310) IGROVl Ovarian</p><p>RVS LRVSNPR (1283) UACC62 Melanoma LLR IGROVl Ovarian</p><p>RSS UACC62 Melanoma LRV LSVLRVL (1311) IGROVl Ovarian</p><p>AGS PGFMAGS (1284) UACC62 Melanoma LRS SRYTLRS (1312) IGROVl Ovarian</p><p>AGR AGRGISQ (1285) UACC62 Melanoma RVS IGROVl Ovarian</p><p>RAGRDAP (1286) UACC62 Melanoma RSS LFHTRSS (1313) IGROVl Ovarian</p><p>RAGRGFE (1287) UACC62 Melanoma VARSSFR (1314) IGROVl Ovarian</p><p>AGL UACC62 Melanoma AGS CTAGSVS (1315) IGROVl Ovarian</p><p>AGG HQAGGVT (1288) UACC62 Melanoma RAAGSAG (1316) IGROVl Ovarian</p><p>GVR SLRGVRV (1289) UACC62 Melanoma HAGSRAS (1317) IGROVl Ovarian</p><p>GVL DWVGVLM (1290) UACC62 Melanoma AGR IGROVl Ovarian AGL GAGLGVS (1318) IGROVl Ovarian AVS OVCAR-3 Ovarian</p><p>PTGAGLL (1319) IGROVl Ovarian LLS OVCAR-3 Ovarian</p><p>ASYAGLV (2) LLR OVCAR-3 Ovarian (1320) IGROVl Ovarian LRV OVCAR-3 Ovarian</p><p>AGG AGGFGVL (1321) IGROVl Ovarian RREGLRS (10)</p><p>NMAGGQE (1322) IGROVl Ovarian LRS (1348) OVCAR-3 Ovarian</p><p>LRAGGSY (1323) IGROVl Ovarian RVS ERVSAAV (1349) OVCAR-3 Ovarian</p><p>YLAGGKA (1324) IGROVl Ovarian RSS OVCAR-3 Ovarian</p><p>GVR PYYNGVR (1325) IGROVl Ovarian AGS AGSMMEF (1350) OVCAR-3 Ovarian</p><p>GVL AGGFGVL (1326) IGROVl Ovarian AGR OVCAR-3 Ovarian</p><p>LIGGVLH (1327) IGROVl Ovarian AGL OVCAR-3 Ovarian</p><p>GAV IGROVl Ovarian AGG OVCAR-3 Ovarian</p><p>GLV DGLVPVA (1328) IGROVl Ovarian GVR OVCAR-3 Ovarian</p><p>GLVASMP (1329) IGROVl Ovarian GVL RHGPGVL (1351) OVCAR-3 Ovarian</p><p>ASYAGLV (2) GAV OVCAR-3 Ovarian (1330) IGROVl Ovarian GLV OVCAR-3 Ovarian</p><p>GLR IGROVl Ovarian GLR GLRRDNG (1352) OVCAR-3 Ovarian LVS LVRLVSL (1331) IGROVl Ovarian RREGLRS (10)</p><p>ARG IGROVl Ovarian (1353) OVCAR-3 Ovarian</p><p>ASL VLASLSG (1332) IGROVl Ovarian LVS OVCAR-3 Ovarian</p><p>AAV IGROVl Ovarian ARG OVCAR-3 Ovarian</p><p>AAS IGROVl Ovarian ASL OVCAR-3 Ovarian</p><p>GGS GSITGGS (1333) IGROVl Ovarian AAV ERVSAAV (1354) OVCAR-3 Ovarian</p><p>LRAGGSY (1334) IGROVl Ovarian AAS VAASVRE (1355) OVCAR-3 Ovarian</p><p>TGGSLLG(1335) IGROVl Ovarian GGS OVCAR-3 Ovarian</p><p>DEGGSRW (1336) IGROVl Ovarian GGR OVCAR-3 Ovarian</p><p>GGR IGROVl Ovarian GLG OVCAR-3 Ovarian</p><p>GLG GAGLGVS (1337) IGROVl Ovarian GGL OVCAR-3 Ovarian</p><p>GGL IGROVl Ovarian GSS OVCAR-3 Ovarian</p><p>GSS WGSSAVK (1338) IGROVl Ovarian GSG OVCAR-3 Ovarian</p><p>QGSSNSV(1339) IGROVl Ovarian GSV PWYDGSV (1356) OVCAR-3 Ovarian</p><p>GSG IGROVl Ovarian GRV GRVTLES (1357) OVCAR-3 Ovarian</p><p>GSV CTAGSVS (1340) IGROVl Ovarian GRL OVCAR-3 Ovarian</p><p>SVTGSVG (1341) IGROVl Ovarian GPS OVCAR-3 Ovarian</p><p>GRV SPGRVAD (1342) IGROVl Ovarian GVS OVCAR-3 Ovarian</p><p>GRL IGROVl Ovarian</p><p>GPS DAVRGPS (1343) IGROVl Ovarian RLS GRLSRAP (1358) OVCAR-4 Ovarian</p><p>GVS GAGLGVS (1344) IGROVl Ovarian SRLSYCN (1359) OVCAR-4 Ovarian</p><p>GVSGTVS (1345) IGROVl Ovarian RGV OVCAR-4 Ovarian</p><p>SGVSISC(1346) IGROVl Ovarian RGS QARGSWL (1360) OVCAR-4 Ovarian</p><p>FVPRGSY (1361) OVCAR-4 Ovarian</p><p>RRLSYHS (65) RAV AALLRAV (1362) OVCAR-4 Ovarian</p><p>RLS (1347) OVCAR-3 Ovarian RAS LAGRASE (1363) OVCAR-4 Ovarian RGV OVCAR-3 Ovarian GAG AAGAGWR (1364) OVCAR-4 Ovarian RGS OVCAR-3 Ovarian ADLGAGW (1365) OVCAR-4 Ovarian RAV OVCAR-3 Ovarian ADLGAGW (1366) OVCAR-4 Ovarian RAS OVCAR-3 Ovarian GGAGRGA (1367) OVCAR-4 Ovarian GAG OVCAR-3 Ovarian AVS DVWVAVS (1368) OVCAR-4 Ovarian APGRLGP (1408) OVCAR-4 Ovarian</p><p>LLS OVCAR-4 Ovarian APGRLGP (1409) OVCAR-4 Ovarian</p><p>LLR AALLRAV (1369) OVCAR-4 Ovarian GPS RDLAGPS (1410) OVCAR-4 Ovarian</p><p>LRV NLRVGAE (1370) OVCAR-4 Ovarian GVS OVCAR-4 Ovarian</p><p>LRS NCYSLRS (1371) OVCAR-4 Ovarian</p><p>RVS LAGSRVS (1372) OVCAR-4 Ovarian RLS RLSGAGD (1411) OVCAR-5 Ovarian</p><p>RSS OVCAR-4 Ovarian RGV LQRGVAR (1412) OVCAR-5 Ovarian</p><p>AGS SGPAGSF (1373) OVCAR-4 Ovarian RGS OVCAR-5 Ovarian</p><p>LAGSRVS (1374) OVCAR-4 Ovarian RAV RAVGRQL (1413) OVCAR-5 Ovarian</p><p>AGR GGAGRGA (1375) OVCAR-4 Ovarian SRAVIRL (1414) OVCAR-5 Ovarian</p><p>LAGRASE (1376) OVCAR-4 Ovarian RAS VRASSKR (1415) OVCAR-5 Ovarian</p><p>VAGRLQM (1377) OVCAR-4 Ovarian GAG DGAGSLR (1416) OVCAR-5 Ovarian</p><p>AGL WGAGLDA (1378) OVCAR-4 Ovarian SVSGAGS (1417) OVCAR-5 Ovarian</p><p>WGAGLDA (1379) OVCAR-4 Ovarian AVS OVCAR-5 Ovarian</p><p>AGG AGRGAGG (1380) OVCAR-4 Ovarian LLS TTLLSRQ (1418) OVCAR-5 Ovarian</p><p>GVR EAGVRLN (1381) OVCAR-4 Ovarian VAELLSM (1419) OVCAR-5 Ovarian</p><p>GVL OVCAR-4 Ovarian LLR OVCAR-5 Ovarian</p><p>GAV MQLRGAV (1382) OVCAR-4 Ovarian LRV LPGRLRV (1420) OVCAR-5 Ovarian</p><p>GLV GGPGLVM (1383) OVCAR-4 Ovarian LRS LKAGLRS ( 1421 ) OVCAR-5 Ovarian</p><p>QGLVRGG (1384) OVCAR-4 Ovarian RVS HRVSESV(1422) OVCAR-5 Ovarian</p><p>GLR PGLRGPA (1385) OVCAR-4 Ovarian RSS YYGERSS (1423) OVCAR-5 Ovarian</p><p>PGLRGPA (1386) OVCAR-4 Ovarian AGS DGAGSLR (1424) OVCAR-5 Ovarian</p><p>LVS GRMLVSG (1387) OVCAR-4 Ovarian SVSGAGS (1425) OVCAR-5 Ovarian</p><p>ARG ESARGAL (1388) OVCAR-4 Ovarian AGSVYSV (1426) OVCAR-5 Ovarian</p><p>QARGSWL (1389) OVCAR-4 Ovarian AGR OVCAR-5 Ovarian</p><p>ASL OVCAR-4 Ovarian AGL SAGLLPS (1427) OVCAR-5 Ovarian</p><p>AAV OVCAR-4 Ovarian LKAGLRS ( 1428 ) OVCAR-5 Ovarian</p><p>AAS OVCAR-4 Ovarian AGG RRAGGSV (1429) OVCAR-5 Ovarian</p><p>GGS GGGSGGG (1390) OVCAR-4 Ovarian GVR SWAGVRF (1430) OVCAR-5 Ovarian</p><p>NNVGGSS (1391) OVCAR-4 Ovarian GVL OVCAR-5 Ovarian</p><p>GGR GGRVLGQ (1392) OVCAR-4 Ovarian GAV IYPGAVL (1431) OVCAR-5 Ovarian</p><p>GGRVRGG (1393) OVCAR-4 Ovarian GLV OVCAR-5 Ovarian</p><p>GGRVRGG (1394) OVCAR-4 Ovarian GLR LKAGLRS (1432) OVCAR-5 Ovarian</p><p>WYGGRGN (1395) OVCAR-4 Ovarian LVS SLVSPRT (1433) OVCAR-5 Ovarian</p><p>GLG CVGLGCH (1396) OVCAR-4 Ovarian ARG OVCAR-5 Ovarian</p><p>GGL OVCAR-4 Ovarian ASL OVCAR-5 Ovarian</p><p>GSS NNVGGSS (1397) OVCAR-4 Ovarian AAV HAAVEPS (1434) OVCAR-5 Ovarian</p><p>GSG FMTYGSG (1398) OVCAR-4 Ovarian TAAAVLL (1435) OVCAR-5 Ovarian</p><p>GGGSGGG (1399) OVCAR-4 Ovarian AAS OVCAR-5 Ovarian</p><p>WDQGSGY (1400) OVCAR-4 Ovarian GGS FHFGGSG (1436) OVCAR-5 Ovarian</p><p>GSV GSVLMRG (1401) OVCAR-4 Ovarian GEGGSGG (1437) OVCAR-5 Ovarian</p><p>GRV GGRVLGQ (1402) OVCAR-4 Ovarian RRAGGSV (1438) OVCAR-5 Ovarian</p><p>GGRVRGG (1403) OVCAR-4 Ovarian GGR ALPGGGR (1439) OVCAR-5 Ovarian</p><p>GGRVRGG (1404) OVCAR-4 Ovarian YVGGRLR (1440) OVCAR-5 Ovarian</p><p>YMYHGRV (1405) OVCAR-4 Ovarian GLG GKGMGLG (1441) OVCAR-5 Ovarian</p><p>GRL GRLSRAP (1406) OVCAR-4 Ovarian SLGLGGL(1442) OVCAR-5 Ovarian</p><p>VAGRLQM (1407) OVCAR-4 Ovarian GGL DGGLNDC (1443) OVCAR-5
&lt;EMI ID=54.1&gt;
Ovarian LGGLGLS (1444) OVCAR-5 Ovarian GGL TATGGLL (1473) OVCAR-8 Ovarian</p><p>GSS OVCAR-5 Ovarian GSNGSSH (3)</p><p>GSS (1474) OVCAR-8 Ovarian</p><p>GSG FHFGGSG(1445) OVCAR-5 Ovarian LOGSGAY (2 )</p><p>GEGGSGG(1446) OVCAR-5 Ovarian GSG (1475) OVCAR-8 Ovarian</p><p>GSV RRAGGSV (1447) OVCAR-5 Ovarian LQHLGSG (1476) OVCAR-8 Ovarian</p><p>SGAGSVS (1448) OVCAR-5 Ovarian GSV OVCAR-8 Ovarian</p><p>AGSVYSV (1449) OVCAR-5 Ovarian GRV OVCAR-8 Ovarian</p><p>GRV GRVTWRS (1450) OVCAR-5 Ovarian GRL OVCAR-8 Ovarian</p><p>GRL LPGRLRV (1451) OVCAR-5 Ovarian GPS GPSVLDI (1477) OVCAR-8 Ovarian</p><p>YVGGRLR (1452) OVCAR-5 Ovarian GVS GATGVSS (1478) OVCAR-8 Ovarian</p><p>GPS GPSSAVE (1453) OVCAR-5 Ovarian</p><p>GVS OVCAR-5 Ovarian RLS TRLSFRH (1479) SK-OV-3-3 Ovarian</p><p>RGV FLRGVEL (1480) SK-OV-3-3 Ovarian</p><p>RRLSYRE (28)</p><p>RGS NSVRGSR (1481) SK-OV-3-3 Ovarian</p><p>RLS (1454) OVCAR-8 Ovarian</p><p>RAV NRAVLSA (1482) SK-OV-3-3 Ovarian</p><p>RGV OVCAR-8 Ovarian</p><p>RAS LIGRASM(1483) SK-OV-3-3 Ovarian</p><p>RGS OVCAR-8 Ovarian</p><p>GAG RVGAGAF (1484) SK-OV-3-3 Ovarian</p><p>RAV HTRAVSE (1455) OVCAR-8 Ovarian</p><p>AVS WISAVSK(1485) SK-OV-3-3 Ovarian</p><p>NVSRAVG (1456) OVCAR-8 Ovarian</p><p>SAVSESP (1486) SK-OV-3-3 Ovarian</p><p>RAS PRHRASQ (1457) OVCAR-8 Ovarian</p><p>LLS SK-OV-3-3 Ovarian</p><p>GAG LGAGMIA (1458) OVCAR-8 Ovarian</p><p>LLR SK-OV-3-3 Ovarian</p><p>AVS AVSLVVL (1459) OVCAR-8 Ovarian</p><p>RVGTLRV ( 4 )</p><p>HTRAVSE (1460) OVCAR-8 Ovarian LRV (1487) SK-OV-3-3 Ovarian</p><p>LLS OVCAR-8 Ovarian LRS SK-OV-3-3 Ovarian</p><p>LLR OVCAR-8 Ovarian RVS RVSGDGK (1488) SK-OV-3-3 Ovarian</p><p>LRV ELGLRVP (1461) OVCAR-8 Ovarian RSGRVSN (1489) SK-OV-3-3 Ovarian</p><p>LRS OVCAR-8 Ovarian RVSNEAL (1490) SK-OV-3-3 Ovarian</p><p>RVS OVCAR-8 Ovarian RVSSDPI (1491) SK-OV-3-3 Ovarian</p><p>RSS GRSSVSD(1462) OVCAR-8 Ovarian RSS VRSSGVL (1492) SK-OV-3-3 Ovarian</p><p>YAGSGQL (2 )</p><p>AGS SGWFAGS (1493) SK-OV-3-3 Ovarian</p><p>AGS (1463) OVCAR-8 Ovarian</p><p>AGR an</p><p>AGR SK-OV-3-3 Ovari</p><p>AGRFGAR (1464) OVCAR-8 Ovarian</p><p>AGL AGLGLLD (1494) SK-OV-3-3 Ovarian</p><p>AGL AIMGAGL (1465) OVCAR-8 Ovarian</p><p>SAAGLAR (1495) SK-OV-3-3 Ovarian</p><p>AGG OVCAR-8 Ovarian</p><p>AGG SK-OV-3-3 Ovarian</p><p>GVR THVGGVR (1466) OVCAR-8 Ovarian</p><p>GVR FAGAGVR (1496) SK-OV-3-3 Ovarian</p><p>GVL GVLTRGN (1467) OVCAR-8 Ovarian VRT TRVR I [Delta] \</p><p>GAV OVCAR-8 Ovarian (1497) SK-OV-3-3 Ovarian</p><p>GLV OVCAR-8 Ovarian GVL VRSSGVL (1498) SK-OV-3-3 Ovarian</p><p>GLR ELGLRVP (1468) OVCAR-8 Ovarian GAV RPWGAVA (1499) SK-OV-3-3 Ovarian</p><p>GLGLRLG (1469) OVCAR-8 Ovarian GLV PVSDGLV(1500) SK-OV-3-3 Ovarian</p><p>LVS IDLVSPG(1470) OVCAR-8 Ovarian GLR NKGGLRQ (1501) SK-OV-3-3 Ovarian</p><p>ARG OVCAR-8 Ovarian LVS GGFLLVS (1502) SK-OV-3-3 Ovarian</p><p>ASL OVCAR-8 Ovarian LVPLVSG (1503) SK-OV-3-3 Ovarian</p><p>AAV OVCAR-8 Ovarian ARG ARGGESA (1504) SK-OV-3-3 Ovarian</p><p>AAS OVCAR-8 Ovarian MSARGIL (1505) SK-OV-3-3 Ovarian</p><p>GGS GGSTVPQ(1471) OVCAR-8 Ovarian ASL ASLVARN (1506) SK-OV-3-3 Ovarian</p><p>GGR OVCAR-8 Ovarian AAV RVEAAVP (1507) SK-OV-3-3 Ovarian</p><p>GLG GLGLRLG (1472) OVCAR-8 Ovarian AAS RALGAAS (1508) SK-OV-3-3 Ovarian GLV GDCGLVG (1546) PC3 Prostate</p><p>GGS SK-OV-3-3 Ovarian GLR GGLRVGG (1547) PC3 Prostate</p><p>GGR ASEGGRA (1509) SK-OV-3-3 Ovarian GLRVYEP (1548) PC3 Prostate</p><p>IGGRWVV (1510) SK-OV-3-3 Ovarian LVS PC3 Prostate</p><p>GLG AGLGLLD (1511) SK-OV-3-3 Ovarian ARG ARGRGSQ (1549) PC3 Prostate</p><p>GGL LGGLSER(1512) SK-OV-3-3 Ovarian ASL PC3 Prostate</p><p>NKGGLRQ (1513) SK-OV-3-3 Ovarian AAV PC3 Prostate</p><p>GSS LVGSSRV(1514) SK-OV-3-3 Ovarian AAS PC3 Prostate</p><p>YTGSSPS(1515) SK-OV-3-3 Ovarian GGS PC3 Prostate</p><p>GSG SK-OV-3-3 Ovarian GGR GGRELKA (1550) PC3 Prostate</p><p>GSV GSVLPVL (1516) SK-OV-3-3 Ovarian GGGRRAL (1551) PC3 Prostate</p><p>KGDGSVR (1517) SK-OV-3-3 Ovarian RPAGGRT (1552) PC3 Prostate</p><p>GSVSHRR(1518) SK-OV-3-3 Ovarian GLG PC3 Prostate</p><p>RLWGSVV (1519) SK-OV-3-3 Ovarian GGL GGLKVWR (1553) PC3 Prostate</p><p>GRV MQGRVIV (1520) SK-OV-3-3 Ovarian GGLRVGG (1554) PC3 Prostate</p><p>RSGRVSN (1521) SK-OV-3-3 Ovarian GGLPVQM (1555) PC3 Prostate</p><p>GRL LEVGRLF (1522) SK-OV-3-3 Ovarian RQDGGLY (1556) PC3 Prostate</p><p>SQFGPSF(3) GSS YATLGSS (1557) PC3 Prostate</p><p>GPS (1523) SK-OV-3-3 Ovarian</p><p>GSG SGSGCVF (1558) PC3 Prostate</p><p>GVS ATLDGVS (1524) SK-OV-3-3 Ovarian</p><p>VSGSGTA(1559) PC3 Prostate</p><p>GSV VGSVKAS (1560) PC3 Prostate</p><p>RLS RLSWTVL (1525) PC3 Prostate</p><p>ATGSGSV(1561) PC3 Prostate</p><p>RGV LRFRRGV (1526) PC3 Prostate</p><p>GRV PC3 Prostate</p><p>RGS ARGRGSQ (1527) PC3 Prostate</p><p>GRL PTSGRLV (1562) PC3 Prostate</p><p>VLRGSTP(1528) PC3 Prostate</p><p>GPS LACRGPS (1563) PC3 Prostate</p><p>RAV PC3 Prostate</p><p>RGPSQVL (1564) PC3 Prostate</p><p>RAS ARLRASR (1529) PC3 Prostate</p><p>GVS PC3 Prostate</p><p>GAG RIGAGHR (1530) PC3 Prostate</p><p>AVS PC3 Prostate</p><p>RLS TLGRLSS (1565) DU-145 Prostate</p><p>LLS WLLSSEI (1531) PC3 Prostate</p><p>RGV AGDRGVA (1566) DU-145 Prostate</p><p>LLR PC3 Prostate</p><p>RGS DU-145 Prostate</p><p>LRV GGLRVGG (1532) PC3 Prostate</p><p>RAV LPRRAVF (1567) DU-145 Prostate</p><p>GLRVYEP (1533) PC3 Prostate RASCVWR ( 6)</p><p>LRS YLRSAGM (1534) PC3 Prostate RAS (1568) DU-145 Prostate</p><p>RVS RVSRAGG (1535) PC3 Prostate FSKMRAS (1569) DU-145 Prostate</p><p>RSS PC3 Prostate GAG DYVGAGT (1570) DU-145 Prostate</p><p>AGS PC3 Prostate AVS DU-145 Prostate</p><p>AGR AGRPGGY (1536) PC3 Prostate LLS DU-145 Prostate</p><p>AGL YGALAGL (1537) PC3 Prostate LLR ARLLRGG (1571) DU-145 Prostate</p><p>AGG RVSRAGG (1538) PC3 Prostate LLRSVGY (1572) DU-145 Prostate</p><p>SHTAGGG (1539) PC3 Prostate LRV DU-145 Prostate</p><p>AGGVRDL (1540) PC3 Prostate LRS HLRSGFS (1573) DU-145 Prostate</p><p>RPAGGRT (1541) PC3 Prostate LLRSVGY (1574) DU-145 Prostate</p><p>GVR GGVRLGG (1542) PC3 Prostate RVS DU-145 Prostate</p><p>AGGVRDL (1543) PC3 Prostate RSS DU-145 Prostate</p><p>GVL GVLGCDG (1544) PC3 Prostate AGS DU-145 Prostate</p><p>GAV CGAVAEW (1545) PC3 Prostate AGR AGRPDGV (1575) DU-145 Prostate AGL DENRAGL (1576) DU-145 Prostate LRV 786-0 Renal</p><p>AGG AWAGGDM (1577) DU-145 Prostate LRS ARYSLRS (1613) 786-0 Renal</p><p>LNAGGSG (1578) DU-145 Prostate RLRSYVA (1614) 786-0 Renal</p><p>GVR DU-145 Prostate SRKGLRS (1615) 786-0 Renal</p><p>GVL DU-145 Prostate RVS SVTGRVS (1616) 786-0 Renal</p><p>GAV NMGAVGS (1579) DU-145 Prostate RSS 786-0 Renal</p><p>PIGAVMN (1580) DU-145 Prostate AGS AGSAFWA (1617) 786-0 Renal</p><p>GLV LTGGLVF (1581) DU-145 Prostate DQQEAGS (1618) 786-0 Renal</p><p>CGEGLVV (1582) DU-145 Prostate FAAGAGS (1619) 786-0 Renal</p><p>GLR SDLGLRR(1583) DU-145 Prostate AGR GAGRFPH (1620) 786-0 Renal</p><p>LVS HADVLVS (1584) DU-145 Prostate AGL 786-0 Renal</p><p>ARG FSNARGY (1585) DU-145 Prostate AGG GAGGVDV (1621) 786-0 Renal</p><p>ASL DU-145 Prostate GVR 786-0 Renal</p><p>AAV AAVWWAA (1586) DU-145 Prostate GVL 786-0 Renal</p><p>AAS DU-145 Prostate GAV ASAGAVS (1622) 786-0 Renal</p><p>GGS LNAGGSG (1587) DU-145 Prostate GLV RRDGLVE (1623) 786-0 Renal</p><p>GGSAWWG (1588) DU-145 Prostate GLR SRKGLRS (1624) 786-0 Renal</p><p>VYGWGGS (1589) DU-145 Prostate LVS GDATLVS (1625) 786-0 Renal</p><p>GGR GGRLLRA (1590) DU-145 Prostate GDATLVS (1626) 786-0 Renal</p><p>LGGRTIS (1591) DU-145 Prostate ARG YFRARGS (1627) 786-0 Renal</p><p>GLG YLGLGGL (1592) DU-145 Prostate ASL 786-0 Renal</p><p>GGL SITRGGL (1593) DU-145 Prostate AAV 786-0 Renal</p><p>LTGGLVF (1594) DU-145 Prostate AAS 786-0 Renal</p><p>LGGLGLY (1595) DU-145 Prostate GGS 786-0 Renal</p><p>GSS GSSELSR(1596) DU-145 Prostate GGR 786-0 Renal</p><p>GSG GSGGANL (1597) DU-145 Prostate GLG DRGLGMS (1628) 786-0 Renal</p><p>VDGSGDD (1598) DU-145 Prostate GGL 786-0 Renal</p><p>GSV RSLGSVG (1599) DU-145 Prostate GSS 786-0 Renal</p><p>GRV GRVKPGA (1600) DU-145 Prostate GSG GSGYFIT (1629) 786-0 Renal</p><p>GRL GGRLLRA (1601) DU-145 Prostate GSV 786-0 Renal</p><p>GRLWYVA (1602) DU-145 Prostate GRV SVTGRVS (1630) 786-0 Renal</p><p>TLGRLSS (1603) DU-145 Prostate GRL 786-0 Renal</p><p>GPS DU-145 Prostate GPS VGPSVHL (1631) 786-0 Renal</p><p>GVS GVSGLSR (1604) DU-145 Prostate GVS 786-0 Renal</p><p>YGVSRLL (1605) DU-145 Prostate</p><p>RLS A498 Renal</p><p>RLS SRLSYRA (1606) 786-0 Renal RGV EGVRGVF (1632) A498 Renal</p><p>RGV IHRGVWG (1607) 786-0 Renal GDRGVRG (1633) A498 Renal</p><p>RGS YFRARGS (1608) 786-0 Renal MRGVARK (1634) A498 Renal</p><p>RAV 786-0 Renal RGS A498 Renal</p><p>RAS 786-0 Renal RAV KRAVGRM (1635) A498 Renal</p><p>GAG GAGRFPH (1609) 786-0 Renal RAS DRASSWA (1636) A498 Renal</p><p>SGAGAAF (1610) 786-0 Renal GAG LQGAGIH (1637) A498 Renal</p><p>VDVGGAG (1611) 786-0 Renal AVS A498 Renal</p><p>AVS ASAGAVS (1612) 786-0 Renal LLS A498 Renal</p><p>LLS 786-0 Renal LLR WLLRGFG (1638) A498 Renal</p><p>LLR 786-0 Renal LRV A498 Renal LRS ASPPLRS (1639) A498 Renal LLR PLLRQQL (1670) ACHN Renal</p><p>RVS RVSSETF(1640) A498 Renal LRV SNGLRVV (1671) ACHN Renal</p><p>RSS A498 Renal LRS LRSMAVM (1672) ACHN Renal</p><p>AGS ARAGSTF (1641) A498 Renal VDLRSAF (1673) ACHN Renal</p><p>AGR TFAGRSL (1642) A498 Renal RVS FRVSLGY (1674) ACHN Renal</p><p>AGL A498 Renal RSS RSSYAPP (1675) ACHN Renal</p><p>AGG YAAGGST (1643) A498 Renal AGS FPGSAGS (1676) ACHN Renal</p><p>GVR EGVRGVF (1644) A498 Renal AGR FAGRAPR (1677) ACHN Renal</p><p>GDRGVRG (1645) A498 Renal AGL ACHN Renal</p><p>GVL PGVLREP (1646) A498 Renal AGG FIAGGVG (1678) ACHN Renal</p><p>GAV A498 Renal LIHAGGQ (1679) ACHN Renal</p><p>GLV A498 Renal RAGGGAP (1680) ACHN Renal</p><p>GLR GLRDGVE (1647) A498 Renal TWHAGGI (1681) ACHN Renal</p><p>LVS A498 Renal GVR GVRSITL(1682) ACHN Renal</p><p>ARG FPARGED (1648) A498 Renal GVL GLSRGVL (1683) ACHN Renal</p><p>ASL MLGSASL(1649) A498 Renal GAV RVVGAVL (1684) ACHN Renal</p><p>AAV A498 Renal GLV ACHN Renal</p><p>AAS A498 Renal GLR FGLRMSN (1685) ACHN Renal</p><p>GGS HGGSNDR(1650) A498 Renal LGLRGWT (1686) ACHN Renal</p><p>YAAGGST (1651) A498 Renal AFFMGLR (1687) ACHN Renal</p><p>GGR QGGRSGV (1652) A498 Renal SNGLRVV (1688) ACHN Renal</p><p>WTVGGRV (1653) A498 Renal LVS ACHN Renal</p><p>GLG A498 Renal ARG ARGTMTG (1689) ACHN Renal</p><p>GGL A498 Renal RPARGAF (1690) ACHN Renal</p><p>GSS VKGSSMR (1654) A498 Renal ASL ASLPMLH (1691) ACHN Renal</p><p>GSG A498 Renal AAV ACHN Renal</p><p>GSV A498 Renal AAS ACHN Renal</p><p>GRV FVGRVGE (1655) A498 Renal GGS GGSVEGQ (1692) ACHN Renal</p><p>GRVGRDG (1656) A498 Renal GGR LGGRQES (1693) ACHN Renal</p><p>SVSRGRV (1657) A498 Renal NGGRVLS (1694) ACHN Renal</p><p>WTVGGRV (1658) A498 Renal GLG ACHN Renal</p><p>GRL GFGRLLW (1659) A498 Renal GGL PIGGLFG(1695) ACHN Renal</p><p>GPS AAYWGPS (1660) A498 Renal AECCGGL (1696) ACHN Renal</p><p>GVS MDGVSTE (1661) A498 Renal SEQRGGL (1697) ACHN Renal</p><p>VYWWGVS (1662) A498 Renal GSS DRFGSSA(1698) ACHN Renal</p><p>GSG GHGSGSR(1699) ACHN Renal</p><p>RLS RLSMASR (1663) ACHN Renal GSV GGSVEGQ (1700) ACHN Renal</p><p>GRLSFGV(1664) ACHN Renal GSVVSSW(1701) ACHN Renal</p><p>RGV GLSRGVL (1665) ACHN Renal GRV NGGRVLS (1702) ACHN Renal</p><p>RGS LRGSHVA (1666) ACHN Renal GRL GRLMPGG (1703) ACHN Renal</p><p>NMGRGSL (1667) ACHN Renal TWGRLGL (1704) ACHN Renal</p><p>SVVRRGS (1668) ACHN Renal AVHSGRL (1705) ACHN Renal</p><p>RAV ACHN Renal GRLSFGV(1706) ACHN Renal</p><p>RAS ACHN Renal GPS PQGPSSV(1707) ACHN Renal</p><p>GAG VMGAGVQ (1669) ACHN Renal GVS ACHN Renal</p><p>AVS ACHN Renal</p><p>LLS ACHN Renal RLS AGWRLSQ (1708) CAIK-I Renal RGV CAIK-I Renal GVAIGRL (1739) CAIK-I Renal</p><p>RGS RVDRGSL (1709) CAIK-I Renal GPS CAIK-I Renal</p><p>RAV RAVCEWD (1710) CAIK-I Renal GVS FGVSQVH (1740) CAIK-I Renal</p><p>RAVERVA (1711) CAIK-I Renal GGVSRMR (1741) CAIK-I Renal</p><p>RAS AVFRASR (1712) CAIK-I Renal</p><p>GAG GAGSSVW (1713) CAIK-I Renal RLS GRIRLSF(1742) RXF393 Renal</p><p>GAGSSVW (1714) CAIK-I Renal RGV RGVNYRS (1743) RXF393 Renal</p><p>AVS CAIK-I Renal TEGTRGV (1744) RXF393 Renal</p><p>LLS CAIK-I Renal RGS GYARGSG (1745) RXF393 Renal</p><p>LLR WLLRSWS (1715) CAIK-I Renal GVWLRGS (1746) RXF393 Renal</p><p>LRV RKEALRV (1716) CAIK-I Renal RAV AARAVWG (1747) RXF393 Renal</p><p>RLRVSVR (1717) CAIK-I Renal RAS RASYYGV (1748) RXF393 Renal</p><p>LRS LRPGLRS (1718) CAIK-I Renal GAG GAGVEYF (1749) RXF393 Renal</p><p>QRYHLRS (13) AVS RXF393 Renal</p><p>(1719) CAIK-I Renal LLS LLLLSGS (1750) RXF393 Renal</p><p>WLLRSWS (1720) CAIK-I Renal VLLSAGL (1751) RXF393 Renal GRERVSH (2)</p><p>RVS (1721) CAIK-I Renal LLR TGLLRLY (1752) RXF393 Renal</p><p>RVSVRLR (1722) CAIK-I Renal LRV RXF393 Renal</p><p>RSS CAIK-I Renal LRS LRSSLVS (1753) RXF393 Renal</p><p>AGS GAGSSVW (1723) CAIK-I Renal RVS RXF393 Renal</p><p>GAGSSVW (1724) CAIK-I Renal RSS LRSSLVS (1754) RXF393 Renal</p><p>AGR CAIK-I Renal PRSSGPM(1755) RXF393 Renal</p><p>AGL AGLWPWN (1725) CAIK-I Renal AGS RXF393 Renal</p><p>AGG CAIK-I Renal AGR TAGRLEV (1756) RXF393 Renal</p><p>GVR GVRGGGD (1726) CAIK-I Renal AGL AGLEDLG (1757) RXF393 Renal</p><p>GVL CAIK-I Renal MPAGLGV (1758) RXF393 Renal</p><p>GAV CAIK-I Renal VLLSAGL (1759) RXF393 Renal</p><p>GLV GLVRRVV (1727) CAIK-I Renal AGG RXF393 Renal</p><p>GLR LRPGLRS (1728) CAIK-I Renal GVR GVRWNWS (1760) RXF393 Renal</p><p>LVS CAIK-I Renal TRDGVRW (1761) RXF393 Renal</p><p>ARG CAIK-I Renal GVL RXF393 Renal</p><p>ASL CAIK-I Renal GAV RXF393 Renal</p><p>AAV CAIK-I Renal GLV RAHGLVC (1762) RXF393 Renal</p><p>AAS WAHAASY (1729) CAIK-I Renal GLR LGSSGLR(1763) RXF393 Renal</p><p>GGS CAIK-I Renal LVS LLVSLSS (1764) RXF393 Renal</p><p>GGR DGGGRVG (1730) CAIK-I Renal LRSSLVS (1765) RXF393 Renal</p><p>VGVMGGR (1731) CAIK-I Renal LVSTRWA(1766) RXF393 Renal</p><p>VYGGRSE (1732) CAIK-I Renal LVSYSAV (1767) RXF393 Renal</p><p>GLG TICLGLG(1733) CAIK-I Renal ARG GYARGSG (1768) RXF393 Renal</p><p>GGL CAIK-I Renal ASL LGASLLV (1769) RXF393 Renal</p><p>GSS GAGSSVW (1734) CAIK-I Renal AAV GTGAAVF (1770) RXF393 Renal</p><p>GAGSSVW (1735) CAIK-I Renal AAVGTAL (1771) RXF393 Renal</p><p>GSG CAIK-I Renal AAS VSAASSV (1772) RXF393 Renal</p><p>GSV DHVSGSV(1736) CAIK-I Renal GGS RGGSPPV(1773) RXF393 Renal</p><p>GRV DGGGRVG (1737) CAIK-I Renal GGR VPPSGGR(1774) RXF393 Renal</p><p>GRL GEGRLCG (1738) CAIK-I Renal GLG GLGSCAP (1775) RXF393 Renal</p><p>MPAGLGV (1776) RXF393 Renal GGL RXF393 Renal AAV WWAAVPG (1812) SN12C Renal</p><p>GSS MPGSSRP(1777) RXF393 Renal AAS KAASTED (1813) SN12C Renal</p><p>GSSLSRP(1778) RXF393 Renal SYMGAAS (1814) SN12C Renal</p><p>RLGSSGL(1779) RXF393 Renal GGS GGSIDCC(1815) SN12C Renal</p><p>GSG GYARGSG (1780) RXF393 Renal GPGGSKR(1816) SN12C Renal</p><p>GSV RXF393 Renal AFGGGSM (1817) SN12C Renal</p><p>GRV RXF393 Renal GGR PEGGRRP (1818) SN12C Renal</p><p>GRL SGRLWVG (1781) RXF393 Renal GLG SN12C Renal</p><p>TAGRLEV (1782) RXF393 Renal GGL GGLEQDG (1819) SN12C Renal</p><p>GPS GPSFDAK(1783) RXF393 Renal FDPGGLR(1820) SN12C Renal</p><p>GVS ACTGVSR(1784) RXF393 Renal GSS LFGSSVS (1821) SN12C Renal</p><p>WDGSSVS (1822) SN12C Renal</p><p>RLS SN12C Renal GSG SN12C Renal</p><p>RGV LGMGRGV (1785) SN12C Renal GSV PNSAGSV (1823) SN12C Renal</p><p>RGS MLGRGSV (1786) SN12C Renal MLGRGSV (1824) SN12C Renal</p><p>RAV SN12C Renal GRV SN12C Renal</p><p>RAS PRASSTG (1787) SN12C Renal GRL TRRGRLD (1825) SN12C Renal</p><p>RASCFWD (1788) SN12C Renal GPS SN12C Renal</p><p>RASCFWD (1789) SN12C Renal GVS GVSISDG(1826) SN12C Renal</p><p>GAG SN12C Renal GVSIYDL(1827) SN12C Renal</p><p>AVS SN12C Renal</p><p>LLS FLLLSHR(1790) SN12C Renal RLS ARLSLEL (1828) TK-IO Renal</p><p>LLSVTSX (1791) SN12C Renal RLRLSSW(1829) TK-IO Renal</p><p>LLR PLLREVG (1792) SN12C Renal RRLSSIA(1830) TK-IO Renal</p><p>LRV LRVGHAG (1793) SN12C Renal SRLSYRT (1831) TK-IO Renal</p><p>NELRVCR (1794) SN12C Renal RGV TK-IO Renal</p><p>LRS MRYELRS (1795) SN12C Renal RGS ARGSWRE (1832) TK-IO Renal</p><p>RVS RVSVWWA (1796) SN12C Renal RAV VRLRAVF (1833) TK-IO Renal</p><p>FAQRRVS (1797) SN12C Renal RAS RASRIGL (1834) TK-IO Renal</p><p>RSS SHHRSSI (1798) SN12C Renal GAG GAGTSEG (1835) TK-IO Renal</p><p>AGS CMAGSQD (1799) SN12C Renal AVS TK-IO Renal</p><p>RYGTAGS (1800) SN12C Renal LLS LLSTVWV (1836) TK-IO Renal</p><p>SAGSHPA(1801) SN12C Renal ELRRLLS (1837) TK-IO Renal</p><p>PNSAGSV(1802) SN12C Renal LLR LLRGLRP (1838) TK-IO Renal</p><p>AGR KMRIAGR (1803) SN12C Renal SLLRRLE (1839) TK-IO Renal</p><p>MERVAGR (1804) SN12C Renal LRV LRVSRGL (1840) TK-IO Renal</p><p>AGL WAGLSRP (1805) SN12C Renal TLGLRVP (1841) TK-IO Renal</p><p>AGG SN12C Renal FVARLRV (1842) TK-IO Renal</p><p>GVR GAHGVRL (1806) SN12C Renal LRS GVYWLRS (1843) TK-IO Renal</p><p>RVPTGVR (1807) SN12C Renal SFWWLRS (1844) TK-IO Renal</p><p>GVL SN12C Renal TRYSLRS (1845) TK-IO Renal</p><p>GAV RGAVREM (1808) SN12C Renal RVS LRVSRGL (1846) TK-IO Renal</p><p>GLV SN12C Renal RSS RSSSGSG(1847) TK-IO Renal</p><p>GLR FDPGGLR(1809) SN12C Renal TRSSLTH (1848) TK-IO Renal</p><p>LVS ILSDLVS (1810) SN12C Renal TGRSSFW(1849) TK-IO Renal</p><p>ARG LLNPARG (1811) SN12C Renal AGS TK-IO Renal</p><p>ASL SN12C Renal AGR NAGRGAS (1850) TK-IO Renal AGL HAGLLVV (1851) TK-IO Renal SSSLAGS (1884) UO31 Renal</p><p>AGG TK-IO Renal AGR RSWNAGR (1885) UO31 Renal</p><p>GVR HTYGVRF (1852) TK-IO Renal AGL AGLPHRF(1886) UO31 Renal</p><p>GVL TK-IO Renal RNSRAGL (1887) UO31 Renal</p><p>GAV GAVRSVM (1853) TK-IO Renal AGG RRSGAGG (1888) UO31 Renal</p><p>VLVEGAV (1854) TK-IO Renal AGGPSSY(1889) UO31 Renal</p><p>GLV TK-IO Renal GVR TGVRNSP (1890) UO31 Renal</p><p>GLR LLRGLRP(1855) TK-IO Renal LLRAGVR (1891) UO31 Renal</p><p>TLGLRVP (1856) TK-IO Renal GVL UO31 Renal</p><p>LVS TK-IO Renal GAV UO31 Renal</p><p>ARG ARGSWRE (1857) TK-IO Renal GLV UO31 Renal</p><p>ASL TK-IO Renal GLR UO31 Renal</p><p>AAV GLWAAVL (1858) TK-IO Renal LVS ALVSTIL(1892) UO31 Renal</p><p>AAS GWTMAAS (1859) TK-IO Renal ARG ARGRDEG (1893) UO31 Renal</p><p>GGS LYMGGSH(1860) TK-IO Renal ASL ASLSVVI (1894) UO31 Renal</p><p>GGR GVGGRQS (1861) TK-IO Renal AAV UO31 Renal</p><p>GLG RRGLGDA (1862) TK-IO Renal AAS UO31 Renal</p><p>GGL TGGLHWY (1863) TK-IO Renal GGS GGSRGYR(1895) UO31 Renal</p><p>GSS GSGSSSR(1864) TK-IO Renal YWGGSVP (1896) UO31 Renal</p><p>GSSTLQW (1865) TK-IO Renal GGR GGRPVER (1897) UO31 Renal</p><p>GSG RSSSGSG(1866) TK-IO Renal GGRSQEG (1898) UO31 Renal</p><p>GSV DELGSVQ (1867) TK-IO Renal PGGGRGR (1899) UO31 Renal</p><p>GRV TK-IO Renal GLG UO31 Renal</p><p>GRL GRLRPFS (1868) TK-IO Renal GGL UO31 Renal</p><p>PRLGRLL (1869) TK-IO Renal GSS FSLGSSP(1900) UO31 Renal</p><p>GPS TK-IO Renal GSG UO31 Renal</p><p>GVS VGVSQEW (1870) TK-IO Renal GSV GSVFGTP (1901) UO31 Renal</p><p>DGVSPLW(1871) TK-IO Renal AGSVTEQ (1902) UO31 Renal YWGGSVP (1903) UO31 Renal</p><p>RLS UO31 Renal GRV LSGRVIV (1904) UO31 Renal</p><p>RGV UO31 Renal LSTPGRV(1905) UO31 Renal</p><p>RGS PRGSLFA(1872) UO31 Renal GRL UO31 Renal</p><p>VIVRGSL (1873) UO31 Renal GPS AGGPSSY (1906) UO31 Renal</p><p>RAV GDRAVGL (1874) UO31 Renal UO31 Renal</p><p>VHKRAVL (1875) UO31 Renal GVS UO31 Renal</p><p>RAS UO31 Renal</p><p>GAG GGAGSRR (1876) UO31 Renal RLS MCF-7 Breast</p><p>AVS UO31 Renal RGV MCF-7 Breast</p><p>LLS RLETLLS (1877) UO31 Renal RGS RVMRGSL (1907; MCF-7 Breast</p><p>LLR LLRAGVR (1878) UO31 Renal RAV MCF-7 Breast</p><p>LRV PAILRVR (1879) UO31 Renal RAS RASCVWA (1908; MCF-7 Breast</p><p>GDLRVSV(1880) UO31 Renal GAG MCF-7 Breast</p><p>LRS UO31 Renal AVS MCF-7 Breast</p><p>RVS GDLRVSV (1881) UO31 Renal LLS QLLSQVY (1909) MCF-7 Breast</p><p>RSS UO31 Renal LLR MCF-7 Breast</p><p>AGS GGAGSRR (1882) UO31 Renal LRV MCF-7 Breast</p><p>AGSVTEQ (1883) UO31 Renal LRS ERYYLRS (1910) MCF-7 Breast GLVKLRS (1911) MCF-7 Breast AGR AGRRLRD (1932) NCI/ADR-RES Breast</p><p>RVS MCF-7 Breast AGL WRLAGLG (1933) NCI/ADR-RES Breast</p><p>RSS MCF-7 Breast PTVSAGL (1934) NCI/ADR-RES Breast</p><p>AGS GRLAAGS (1912) MCF-7 Breast AGLLSDV (1935) NCI/ADR-RES Breast</p><p>AGR MCF-7 Breast AGG NCI/ADR-RES Breast</p><p>AGL MCF-7 Breast GVR NCI/ADR-RES Breast</p><p>AGG MCF-7 Breast GVL TLGVLVT (1936) NCI/ADR-RES Breast</p><p>GVR MCF-7 Breast GAV NCI/ADR-RES Breast</p><p>GVL MCF-7 Breast GLV NCI/ADR-RES Breast</p><p>GAV MCF-7 Breast GLR NCI/ADR-RES Breast</p><p>GLV GLVKLRS (1913) MCF-7 Breast LVS GDRRLVS (1937) NCI/ADR-RES Breast</p><p>GLR MCF-7 Breast LMLVSGK (1938) NCI/ADR-RES Breast</p><p>LVS LWFELVS (1914) MCF-7 Breast ARG DVHARGD (1939) NCI/ADR-RES Breast</p><p>ARG MCF-7 Breast ASL NCI/ADR-RES Breast</p><p>ASL MCF-7 Breast AAV NCI/ADR-RES Breast</p><p>AAV MCF-7 Breast AAS NCI/ADR-RES Breast</p><p>AAS IGAASWF (1915) MCF-7 Breast GGS REGGSDT (1940) NCI/ADR-RES Breast</p><p>GGS MCF-7 Breast GGR GGRRVVV (1941) NCI/ADR-RES Breast</p><p>GGR GGRRGTS (1916) MCF-7 Breast NVGGGRF (1942) NCI/ADR-RES Breast</p><p>RDLGGRW (1917) MCF-7 Breast GLG GLGALRW (1943) NCI/ADR-RES Breast</p><p>GLG MCF-7 Breast LGLSGLG (1944) NCI/ADR-RES Breast</p><p>GGL WRGGLDR (1918) MCF-7 Breast RGLGRPV (1945) NCI/ADR-RES Breast</p><p>GSS GRWTGSS (1919) MCF-7 Breast GGL NCI/ADR-RES Breast</p><p>SYWVGSS (1920) MCF-7 Breast GSS GSSGLLA(1946) NCI/ADR-RES Breast</p><p>GSG MCF-7 Breast LGSSSHI (1947) NCI/ADR-RES Breast</p><p>GSV MCF-7 Breast GSG IGSGVGV (1948) NCI/ADR-RES Breast</p><p>GRV MCF-7 Breast GSV KGSVLML (1949) NCI/ADR-RES Breast</p><p>GRL GRLAAGS (1921) MCF-7 Breast VPSGSVR(1950) NCI/ADR-RES Breast</p><p>GPS MCF-7 Breast GRV NCI/ADR-RES Breast</p><p>GVS AKAGVSR (1922) MCF-7 Breast GRL GYLGRLP (1951) NCI/ADR-RES Breast</p><p>AVYVGRL (1952) NCI/ADR-RES Breast</p><p>RLS LRLSGHD (1923) NCI/ADR-RES Breast GPS NCI/ADR-RES Breast</p><p>RGV RGVGAKA (1924) NCI/ADR-RES Breast GVS NCI/ADR-RES Breast</p><p>LRGVYVA (1925) NCI/ADR-RES Breast</p><p>RGS NCI/ADR-RES Breast RLS LGGRLSL (1953) MDA-MB-231 Breast</p><p>RAV NCI/ADR-RES Breast RGV RGVGKTK (1954) MDA-MB-231 Breast</p><p>RAS NCI/ADR-RES Breast LGGARGV (1955) MDA-MB-231 Breast</p><p>GAG NCI/ADR-RES Breast HAWDRGV (1956) MDA-MB-231 Breast</p><p>AVS GTPAVSY (1926) NCI/ADR-RES Breast DWGSRGV (1957) MDA-MB-231 Breast</p><p>LLS FLLSRSA (1927) NCI/ADR-RES Breast RGS PYRRGSC (1958) MDA-MB-231 Breast</p><p>AGLLSDV (1928) NCI/ADR-RES Breast ALNRGSR (3)</p><p>(1959) MDA-MB-231 Breast</p><p>LLR NCI/ADR-RES Breast</p><p>RAV MDA-MB-231 Breast</p><p>LRV LRVGXPG (1929) NCI/ADR-RES Breast</p><p>RAS MDA-MB-231 Breast</p><p>LRS NCI/ADR-RES Breast</p><p>GAG TFRGAGV (1960) MDA-MB-231 Breast</p><p>RVS RVSGSPV (1930) NCI/ADR-RES Breast</p><p>AVS MDA-MB-231 Breast</p><p>RSS RSSIDVG (1931) NCI/ADR-RES Breast</p><p>LLS LLSAARF (1961) MDA-MB-231 Breast</p><p>AGS NCI/ADR-RES Breast LLR MDA-MB-231 Breast GRL DTPAGRL (1997) MDA-MB-231 Breast</p><p>LRV MDA-MB-231 Breast LGGRLSL(1998) MDA-MB-231 Breast</p><p>LRS MRPGLRS (1962) MDA-MB-231 Breast GPS MDA-MB-231 Breast</p><p>RVS PRVSALV (1963) MDA-MB-231 Breast GVS AVGVSAA (1999) MDA-MB-231 Breast</p><p>VRVSLNS (1964) MDA-MB-231 Breast SGVSNPG (2000) MDA-MB-231 Breast</p><p>RSS GRSSAGP (1965) MDA-MB-231 Breast FGVSGGS (2001) MDA-MB-231 Breast</p><p>AGS LHAGSSV (1966) MDA-MB-231 Breast ESATGVS (2002) MDA-MB-231 Breast</p><p>VVMIAGS (1967) MDA-MB-231 Breast AAIVGVS (2003) MDA-MB-231 Breast</p><p>AGR DTPAGRL (1968) MDA-MB-231 Breast</p><p>VGAGRFT (1969) MDA-MB-231 Breast RLS MDA-MB-435-Breast</p><p>AGL MDA-MB-231 Breast RGV MDA-MB-435-Breast</p><p>AGG AGGTDRT (1970) MDA-MB-231 Breast RGS LRSGRGS (2004) MDA-MB-435-Breast</p><p>FISAGGW (1971) MDA-MB-231 Breast LRSGRGS (2005) MDA-MB-435-Breast</p><p>TIPAGGG (1972) MDA-MB-231 Breast RGRGSTL (2006) MDA-MB-435-Breast</p><p>VGRAGGL (1973) MDA-MB-231 Breast RGSPAAA (2007) MDA-MB-435-Breast</p><p>GVR MDA-MB-231 Breast SRGSYGS (2008) MDA-MB-435-Breast</p><p>GVL MDA-MB-231 Breast MDA-MB-435-Breast</p><p>GAV MDA-MB-231 Breast RAV MDA-MB-435-Breast</p><p>GLV NPGLVWN (1974) MDA-MB-231 Breast RAS MDA-MB-435-Breast</p><p>LGLVHWV (1975) MDA-MB-231 Breast GAG GVGGGAG (2009) MDA-MB-435-Breast</p><p>GLR MRPGLRS (1976) MDA-MB-231 Breast MDA-MB-435-Breast</p><p>LVS MDA-MB-231 Breast AVS MDA-MB-435-Breast</p><p>ARG ARGNVRF (1977) MDA-MB-231 Breast LLS MDA-MB-435-Breast</p><p>LGGARGV (1978) MDA-MB-231 Breast LLR MDA-MB-435-Breast</p><p>ASL FRAASLL (1979) MDA-MB-231 Breast LRV MDA-MB-435-Breast</p><p>AAV MDA-MB-231 Breast LRSGRGS (49)</p><p>LRS (2010)</p><p>AAS AASVGVA (1980) MDA-MB-435-Breast</p><p>MDA-MB-231 Breast</p><p>RVS</p><p>FRAASLL MDA-MB-435-Breast</p><p>(1981) MDA-MB-231 Breast</p><p>RSS MDA-MB-435-Breast</p><p>GGS PVFRGGS (1982) MDA-MB-231 Breast</p><p>AGS</p><p>SGGSVGF (1983) MDA-MB-435-Breast</p><p>MDA-MB-231 Breast</p><p>AGR</p><p>VRANGGS (1984) MDA-MB-435-Breast</p><p>MDA-MB-231 Breast</p><p>AGL</p><p>GGR FHIWGGR MDA-MB-435-Breast</p><p>(1985) MDA-MB-231 Breast</p><p>AGG</p><p>LGGRLSL AGGGGYH (2011) MDA-MB-435-Breast</p><p>(1986) MDA-MB-231 Breast</p><p>SGGRFVP GAGGGVG (2012)</p><p>(1987) MDA-MB-435-Breast</p><p>MDA-MB-231 Breast YRALAGG ( 2 )</p><p>GLG MDA-MB-231 Breast (2013) MDA-MB-435-Breast</p><p>GGL GGGLPVD (1988) MDA-MB-231 Breast MDA-MB-435-Breast</p><p>LSLRGGL (1989) MDA-MB-231 Breast GVR MDA-MB-435-Breast</p><p>VGRAGGL (1990) MDA-MB-231 Breast GVL MDA-MB-435-Breast</p><p>GSS ANGSSKK (1991) MDA-MB-231 Breast GAV MDA-MB-435-Breast</p><p>DFTLGSS (1992) MDA-MB-231 Breast GLV MDA-MB-435-Breast</p><p>LHAGSSV (1993) MDA-MB-231 Breast GLR MDA-MB-435-Breast</p><p>GSG MDA-MB-231 Breast LVS MDA-MB-435-Breast</p><p>GSV NSGSVVS (1994) MDA-MB-231 Breast ARG MDA-MB-435-Breast</p><p>SGGSVGF (1995) MDA-MB-231 Breast ASL LYVDASL (2014) MDA-MB-435-Breast</p><p>WSISGSV (1996) MDA-MB-231 Breast AAV MDA-MB-435-Breast</p><p>GRV MDA-MB-231 Breast AAS MDA-MB-435-Breast GGS MDA-MB-435-Breast GLR VGLRCSV (2045) BT-549 Breast</p><p>GGR MDA-MB-435-Breast VGLRVRF (2046) BT-549 Breast</p><p>GLG MDA-MB-435-Breast YGLRSLV (2047) BT-549 Breast</p><p>GGL MDA-MB-435-Breast LVS GLVSTLI (2048) BT-549 Breast</p><p>GSS MDA-MB-435-Breast ARG PRGMARG (2049) BT-549 Breast</p><p>GSG GEGSGSA(2015) MDA-MB-435-Breast ASL BT-549 Breast</p><p>GSV MDA-MB-435-Breast AAV BT-549 Breast</p><p>GRV MDA-MB-435-Breast AAS BT-549 Breast</p><p>GRL MDA-MB-435-Breast GGS RGGSDEA(2050) BT-549 Breast</p><p>GPS MDA-MB-435-Breast GGR AEDSGGR(2051) BT-549 Breast</p><p>GVS MDA-MB-435-Breast GGRCGAE (2052) BT-549 Breast</p><p>GLG BT-549 Breast</p><p>RLS BT-549 Breast GGL GGLMPRY (2053) BT-549 Breast</p><p>RGV RVRGVLD (2016) BT-549 Breast GSS GSSVSLG(2054) BT-549 Breast</p><p>SMRGVLS (2017) BT-549 Breast GSG GSGRQLP (2055) BT-549 Breast</p><p>EAGPRGV (2018) BT-549 Breast RKGSGTA (2056) BT-549 Breast</p><p>RGS CRGSIGA(2019) BT-549 Breast TRVSGSG (2057) BT-549 Breast</p><p>PLQRGSG(2020) BT-549 Breast GSV GSGSVRT (2058) BT-549 Breast</p><p>RGSRWSS (2021) BT-549 Breast GRV DDGRVHR (2059) BT-549 Breast</p><p>RGSYVER (2022) BT-549 Breast DLVGRVR (2060) BT-549 Breast</p><p>RAV TYCDRAV (2023) BT-549 Breast GRL WGRLEST (2061) BT-549 Breast</p><p>RAS LGVRASP (2024) BT-549 Breast GPS MGPSARW (2062) BT-549 Breast</p><p>WRASPGM (2025) BT-549 Breast GVS ISGVSDD(2063) BT-549 Breast</p><p>PRASDIL (2026) BT-549 Breast</p><p>GAG RVGAGWP (2027) BT-549 Breast RLS GHSERLS (2064) T-47D Breast</p><p>AVS BT-549 Breast RGV ERGVFVY (2065) T-47D Breast</p><p>LLS LLSRAQA(2028) BT-549 Breast TRGVIGG(2066) T-47D Breast</p><p>LLR BT-549 Breast RGS RGSFGLG (2067) T-47D Breast</p><p>LRV SALRVGL (2029) BT-549 Breast RAV PFHRRAV (2068) T-47D Breast</p><p>VGLRVRF (2030) BT-549 Breast RAS T-47D Breast</p><p>LRS YGLRSLV (2031) BT-549 Breast VGIGAGG (2)</p><p>GAG (2069) T-47D Breast</p><p>RVS TRVSGSG (2032) BT-549 Breast AVS AVSLAWQ (2070) T-47D Breast</p><p>RSS VRRSSKF(2033) BT-549 Breast FPAVSTE (2071) T-47D Breast</p><p>AGS BT-549 Breast</p><p>LLS T-47D Breast</p><p>AGR BT-549 Breast LLR T-47D Breast</p><p>AGL TFAGLAQ (2034) BT-549 Breast LRV T-47D Breast</p><p>AGG BT-549 Breast LRS SGARLRS (2072) T-47D Breast</p><p>GVR LGVRASP (2035) BT-549 Breast</p><p>LGVRLAS (2036) BT-549 Breast RVS T-47 D Breast</p><p>PWGAGVR (2037) BT-549 Breast RSS SHRSSTG (2073) T- 47 D Breast</p><p>GVL GVLTIGA(2038) BT-549 Breast AGS SRLRAGS (2074) T- 47 D Breast</p><p>RVRGVLD (2039) BT-549 Breast AGR SFAGRIL (2075) T- 47 D Breast</p><p>IGWGVLG (2040) BT-549 Breast AGL T- 47 D Breast</p><p>SMRGVLS (2041) BT-549 Breast AGG RVAAGGL (2076) T-47D Breast</p><p>GAV GAVLTSC (2042) BT-549 Breast VGIGAGG (2077) T- 47 D Breast</p><p>GLV GLVSTLI (2043) BT-549 Breast VGIGAGG (2078) T- 47 D Breast</p><p>GLVGWGI (2044) BT-549 Breast GVR T-47D Breast GAGSGRT (2112) HS 578 T Breast</p><p>GVL T-47D Breast PAVAGST (2113) HS 578 T Breast</p><p>GAV QKPGAVG (2079) T-47D Breast AGR AGRHLDA (2114) HS 578 T Breast</p><p>LGYYGAV (2080) T-47D Breast DRQLAGR (2115) HS 578 T Breast</p><p>GLV LPLGLVS (2081) T-47D Breast AGL HS 578 T Breast</p><p>LGLVFTR(2082) T-47D Breast AGG HS 578 T Breast</p><p>GLR T-47D Breast GVR LGVREVG (2116) HS 578 T Breast</p><p>LVS LPLGLVS (2083) T-47D Breast VAVGVRS (2117) HS 578 T Breast</p><p>NSKPLVS (2084) T-47D Breast GVL SFGVLSG(2118) HS 578 T Breast</p><p>ARG TNRFARG (2085) T-47D Breast GAV TSGAVAP (2119) HS 578 T Breast</p><p>ASL LASLARP (2086) T-47D Breast GLV HS 578 T Breast</p><p>AAV LGGAAVR (2087) T-47D Breast GLR GLREVQD (2120) HS 578 T Breast</p><p>AAS AASPHPG (2088) T-47D Breast LVS SLVSERA (2121) HS 578 T Breast</p><p>GGS LSKGGSE(2089) T-47D Breast SVHLVSG (2122) HS 578 T Breast</p><p>GGR T-47D Breast ARG TQVEARG (2123) HS 578 T Breast</p><p>GLG GLGRSVN (2090) T-47D Breast ASL HS 578 T Breast</p><p>PGLGYAL (2091) T-47D Breast AAV HS 578 T Breast</p><p>RGSFGLG (2092) T-47D Breast AAS HS 578 T Breast</p><p>GGL GRDWGGL (2093) T-47D Breast GGS HS 578 T Breast</p><p>RVAAGGL (2094) T-47D Breast GGR GGRPTVT (2124) HS 578 T Breast</p><p>GSS TVGSSLG (2095) T-47D Breast VVGGRRT (2125) HS 578 T Breast</p><p>GSG T-47D Breast GLG HS 578 T Breast</p><p>GSV T-47D Breast GGL GVGGLSS (2126) HS 578 T Breast</p><p>GRV GRVDPVD (2096) T-47D Breast GSS TAAGSSF (2127) HS 578 T Breast</p><p>GRL SLYRGRL (2097) T-47D Breast GSG TRGSGAG (2128) HS 578 T Breast</p><p>GPS T-47D Breast GSV RRGSVAE (2129) HS 578 T Breast</p><p>GVS VALGVSS (2098) T-47D Breast GSVLHVS (2130) HS 578 T Breast</p><p>GRV SGRVFRF (2131) HS 578 T Breast</p><p>RLS VSVTRLS (2099) HS 578 T Breast GRL HS 578 T Breast</p><p>RGV HS 578 T Breast GPS HS 578 T Breast</p><p>RGS AGATRGS (2100) HS 578 T Breast GVS WSATGVS (2132) HS 578 T Breast</p><p>RRGSVAE (2101) HS 578 T Breast</p><p>FRFVRGS (2102) HS 578 T Breast</p><p>TRGSGAG (2103) HS 578 T Breast</p><p>RAV GARAVAP (2104) HS 578 T Breast</p><p>RAS HS 578 T Breast</p><p>GAG TRGSGAG (2105) HS 578 T Breast</p><p>AVS EAVSGRR (2106) HS 578 T Breast</p><p>LLS HS 578 T Breast</p><p>LLR HS 578 T Breast</p><p>LRV HS 578 T Breast</p><p>LRS HS 578 T Breast</p><p>RVS PVRRVSS (2107) HS 578 T Breast</p><p>IRVSAVV (2108) HS 578 T Breast</p><p>RSS HVRSSYA (2109) HS 578 T Breast</p><p>RVRSSLA (2110) HS 578 T Breast</p><p>AGS TAAGSSF(2111) HS 578 T Breast REFERENCES</p><p>The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Arap et al, Nature Med. 8, 121-127, 2002</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Arap et al, Science, 279:377-80, 1998</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Blower et al, Pharmacogenomics J, 2:259-271, 2002</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Brown, Oncol. Res., 1997;9:213-5, 1997</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Giordano et al, Nat. Med., 7:1249-1253, 2001</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Hafner et al, Clin. Chem., 50:490-499, 2004</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Holbeck, Eur. J. Cancer, 40:785-793, 2004</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Kolonin et al, Cancer Res., 66(l):l-7, 2006</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Kolonin et al, Curr. Opin. Chem. Biol, 5:308-13, 2001</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Kolonin et al, Nat. Med., 6:625-632, 2004</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Kolonin et al, Proc. Natl Acad. ScL USA, 99:13055-13060, 2002</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Maihle and Lafky, Trends Cell Biol, 12:160-161, 2002</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Monks et al, J. Natl. Cancer Inst., 1991;83:757-66, 1991</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Myers et al, Electrophoresis, 18:647-653, 1997</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Nishizuka et al, Proc. Natl Acad. Sci. USA, 100:14229-14234, 2003</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Pasqualini and Ruoslahti, Nature, 380:364-366, 1996</bibl>.</p><p><bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Pasqualini et al, Cancer Res., 60:722-727, 2000</bibl>.</p><p><bibl next="bibl310" type="book" xmlns="http://www.tei-c.org/ns/1.0">Pasqualini et al, In: Phage Display, A Laboratory Manual, Barbas et al. (Eds.), NY, Cold Spring Harbor Laboratory Press, 22:1-24, 2001</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Rabow et al, J. Med. Chem., 45:818-40, 2002</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Scherf et al, Nat. Genet., 24:236-244, 2000</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Szakacs et al, Cancer Cell, 6:129-37, 2004</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Vogelstein and Kinzler, Nat. Med., 10:789-799, 2004</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Walloyist et al, Bioinformatics, 19:2212-24, 2003</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Wallqvist et al, MoI. Cancer Ther., 1:311-20, 2002</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Weinstein et al, Science, Ti '5:343-349, 1997</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Zaharevitz et al, J. MoI Graph. Model, 30:297-303, 2002</bibl>. <bibl type="journal" xmlns="http://www.tei-c.org/ns/1.0">Zurita et al, Cancer Res., 2004:64:435-9, 2004</bibl>.</p></description></fulltext-document>